Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:boron atom
go back to main search page
Accession:CHEBI:27560 term browser browse the term
Definition:A boron group element atom that has formula B.
Synonyms:related_synonym: 5B;   B;   Bor;   Formula=B;   InChI=1S/B;   InChIKey=ZOXJGFHDIHLPTG-UHFFFAOYSA-N;   SMILES=[B];   boracium;   bore;   boro;   boron
 alt_id: CHEBI:22915;   CHEBI:3152
 xref: CAS:7440-42-8;   KEGG:C06266
 xref_mesh: MESH:D001895
 xref: WebElements:B



show annotations for term's descendants           Sort by:
boron atom term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Atrnl1 attractin like 1 increases expression ISO Boron results in increased expression of ATRNL1 mRNA CTD PMID:21625915 NCBI chr19:57,599,248...58,121,775
Ensembl chr19:57,599,466...58,121,775
JBrowse link
G Bax BCL2-associated X protein multiple interactions ISO [boric acid results in increased abundance of Boron] which affects the expression of BAX mRNA; [boric acid results in increased abundance of Boron] which affects the expression of BAX protein CTD PMID:33137424 NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322
JBrowse link
G Bcl2 B cell leukemia/lymphoma 2 multiple interactions ISO [boric acid results in increased abundance of Boron] which results in decreased expression of BCL2 mRNA; [boric acid results in increased abundance of Boron] which results in decreased expression of BCL2 protein CTD PMID:33137424 NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004
JBrowse link
G Bglap bone gamma carboxyglutamate protein increases expression ISO Boron results in increased expression of BGLAP mRNA CTD PMID:21625915 NCBI chr 3:88,290,802...88,291,773
Ensembl chr 3:88,290,808...88,291,771
JBrowse link
G Bmp7 bone morphogenetic protein 7 increases expression ISO Boron results in increased expression of BMP7 mRNA CTD PMID:21625915 NCBI chr 2:172,709,805...172,782,114
Ensembl chr 2:172,709,805...172,782,114
JBrowse link
G Casp3 caspase 3 increases expression ISO Boron results in increased expression of CASP3 protein modified form CTD PMID:23462526 NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724
JBrowse link
G Cat catalase multiple interactions ISO [boric acid results in increased abundance of Boron] inhibits the reaction [bisphenol A results in decreased activity of CAT protein]; Boron inhibits the reaction [Dietary Fats results in decreased activity of CAT protein] CTD PMID:30997025 PMID:36419211 NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505
JBrowse link
G Ccnd1 cyclin D1 decreases expression ISO Boron results in decreased expression of CCND1 protein CTD PMID:23462526 NCBI chr 7:144,483,668...144,493,568
Ensembl chr 7:144,483,668...144,493,662
JBrowse link
G Col1a1 collagen, type I, alpha 1 increases expression ISO Boron results in increased expression of COL1A1 mRNA CTD PMID:21625915 NCBI chr11:94,827,050...94,843,868
Ensembl chr11:94,827,050...94,843,868
JBrowse link
G Crp C-reactive protein, pentraxin-related multiple interactions ISO Boron inhibits the reaction [Dietary Fats results in increased expression of CRP mRNA] CTD PMID:36419211 NCBI chr 1:172,525,623...172,527,533
Ensembl chr 1:172,525,622...172,660,598
JBrowse link
G Cst3 cystatin C multiple interactions ISO [boric acid results in increased abundance of Boron] inhibits the reaction [Acetaminophen results in increased expression of CST3 protein] CTD PMID:35020164 NCBI chr 2:148,713,642...148,717,432
Ensembl chr 2:148,713,642...148,717,612
JBrowse link
G Gpt glutamic pyruvic transaminase, soluble multiple interactions ISO [boric acid results in increased abundance of Boron] inhibits the reaction [bisphenol A results in increased expression of GPT protein] CTD PMID:30997025 NCBI chr15:76,580,926...76,583,875
Ensembl chr15:76,579,916...76,583,886
JBrowse link
G Havcr1 hepatitis A virus cellular receptor 1 multiple interactions ISO [boric acid results in increased abundance of Boron] inhibits the reaction [Acetaminophen results in increased expression of HAVCR1 protein] CTD PMID:35020164 NCBI chr11:46,630,644...46,670,405
Ensembl chr11:46,625,907...46,670,405
JBrowse link
G Ifng interferon gamma multiple interactions ISO [boric acid results in increased abundance of Boron] promotes the reaction [4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta(c)quinoline results in decreased secretion of IFNG protein]; [boric acid results in increased abundance of Boron] which affects the secretion of IFNG protein CTD PMID:33137424 NCBI chr10:118,276,951...118,281,799
Ensembl chr10:118,276,951...118,281,797
JBrowse link
G Il10 interleukin 10 multiple interactions ISO [boric acid results in increased abundance of Boron] inhibits the reaction [bisphenol A results in decreased expression of IL10 mRNA] CTD PMID:30997025 NCBI chr 1:130,947,459...130,952,707
Ensembl chr 1:130,947,582...130,952,711
JBrowse link
G Il18 interleukin 18 multiple interactions ISO [boric acid results in increased abundance of Boron] inhibits the reaction [Acetaminophen results in increased expression of IL18 protein] CTD PMID:35020164 NCBI chr 9:50,466,000...50,493,141
Ensembl chr 9:50,466,127...50,493,140
JBrowse link
G Il1b interleukin 1 beta multiple interactions ISO [boric acid results in increased abundance of Boron] inhibits the reaction [bisphenol A results in increased expression of IL1B mRNA]; Boron inhibits the reaction [Dietary Fats results in increased expression of IL1B mRNA] CTD PMID:30997025 PMID:36419211 NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059
JBrowse link
G Il2 interleukin 2 multiple interactions ISO [boric acid results in increased abundance of Boron] promotes the reaction [4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta(c)quinoline results in decreased secretion of IL2 protein]; [boric acid results in increased abundance of Boron] which results in decreased secretion of IL2 protein CTD PMID:33137424 NCBI chr 3:37,174,862...37,180,103
Ensembl chr 3:37,174,672...37,180,108
JBrowse link
G Il4 interleukin 4 multiple interactions ISO [boric acid results in increased abundance of Boron] which affects the secretion of IL4 protein CTD PMID:33137424 NCBI chr11:53,503,287...53,509,492
Ensembl chr11:53,493,809...53,509,496
JBrowse link
G Il6 interleukin 6 multiple interactions ISO [boric acid results in increased abundance of Boron] inhibits the reaction [bisphenol A results in increased expression of IL6 mRNA] CTD PMID:30997025 NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979
JBrowse link
G Lep leptin multiple interactions ISO Boron inhibits the reaction [Dietary Fats results in increased expression of LEP mRNA] CTD PMID:36419211 NCBI chr 6:29,060,220...29,073,875
Ensembl chr 6:29,060,219...29,073,876
JBrowse link
G Pcna proliferating cell nuclear antigen multiple interactions ISO [boric acid results in increased abundance of Boron] promotes the reaction [4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta(c)quinoline results in decreased expression of PCNA protein]; [boric acid results in increased abundance of Boron] which affects the expression of PCNA protein; [boric acid results in increased abundance of Boron] which results in decreased expression of PCNA mRNA CTD PMID:33137424 NCBI chr 2:132,091,206...132,095,100
Ensembl chr 2:132,091,082...132,095,234
JBrowse link
G Ppara peroxisome proliferator activated receptor alpha multiple interactions ISO Boron inhibits the reaction [Dietary Fats results in decreased expression of PPAR mRNA] CTD PMID:36419211 NCBI chr15:85,619,112...85,691,052
Ensembl chr15:85,619,184...85,687,020
JBrowse link
G Sod1 superoxide dismutase 1, soluble multiple interactions ISO Boron inhibits the reaction [Dietary Fats results in decreased activity of SOD1 protein] CTD PMID:36419211 NCBI chr16:90,017,650...90,023,221
Ensembl chr16:90,017,642...90,023,217
JBrowse link
G Tnf tumor necrosis factor multiple interactions ISO [boric acid results in increased abundance of Boron] inhibits the reaction [bisphenol A results in increased expression of TNF mRNA]; Boron inhibits the reaction [Dietary Fats results in increased expression of TNF mRNA] CTD PMID:30997025 PMID:36419211 NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983
JBrowse link
2-[4-[(E)-2-(6,8-dichloro-2-phenyl-2H-chromen-3-yl)ethenyl]phenyl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Nphs1 nephrosis 1, nephrin increases expression EXP BD4 increases expression of Nphs1 mRNA in podocytes RGD PMID:22125642 RGD:40902998 NCBI chr 7:30,157,259...30,188,048
Ensembl chr 7:30,157,740...30,186,648
JBrowse link
G Synpo synaptopodin increases expression EXP BD4 increases expression of Synpo mRNA in podocytes RGD PMID:22125642 RGD:40902998 NCBI chr18:60,727,053...60,793,241
Ensembl chr18:60,727,045...60,793,214
JBrowse link
2-aminoethoxydiphenylborane term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Bax BCL2-associated X protein multiple interactions ISO 2-aminoethoxydiphenylborane inhibits the reaction [cadmium acetate results in increased expression of BAX protein] CTD PMID:29883672 NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322
JBrowse link
G Bcl2 B cell leukemia/lymphoma 2 multiple interactions ISO 2-aminoethoxydiphenylborane inhibits the reaction [cadmium acetate results in decreased expression of BCL2 protein] CTD PMID:29883672 NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004
JBrowse link
G Casp12 caspase 12 multiple interactions ISO 2-aminoethoxydiphenylborane inhibits the reaction [cadmium acetate results in increased cleavage of CASP12 protein] CTD PMID:29883672 NCBI chr 9:5,345,419...5,373,034
Ensembl chr 9:5,345,430...5,373,032
JBrowse link
G Casp3 caspase 3 multiple interactions ISO 2-aminoethoxydiphenylborane inhibits the reaction [cadmium acetate results in increased cleavage of CASP3 protein] CTD PMID:29883672 NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724
JBrowse link
G Cd28 CD28 antigen multiple interactions ISO 2-aminoethoxydiphenylborane inhibits the reaction [CD28 protein results in increased abundance of Calcium]; 2-aminoethoxydiphenylborane inhibits the reaction [CD28 protein results in increased abundance of Nitric Oxide]; 2-aminoethoxydiphenylborane inhibits the reaction [CD28 protein results in increased abundance of Reactive Oxygen Species] CTD PMID:14607919 NCBI chr 1:60,785,547...60,812,521
Ensembl chr 1:60,755,959...60,812,518
JBrowse link
G Grm1 glutamate receptor, metabotropic 1 multiple interactions ISO 2-aminoethoxydiphenylborane inhibits the reaction [3,5-dihydroxyphenylglycine results in increased activity of GRM1 protein] CTD PMID:14622174 NCBI chr10:10,561,803...10,958,126
Ensembl chr10:10,561,803...10,958,100
JBrowse link
G Nfe2l2 nuclear factor, erythroid derived 2, like 2 multiple interactions ISO 2-aminoethoxydiphenylborane inhibits the reaction [bisphenol A results in increased expression of NFE2L2 protein] CTD PMID:33408296 NCBI chr 2:75,505,860...75,535,007
Ensembl chr 2:75,505,857...75,534,985
JBrowse link
4,4-difluoro-4-bora-3a,4a-diaza-s-indacene term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcb11 ATP-binding cassette, sub-family B member 11 affects transport ISO ABCB11 protein affects the transport of 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene CTD PMID:12739759 NCBI chr 2:69,068,626...69,172,960
Ensembl chr 2:69,068,626...69,172,958
JBrowse link
boric acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ace angiotensin I converting enzyme multiple interactions ISO boric acid inhibits the reaction [epigallocatechin gallate results in decreased activity of ACE protein] CTD PMID:28544013 NCBI chr11:105,858,774...105,880,790
Ensembl chr11:105,858,771...105,880,790
JBrowse link
G Acsl4 acyl-CoA synthetase long-chain family member 4 multiple interactions ISO boric acid inhibits the reaction [amyloid beta-protein (1-42) results in increased expression of ACSL4 mRNA]; boric acid inhibits the reaction [amyloid beta-protein (1-42) results in increased expression of ACSL4 protein] CTD PMID:38108610 NCBI chr  X:141,100,989...141,173,792
Ensembl chr  X:141,100,989...141,173,531
JBrowse link
G Acta2 actin alpha 2, smooth muscle, aorta decreases expression ISO boric acid results in decreased expression of ACTA2 protein CTD PMID:25637568 NCBI chr19:34,217,736...34,232,985
Ensembl chr19:34,218,490...34,232,990
JBrowse link
G Adipoq adiponectin, C1Q and collagen domain containing multiple interactions EXP boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of ADIPOQ mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of and results in increased secretion of ADIPOQ protein] CTD PMID:28285642 NCBI chr16:22,965,286...22,976,718
Ensembl chr16:22,965,286...22,976,778
JBrowse link
G Agt angiotensinogen multiple interactions EXP boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of AGT mRNA] CTD PMID:28285642 NCBI chr 8:125,283,326...125,296,445
Ensembl chr 8:125,283,273...125,296,445
JBrowse link
G Akt1 thymoma viral proto-oncogene 1 increases expression EXP boric acid results in increased expression of AKT1 mRNA CTD PMID:31368021 NCBI chr12:112,620,260...112,641,266
Ensembl chr12:112,620,255...112,641,318
JBrowse link
G Arg1 arginase, liver decreases activity ISO boric acid results in decreased activity of ARG1 protein CTD PMID:21232540 NCBI chr10:24,791,105...24,803,368
Ensembl chr10:24,791,119...24,803,382
JBrowse link
G Atf4 activating transcription factor 4 increases expression ISO boric acid results in increased expression of ATF4 mRNA; boric acid results in increased expression of ATF4 protein CTD PMID:25425213 PMID:27587023 NCBI chr15:80,139,385...80,141,746
Ensembl chr15:80,139,385...80,141,742
JBrowse link
G Atf6 activating transcription factor 6 multiple interactions ISO boric acid results in increased cleavage of and affects the localization of ATF6 protein CTD PMID:27587023 NCBI chr 1:170,532,026...170,696,414
Ensembl chr 1:170,532,243...170,695,340
JBrowse link
G Bax BCL2-associated X protein decreases expression
increases expression
multiple interactions
EXP
ISO
boric acid results in decreased expression of BAX mRNA
boric acid results in increased expression of BAX mRNA
[boric acid results in increased abundance of Boron] which affects the expression of BAX mRNA; [boric acid results in increased abundance of Boron] which affects the expression of BAX protein
CTD PMID:31368021 PMID:33137424 PMID:34175401 NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322
JBrowse link
G Bcl2 B cell leukemia/lymphoma 2 increases expression
decreases expression
multiple interactions
EXP
ISO
boric acid results in increased expression of BCL2 mRNA
boric acid results in decreased expression of BCL2 mRNA
[boric acid results in increased abundance of Boron] which results in decreased expression of BCL2 mRNA; [boric acid results in increased abundance of Boron] which results in decreased expression of BCL2 protein
CTD PMID:31368021 PMID:33137424 PMID:34175401 NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004
JBrowse link
G Bcl2l1 BCL2-like 1 decreases expression ISO boric acid results in decreased expression of BCL2L1 mRNA CTD PMID:34175401 NCBI chr 2:152,600,652...152,673,632
Ensembl chr 2:152,622,588...152,673,648
JBrowse link
G Bid BH3 interacting domain death agonist increases expression ISO boric acid results in increased expression of BID mRNA CTD PMID:34175401 NCBI chr 6:120,870,080...120,894,074
Ensembl chr 6:120,868,891...120,893,814
JBrowse link
G Calr calreticulin increases expression ISO boric acid results in increased expression of CALR mRNA CTD PMID:27587023 NCBI chr 8:85,568,717...85,573,560
Ensembl chr 8:85,568,479...85,573,563
JBrowse link
G Casp3 caspase 3 multiple interactions
increases expression
decreases expression
ISO
EXP
boric acid inhibits the reaction [Formaldehyde results in increased expression of CASP3 mRNA]
boric acid results in increased expression of CASP3 mRNA
boric acid results in decreased expression of CASP3 mRNA
CTD PMID:31368021 PMID:31823256 PMID:34175401 NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724
JBrowse link
G Casp9 caspase 9 increases expression ISO boric acid results in increased expression of CASP9 mRNA CTD PMID:34175401 NCBI chr 4:141,520,923...141,543,289
Ensembl chr 4:141,520,923...141,543,287
JBrowse link
G Cat catalase multiple interactions
decreases activity
ISO [boric acid co-treated with Arsenic Trioxide] affects the activity of CAT protein; [boric acid results in increased abundance of Boron] inhibits the reaction [bisphenol A results in decreased activity of CAT protein]; boric acid inhibits the reaction [Acrylamide results in increased activity of CAT protein]
boric acid results in decreased activity of CAT protein
boric acid affects the reaction [Formaldehyde results in decreased activity of CAT protein]
CTD PMID:26184899 PMID:29913234 PMID:30997025 PMID:31823256 NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505
JBrowse link
G Ccnd1 cyclin D1 increases expression
multiple interactions
EXP boric acid results in increased expression of CCND1 mRNA
boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in decreased expression of CCND1 protein]
CTD PMID:28285642 NCBI chr 7:144,483,668...144,493,568
Ensembl chr 7:144,483,668...144,493,662
JBrowse link
G Cebpa CCAAT/enhancer binding protein alpha multiple interactions EXP boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPA mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPA protein]; CTNNB1 protein promotes the reaction [boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPA protein]] CTD PMID:28285642 NCBI chr 7:34,818,718...34,821,353
Ensembl chr 7:34,818,718...34,821,353
JBrowse link
G Cebpb CCAAT/enhancer binding protein beta multiple interactions EXP boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPB mRNA] CTD PMID:28285642 NCBI chr 2:167,530,835...167,532,352
Ensembl chr 2:167,530,835...167,532,338
JBrowse link
G Col1a2 collagen, type I, alpha 2 affects expression EXP boric acid affects the expression of COL1A2 mRNA CTD PMID:24704097 NCBI chr 6:4,505,618...4,541,543
Ensembl chr 6:4,504,814...4,541,544
JBrowse link
G Csf2 colony stimulating factor 2 (granulocyte-macrophage) increases expression ISO boric acid results in increased expression of CSF2 protein CTD PMID:27206737 NCBI chr11:54,138,096...54,140,725
Ensembl chr11:54,138,097...54,140,493
JBrowse link
G Csf3 colony stimulating factor 3 (granulocyte) increases expression ISO boric acid results in increased expression of CSF3 protein CTD PMID:27206737 NCBI chr11:98,591,287...98,594,457
Ensembl chr11:98,592,089...98,594,455
JBrowse link
G Cst3 cystatin C multiple interactions ISO [boric acid results in increased abundance of Boron] inhibits the reaction [Acetaminophen results in increased expression of CST3 protein] CTD PMID:35020164 NCBI chr 2:148,713,642...148,717,432
Ensembl chr 2:148,713,642...148,717,612
JBrowse link
G Ctnnb1 catenin beta 1 multiple interactions EXP boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in decreased expression of CTNNB1 protein]; CTNNB1 protein promotes the reaction [boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPA protein]]; CTNNB1 protein promotes the reaction [boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 protein]]; CTNNB1 protein promotes the reaction [boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of PPARG protein]] CTD PMID:28285642 NCBI chr 9:120,762,466...120,789,573
Ensembl chr 9:120,758,282...120,789,573
JBrowse link
G Ddit3 DNA-damage inducible transcript 3 decreases expression ISO boric acid results in decreased expression of DDIT3 mRNA; boric acid results in decreased expression of DDIT3 protein CTD PMID:27587023 NCBI chr10:127,126,662...127,132,160
Ensembl chr10:127,126,643...127,132,157
Ensembl chr10:127,126,643...127,132,157
JBrowse link
G Des desmin affects expression ISO boric acid affects the expression of DES mRNA CTD PMID:25637568 NCBI chr 1:75,336,936...75,345,223
Ensembl chr 1:75,336,973...75,345,223
JBrowse link
G Dvl2 dishevelled segment polarity protein 2 multiple interactions EXP boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in decreased expression of DVL2 mRNA] CTD PMID:28285642 NCBI chr11:69,891,418...69,900,935
Ensembl chr11:69,891,421...69,903,127
JBrowse link
G Edem1 ER degradation enhancer, mannosidase alpha-like 1 increases expression ISO boric acid results in increased expression of EDEM1 mRNA CTD PMID:27587023 NCBI chr 6:108,800,984...108,836,317
Ensembl chr 6:108,805,602...108,836,317
JBrowse link
G Eif2ak3 eukaryotic translation initiation factor 2 alpha kinase 3 multiple interactions EXP EIF2AK3 protein affects the reaction [boric acid affects the localization of NFE2L2 protein]; EIF2AK3 protein affects the reaction [boric acid results in increased expression of GCLC mRNA]; EIF2AK3 protein affects the reaction [boric acid results in increased phosphorylation of EIF2S1 protein] CTD PMID:30196486 NCBI chr 6:70,821,468...70,882,225
Ensembl chr 6:70,821,499...70,882,229
JBrowse link
G Eif2s1 eukaryotic translation initiation factor 2, subunit 1 alpha increases phosphorylation
multiple interactions
ISO
EXP
boric acid results in increased phosphorylation of EIF2S1 protein
EIF2AK3 protein affects the reaction [boric acid results in increased phosphorylation of EIF2S1 protein]
CTD PMID:25425213 PMID:27587023 PMID:30196486 NCBI chr12:78,908,846...78,933,784
Ensembl chr12:78,908,593...78,933,784
JBrowse link
G Fabp4 fatty acid binding protein 4, adipocyte multiple interactions EXP boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 protein]; CTNNB1 protein promotes the reaction [boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 protein]] CTD PMID:28285642 NCBI chr 3:10,269,406...10,273,653
Ensembl chr 3:10,269,148...10,273,636
JBrowse link
G Fasn fatty acid synthase multiple interactions EXP boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FASN mRNA] CTD PMID:28285642 NCBI chr11:120,696,784...120,715,992
Ensembl chr11:120,696,672...120,715,373
JBrowse link
G Fgf2 fibroblast growth factor 2 multiple interactions EXP boric acid promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FGF2 protein] CTD PMID:28285642 NCBI chr 3:37,402,616...37,464,255
Ensembl chr 3:37,402,495...37,464,257
JBrowse link
G Fgf7 fibroblast growth factor 7 increases expression ISO boric acid results in increased expression of FGF7 protein CTD PMID:27206737 NCBI chr 2:125,876,578...125,933,105
Ensembl chr 2:125,876,578...125,933,105
JBrowse link
G Fn1 fibronectin 1 affects expression
increases expression
ISO
EXP
boric acid affects the expression of FN1 mRNA
boric acid results in increased expression of FN1 mRNA
CTD PMID:27206737 NCBI chr 1:71,624,632...71,692,439
Ensembl chr 1:71,624,679...71,692,359
JBrowse link
G Gapdh glyceraldehyde-3-phosphate dehydrogenase decreases expression EXP boric acid results in decreased expression of GAPDH protein CTD PMID:28285642 NCBI chr 6:125,138,812...125,143,450
Ensembl chr 6:125,138,678...125,143,430
JBrowse link
G Gas6 growth arrest specific 6 multiple interactions EXP boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of GAS6 protein] CTD PMID:28285642 NCBI chr 8:13,515,374...13,544,535
Ensembl chr 8:13,515,374...13,544,490
JBrowse link
G Gck glucokinase increases expression EXP boric acid results in increased expression of GCK mRNA CTD PMID:31368021 NCBI chr11:5,850,816...5,900,081
Ensembl chr11:5,850,820...5,900,081
JBrowse link
G Gclc glutamate-cysteine ligase, catalytic subunit increases expression
multiple interactions
ISO
EXP
boric acid results in increased expression of GCLC mRNA
EIF2AK3 protein affects the reaction [boric acid results in increased expression of GCLC mRNA]
CTD PMID:30196486 NCBI chr 9:77,661,817...77,701,771
Ensembl chr 9:77,661,817...77,701,767
JBrowse link
G Gpt glutamic pyruvic transaminase, soluble multiple interactions ISO [boric acid results in increased abundance of Boron] inhibits the reaction [bisphenol A results in increased expression of GPT protein] CTD PMID:30997025 NCBI chr15:76,580,926...76,583,875
Ensembl chr15:76,579,916...76,583,886
JBrowse link
G Gpx4 glutathione peroxidase 4 multiple interactions ISO boric acid inhibits the reaction [amyloid beta-protein (1-42) results in decreased expression of GPX4 mRNA]; boric acid inhibits the reaction [amyloid beta-protein (1-42) results in decreased expression of GPX4 protein] CTD PMID:38108610 NCBI chr10:79,883,000...79,892,273
Ensembl chr10:79,883,000...79,892,273
JBrowse link
G Havcr1 hepatitis A virus cellular receptor 1 multiple interactions ISO [boric acid results in increased abundance of Boron] inhibits the reaction [Acetaminophen results in increased expression of HAVCR1 protein] CTD PMID:35020164 NCBI chr11:46,630,644...46,670,405
Ensembl chr11:46,625,907...46,670,405
JBrowse link
G Herpud1 homocysteine-inducible, endoplasmic reticulum stress-inducible, ubiquitin-like domain member 1 increases expression ISO boric acid results in increased expression of HERPUD1 mRNA CTD PMID:27587023 NCBI chr 8:95,113,057...95,121,999
Ensembl chr 8:95,113,066...95,122,005
JBrowse link
G Hmox1 heme oxygenase 1 increases expression ISO
EXP
boric acid results in increased expression of HMOX1 mRNA CTD PMID:30196486 NCBI chr 8:75,820,246...75,827,221
Ensembl chr 8:75,820,249...75,827,217
JBrowse link
G Hoxa6 homeobox A6 affects expression ISO boric acid affects the expression of HOXA6 mRNA CTD PMID:12749385 NCBI chr 6:52,181,838...52,185,652
Ensembl chr 6:52,183,268...52,185,702
JBrowse link
G Hoxc6 homeobox C6 affects expression ISO boric acid affects the expression of HOXC6 mRNA CTD PMID:12749385 NCBI chr15:102,906,658...102,920,314
Ensembl chr15:102,906,689...102,920,313
JBrowse link
G Hspa5 heat shock protein 5 increases expression ISO boric acid results in increased expression of HSPA5 mRNA; boric acid results in increased expression of HSPA5 protein CTD PMID:25425213 PMID:27587023 NCBI chr 2:34,662,102...34,666,541
Ensembl chr 2:34,661,982...34,667,559
JBrowse link
G Ifng interferon gamma multiple interactions ISO [boric acid results in increased abundance of Boron] promotes the reaction [4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta(c)quinoline results in decreased secretion of IFNG protein]; [boric acid results in increased abundance of Boron] which affects the secretion of IFNG protein; [Food Preservatives results in increased abundance of boric acid] which results in increased expression of IFNG mRNA; boric acid inhibits the reaction [Acrylamide results in increased expression of IFNG mRNA]; boric acid inhibits the reaction [Arsenic Trioxide results in increased expression of IFNG mRNA]; boric acid inhibits the reaction [Arsenic Trioxide results in increased expression of IFNG protein] CTD PMID:29913234 PMID:30368975 PMID:32179172 PMID:33137424 NCBI chr10:118,276,951...118,281,799
Ensembl chr10:118,276,951...118,281,797
JBrowse link
G Il10 interleukin 10 multiple interactions ISO [boric acid results in increased abundance of Boron] inhibits the reaction [bisphenol A results in decreased expression of IL10 mRNA]; [Food Preservatives results in increased abundance of boric acid] which results in increased expression of IL10 mRNA CTD PMID:30997025 PMID:32179172 NCBI chr 1:130,947,459...130,952,707
Ensembl chr 1:130,947,582...130,952,711
JBrowse link
G Il18 interleukin 18 multiple interactions ISO [boric acid results in increased abundance of Boron] inhibits the reaction [Acetaminophen results in increased expression of IL18 protein] CTD PMID:35020164 NCBI chr 9:50,466,000...50,493,141
Ensembl chr 9:50,466,127...50,493,140
JBrowse link
G Il1b interleukin 1 beta multiple interactions ISO [boric acid results in increased abundance of Boron] inhibits the reaction [bisphenol A results in increased expression of IL1B mRNA]; [Food Preservatives results in increased abundance of boric acid] which results in increased expression of IL1B mRNA; boric acid inhibits the reaction [Acrylamide results in increased expression of IL1B mRNA]; boric acid inhibits the reaction [Arsenic Trioxide results in increased expression of IL1B mRNA]; boric acid inhibits the reaction [Arsenic Trioxide results in increased expression of IL1B protein] CTD PMID:29913234 PMID:30368975 PMID:30997025 PMID:32179172 NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059
JBrowse link
G Il2 interleukin 2 multiple interactions ISO [boric acid results in increased abundance of Boron] promotes the reaction [4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta(c)quinoline results in decreased secretion of IL2 protein]; [boric acid results in increased abundance of Boron] which results in decreased secretion of IL2 protein CTD PMID:33137424 NCBI chr 3:37,174,862...37,180,103
Ensembl chr 3:37,174,672...37,180,108
JBrowse link
G Il4 interleukin 4 increases expression
multiple interactions
EXP
ISO
boric acid results in increased expression of IL4 mRNA
[boric acid results in increased abundance of Boron] which affects the secretion of IL4 protein
CTD PMID:31368021 PMID:33137424 NCBI chr11:53,503,287...53,509,492
Ensembl chr11:53,493,809...53,509,496
JBrowse link
G Il6 interleukin 6 multiple interactions EXP
ISO
boric acid promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of IL6 mRNA]
[boric acid results in increased abundance of Boron] inhibits the reaction [bisphenol A results in increased expression of IL6 mRNA]; [Food Preservatives results in increased abundance of boric acid] which results in increased expression of IL6 mRNA
CTD PMID:28285642 PMID:30997025 PMID:32179172 NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979
JBrowse link
G Ins1 insulin I increases expression EXP boric acid results in increased expression of INS1 mRNA CTD PMID:31368021 NCBI chr19:52,252,735...52,253,453
Ensembl chr19:52,252,735...52,253,914
JBrowse link
G Ins2 insulin II multiple interactions
increases expression
EXP boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in decreased expression of CCND1 protein]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in decreased expression of CTNNB1 protein]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in decreased expression of DVL2 mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of ADIPOQ mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of AGT mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of and results in increased secretion of ADIPOQ protein]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPA mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPA protein]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPB mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 protein]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FASN mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of GAS6 protein]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of KLF5 mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of LEP mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of LIPE mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of PPARG mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of PPARG protein]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of SLC2A4 mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of SLC2A4 protein]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of SREBF1 mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of TNFRSF1A protein]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased phosphorylation of MAPK1 protein]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased phosphorylation of MAPK3 protein]; boric acid promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FGF2 protein]; boric acid promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of IL6 mRNA]; CTNNB1 protein promotes the reaction [boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPA protein]]; CTNNB1 protein promotes the reaction [boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 protein]]; CTNNB1 protein promotes the reaction [boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of PPARG protein]]
boric acid results in increased expression of INS2 mRNA
CTD PMID:28285642 PMID:31368021 NCBI chr 7:142,232,393...142,233,463
Ensembl chr 7:142,232,393...142,297,118
JBrowse link
G Klf5 Kruppel-like transcription factor 5 multiple interactions EXP boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of KLF5 mRNA] CTD PMID:28285642 NCBI chr14:99,536,127...99,550,848
Ensembl chr14:99,536,127...99,552,472
JBrowse link
G Lama5 laminin, alpha 5 increases expression EXP
ISO
boric acid results in increased expression of LAMA5 mRNA CTD PMID:27206737 NCBI chr 2:179,818,166...179,867,652
Ensembl chr 2:179,818,166...179,867,652
JBrowse link
G Lep leptin multiple interactions EXP boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of LEP mRNA]; boric acid results in decreased expression of and results in decreased secretion of LEP protein CTD PMID:28285642 NCBI chr 6:29,060,220...29,073,875
Ensembl chr 6:29,060,219...29,073,876
JBrowse link
G Lipe lipase, hormone sensitive multiple interactions EXP boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of LIPE mRNA] CTD PMID:28285642 NCBI chr 7:25,078,952...25,097,911
Ensembl chr 7:25,078,952...25,098,135
JBrowse link
G Mapk1 mitogen-activated protein kinase 1 multiple interactions EXP boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased phosphorylation of MAPK1 protein] CTD PMID:28285642 NCBI chr16:16,801,246...16,865,317
Ensembl chr16:16,801,246...16,865,317
JBrowse link
G Mapk3 mitogen-activated protein kinase 3 multiple interactions EXP boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased phosphorylation of MAPK3 protein] CTD PMID:28285642 NCBI chr 7:126,358,798...126,364,988
Ensembl chr 7:126,358,773...126,364,991
JBrowse link
G Mir130a microRNA 130a decreases expression ISO boric acid results in decreased expression of MIR130A mRNA CTD PMID:34175401 NCBI chr 2:84,571,459...84,571,522
Ensembl chr 2:84,571,459...84,571,522
JBrowse link
G Mir200a microRNA 200a decreases expression ISO boric acid results in decreased expression of MIR200A mRNA CTD PMID:34175401 NCBI chr 4:156,139,353...156,139,442
Ensembl chr 4:156,139,353...156,139,442
JBrowse link
G Mir21a microRNA 21a decreases expression ISO boric acid results in decreased expression of MIR21 mRNA CTD PMID:34175401 NCBI chr11:86,474,893...86,474,984
Ensembl chr11:86,474,893...86,474,984
JBrowse link
G Mir224 microRNA 224 decreases expression ISO boric acid results in decreased expression of MIR224 mRNA CTD PMID:34175401 NCBI chr  X:71,304,637...71,304,718
Ensembl chr  X:71,304,637...71,304,718
JBrowse link
G Mmp2 matrix metallopeptidase 2 decreases expression EXP boric acid results in decreased expression of MMP2 protein CTD PMID:28285642 NCBI chr 8:93,553,920...93,580,049
Ensembl chr 8:93,553,919...93,580,048
JBrowse link
G Myh1 myosin, heavy polypeptide 1, skeletal muscle, adult affects expression ISO boric acid affects the expression of MYH1 mRNA CTD PMID:25637568 NCBI chr11:67,090,922...67,115,401
Ensembl chr11:67,090,878...67,115,401
JBrowse link
G Myod1 myogenic differentiation 1 affects expression
decreases expression
ISO boric acid affects the expression of MYOD1 mRNA
boric acid results in decreased expression of MYOD1 protein
CTD PMID:25637568 NCBI chr 7:46,025,898...46,028,516
Ensembl chr 7:46,025,898...46,028,523
JBrowse link
G Myog myogenin affects expression ISO boric acid affects the expression of MYOG mRNA CTD PMID:25637568 NCBI chr 1:134,217,742...134,220,286
Ensembl chr 1:134,217,727...134,220,286
JBrowse link
G Nfe2l2 nuclear factor, erythroid derived 2, like 2 affects localization
multiple interactions
EXP
ISO
boric acid affects the localization of NFE2L2 protein
EIF2AK3 protein affects the reaction [boric acid affects the localization of NFE2L2 protein]
CTD PMID:30196486 NCBI chr 2:75,505,860...75,535,007
Ensembl chr 2:75,505,857...75,534,985
JBrowse link
G Nfkb1 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 multiple interactions
affects expression
ISO boric acid affects the reaction [Formaldehyde results in increased expression of NFKB1 mRNA]
boric acid affects the expression of NFKB1 mRNA
CTD PMID:31823256 NCBI chr 3:135,290,416...135,397,422
Ensembl chr 3:135,290,416...135,397,308
JBrowse link
G Nos2 nitric oxide synthase 2, inducible multiple interactions EXP boric acid inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA] CTD PMID:27206737 NCBI chr11:78,811,613...78,851,052
Ensembl chr11:78,811,613...78,851,080
JBrowse link
G Nqo1 NAD(P)H dehydrogenase, quinone 1 increases expression ISO boric acid results in increased expression of NQO1 mRNA CTD PMID:30196486 NCBI chr 8:108,114,856...108,139,012
Ensembl chr 8:108,114,857...108,129,838
JBrowse link
G Pcna proliferating cell nuclear antigen increases expression
multiple interactions
ISO boric acid results in increased expression of PCNA protein
[boric acid results in increased abundance of Boron] promotes the reaction [4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta(c)quinoline results in decreased expression of PCNA protein]; [boric acid results in increased abundance of Boron] which affects the expression of PCNA protein; [boric acid results in increased abundance of Boron] which results in decreased expression of PCNA mRNA
CTD PMID:17943231 PMID:33137424 NCBI chr 2:132,091,206...132,095,100
Ensembl chr 2:132,091,082...132,095,234
JBrowse link
G Pdx1 pancreatic and duodenal homeobox 1 increases expression EXP boric acid results in increased expression of PDX1 mRNA CTD PMID:31368021 NCBI chr 5:147,206,907...147,212,658
Ensembl chr 5:147,206,769...147,212,658
JBrowse link
G Pparg peroxisome proliferator activated receptor gamma multiple interactions EXP boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of PPARG mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of PPARG protein]; CTNNB1 protein promotes the reaction [boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of PPARG protein]] CTD PMID:28285642 NCBI chr 6:115,337,828...115,467,365
Ensembl chr 6:115,337,912...115,467,360
JBrowse link
G Ppp1r15a protein phosphatase 1, regulatory subunit 15A increases expression ISO boric acid results in increased expression of PPP1R15A mRNA; boric acid results in increased expression of PPP1R15A protein CTD PMID:27587023 NCBI chr 7:45,172,341...45,175,692
Ensembl chr 7:45,172,340...45,175,692
JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 multiple interactions EXP boric acid inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA] CTD PMID:27206737 NCBI chr 1:149,975,851...149,983,978
Ensembl chr 1:149,975,782...149,983,978
JBrowse link
G Rela v-rel reticuloendotheliosis viral oncogene homolog A (avian) multiple interactions ISO boric acid inhibits the reaction [Acrylamide results in increased expression of RELA mRNA]; boric acid inhibits the reaction [Arsenic Trioxide results in increased expression of RELA mRNA]; boric acid inhibits the reaction [Arsenic Trioxide results in increased expression of RELA protein] CTD PMID:29913234 PMID:30368975 NCBI chr19:5,686,993...5,698,162
Ensembl chr19:5,687,511...5,698,158
JBrowse link
G Runx2 runt related transcription factor 2 affects expression EXP boric acid affects the expression of RUNX2 mRNA CTD PMID:24704097 NCBI chr17:44,806,873...45,125,518
Ensembl chr17:44,806,874...45,125,684
JBrowse link
G Slc2a2 solute carrier family 2 (facilitated glucose transporter), member 2 increases expression EXP boric acid results in increased expression of SLC2A2 mRNA CTD PMID:31368021 NCBI chr 3:28,752,052...28,782,510
Ensembl chr 3:28,752,052...28,785,508
JBrowse link
G Slc2a4 solute carrier family 2 (facilitated glucose transporter), member 4 multiple interactions EXP boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of SLC2A4 mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of SLC2A4 protein] CTD PMID:28285642 NCBI chr11:69,833,112...69,839,040
Ensembl chr11:69,833,365...69,839,014
JBrowse link
G Slc4a2 solute carrier family 4 (anion exchanger), member 2 increases expression ISO boric acid results in increased expression of SLC4A2 mRNA CTD PMID:22576912 NCBI chr 5:24,628,834...24,645,945
Ensembl chr 5:24,628,835...24,645,948
JBrowse link
G Slc4a3 solute carrier family 4 (anion exchanger), member 3 increases expression ISO boric acid results in increased expression of SLC4A3 mRNA CTD PMID:22576912 NCBI chr 1:75,522,688...75,536,075
Ensembl chr 1:75,522,910...75,538,816
JBrowse link
G Sparc secreted acidic cysteine rich glycoprotein affects expression EXP boric acid affects the expression of SPARC mRNA CTD PMID:24704097 NCBI chr11:55,284,985...55,310,906
Ensembl chr11:55,285,326...55,314,009
JBrowse link
G Srebf1 sterol regulatory element binding transcription factor 1 multiple interactions EXP boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of SREBF1 mRNA] CTD PMID:28285642 NCBI chr11:60,089,910...60,113,407
Ensembl chr11:60,089,915...60,113,407
JBrowse link
G Syvn1 synovial apoptosis inhibitor 1, synoviolin decreases expression ISO boric acid results in decreased expression of SYVN1 mRNA CTD PMID:27587023 NCBI chr19:6,096,586...6,103,748
Ensembl chr19:6,096,606...6,103,742
JBrowse link
G Tfrc transferrin receptor multiple interactions ISO boric acid inhibits the reaction [amyloid beta-protein (1-42) results in increased expression of TFRC mRNA]; boric acid inhibits the reaction [amyloid beta-protein (1-42) results in increased expression of TFRC protein] CTD PMID:38108610 NCBI chr16:32,427,714...32,451,612
Ensembl chr16:32,427,738...32,451,612
JBrowse link
G Tgfb1 transforming growth factor, beta 1 increases expression ISO
EXP
boric acid results in increased expression of TGFB1 protein
boric acid results in increased expression of TGFB1 mRNA
CTD PMID:27206737 PMID:31368021 NCBI chr 7:25,386,406...25,404,503
Ensembl chr 7:25,386,427...25,404,502
JBrowse link
G Tnf tumor necrosis factor multiple interactions
decreases expression
increases secretion
increases expression
ISO boric acid inhibits the reaction [Formaldehyde results in increased expression of TNF mRNA]; boric acid inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; boric acid inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]
boric acid results in decreased expression of TNF mRNA
[boric acid results in increased abundance of Boron] inhibits the reaction [bisphenol A results in increased expression of TNF mRNA]; [Food Preservatives results in increased abundance of boric acid] which results in increased expression of TNF mRNA; boric acid inhibits the reaction [Acrylamide results in increased expression of TNF mRNA]; boric acid inhibits the reaction [Arsenic Trioxide results in increased expression of TNF mRNA]; boric acid inhibits the reaction [Arsenic Trioxide results in increased expression of TNF protein]
boric acid results in increased secretion of TNF protein
boric acid results in increased expression of TNF mRNA
CTD PMID:9618283 PMID:18755394 PMID:29913234 PMID:30368975 PMID:30997025 More... NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983
JBrowse link
G Tnfrsf1a tumor necrosis factor receptor superfamily, member 1a multiple interactions EXP boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of TNFRSF1A protein] CTD PMID:28285642 NCBI chr 6:125,326,686...125,339,446
Ensembl chr 6:125,326,325...125,339,447
JBrowse link
G Trp53 transformation related protein 53 decreases expression EXP boric acid results in decreased expression of TRP53 mRNA CTD PMID:31368021 NCBI chr11:69,471,174...69,482,699
Ensembl chr11:69,471,185...69,482,699
JBrowse link
G Xbp1 X-box binding protein 1 increases expression ISO boric acid results in increased expression of XBP1 mRNA CTD PMID:27587023 NCBI chr11:5,470,641...5,475,993
Ensembl chr11:5,470,659...5,475,893
JBrowse link
boric acids term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ggt1 gamma-glutamyltransferase 1 decreases activity ISO Boric Acids analog results in decreased activity of GGT1 protein CTD PMID:6149445 NCBI chr10:75,396,910...75,422,027
Ensembl chr10:75,397,438...75,422,034
JBrowse link
G Muc1 mucin 1, transmembrane decreases expression ISO Boric Acids results in decreased expression of MUC1 mRNA CTD PMID:21060261 NCBI chr 3:89,136,363...89,140,688
Ensembl chr 3:89,136,364...89,140,688
JBrowse link
G Muc16 mucin 16 decreases expression ISO Boric Acids results in decreased expression of MUC16 mRNA CTD PMID:21060261 NCBI chr 9:18,406,741...18,586,117
Ensembl chr 9:18,406,751...18,585,826
JBrowse link
bortezomib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G 1110059E24Rik RIKEN cDNA 1110059E24 gene increases expression ISO Bortezomib results in increased expression of C9ORF85 mRNA CTD PMID:20977926 NCBI chr19:21,574,677...21,630,155
Ensembl chr19:21,558,566...21,630,340
JBrowse link
G 1810037I17Rik RIKEN cDNA 1810037I17 gene decreases expression ISO Bortezomib results in decreased expression of C4ORF3 mRNA CTD PMID:20977926 NCBI chr 3:122,718,046...122,719,843
Ensembl chr 3:122,717,852...122,719,833
JBrowse link
G 4933434E20Rik RIKEN cDNA 4933434E20 gene decreases expression ISO Bortezomib results in decreased expression of C1ORF43 mRNA CTD PMID:20977926 NCBI chr 3:89,958,941...89,969,754
Ensembl chr 3:89,958,943...89,970,648
Ensembl chr 3:89,958,943...89,970,648
JBrowse link
G Abca2 ATP-binding cassette, sub-family A member 2 decreases expression ISO Bortezomib results in decreased expression of ABCA2 mRNA CTD PMID:20977926 NCBI chr 2:25,318,611...25,338,556
Ensembl chr 2:25,318,715...25,338,552
JBrowse link
G Abcb1a ATP-binding cassette, sub-family B member 1A multiple interactions
decreases expression
decreases activity
ISO
EXP
[Bortezomib co-treated with Doxorubicin] results in decreased expression of ABCB1 protein; ATP2A1 protein affects the reaction [Bortezomib results in decreased expression of ABCB1]; Bortezomib inhibits the reaction [CERS2 protein affects the expression of ABCB1 protein]; Bortezomib inhibits the reaction [CERS6 protein affects the expression of ABCB1 protein]; Bortezomib promotes the reaction [Chloroquine results in decreased expression of ABCB1 mRNA]; Bortezomib promotes the reaction [Chloroquine results in decreased expression of and results in increased nitrosation of ABCB1 protein]; Bortezomib results in decreased expression of and results in increased nitrosation of ABCB1 protein; Chloroquine promotes the reaction [Bortezomib results in decreased expression of ABCB1 mRNA]; Chloroquine promotes the reaction [Bortezomib results in decreased expression of and results in increased nitrosation of ABCB1 protein]
[Chloroquine co-treated with Bortezomib] results in decreased expression of ABCB1A protein; Bortezomib promotes the reaction [Chloroquine results in decreased expression of ABCB1A mRNA]; Bortezomib promotes the reaction [Chloroquine results in decreased expression of and results in increased nitrosation of ABCB1A protein]; Bortezomib results in decreased expression of and results in increased nitrosation of ABCB1A protein; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in decreased expression of ABCB1A protein]; Chloroquine promotes the reaction [Bortezomib results in decreased expression of ABCB1A mRNA]; Chloroquine promotes the reaction [Bortezomib results in decreased expression of and results in increased nitrosation of ABCB1A protein]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in decreased expression of ABCB1A protein]]
Bortezomib results in decreased expression of ABCB1; Bortezomib results in decreased expression of ABCB1 mRNA; Bortezomib results in decreased expression of ABCB1 protein
Bortezomib results in decreased activity of ABCB1 protein
CTD PMID:25576094 PMID:30482226 PMID:33775688 PMID:34915026 NCBI chr 5:8,617,091...8,798,575
Ensembl chr 5:8,710,077...8,798,575
JBrowse link
G Abcc1 ATP-binding cassette, sub-family C member 1 decreases expression
multiple interactions
ISO Bortezomib results in decreased expression of ABCC1 mRNA
[Bortezomib co-treated with Doxorubicin] results in decreased expression of ABCC1 protein
CTD PMID:20977926 PMID:33775688 NCBI chr16:14,179,317...14,292,743
Ensembl chr16:14,179,422...14,293,601
JBrowse link
G Abcc2 ATP-binding cassette, sub-family member 2 increases expression ISO Bortezomib results in increased expression of ABCC2 mRNA CTD PMID:21215737 NCBI chr19:43,770,747...43,826,771
Ensembl chr19:43,770,631...43,829,179
JBrowse link
G Abcc4 ATP-binding cassette, sub-family C member 4 decreases expression ISO Bortezomib results in decreased expression of ABCC4 mRNA CTD PMID:20977926 NCBI chr14:118,720,104...118,945,475
Ensembl chr14:118,720,104...118,943,631
JBrowse link
G Abhd16a abhydrolase domain containing 16A increases expression ISO Bortezomib results in increased expression of ABHD16A mRNA CTD PMID:20977926 NCBI chr17:35,308,210...35,321,963
Ensembl chr17:35,308,239...35,321,963
JBrowse link
G Abhd2 abhydrolase domain containing 2 increases expression ISO Bortezomib results in increased expression of ABHD2 mRNA CTD PMID:20977926 NCBI chr 7:78,923,002...79,015,257
Ensembl chr 7:78,922,947...79,015,256
JBrowse link
G Abi1 abl interactor 1 increases expression ISO Bortezomib results in increased expression of ABI1 mRNA CTD PMID:20977926 NCBI chr 2:22,830,085...22,930,207
Ensembl chr 2:22,830,085...22,930,253
JBrowse link
G Abl1 c-abl oncogene 1, non-receptor tyrosine kinase multiple interactions ISO [alvocidib co-treated with Bortezomib co-treated with ABL1 protein] results in decreased phosphorylation of LYN protein; [alvocidib co-treated with Bortezomib co-treated with ABL1] results in decreased phosphorylation of CRKL protein; [alvocidib co-treated with Bortezomib] results in decreased expression of ABL1 protein; [arsenic trioxide co-treated with Bortezomib] results in decreased expression of ABL1 protein; [Bortezomib co-treated with N,N-dimethylsphingosine] results in decreased expression of ABL1 protein; Bortezomib promotes the reaction [Dichlororibofuranosylbenzimidazole results in decreased expression of ABL1 protein] CTD PMID:15039284 PMID:17495969 PMID:21195056 NCBI chr 2:31,578,256...31,697,105
Ensembl chr 2:31,578,388...31,694,239
JBrowse link
G Ace angiotensin I converting enzyme multiple interactions ISO [Butyrates co-treated with Bortezomib] results in increased activity of ACE protein mutant form CTD PMID:20454656 NCBI chr11:105,858,774...105,880,790
Ensembl chr11:105,858,771...105,880,790
JBrowse link
G Acot7 acyl-CoA thioesterase 7 decreases expression ISO Bortezomib results in decreased expression of ACOT7 mRNA CTD PMID:20977926 NCBI chr 4:152,258,872...152,356,312
Ensembl chr 4:152,262,591...152,356,312
JBrowse link
G Adam10 a disintegrin and metallopeptidase domain 10 decreases expression ISO Bortezomib results in decreased expression of ADAM10 mRNA CTD PMID:20977926 NCBI chr 9:70,586,133...70,687,511
Ensembl chr 9:70,586,279...70,687,511
JBrowse link
G Adm adrenomedullin multiple interactions
decreases expression
ISO Bortezomib inhibits the reaction [arsenic trioxide results in decreased expression of ADM mRNA]
Bortezomib results in decreased expression of ADM mRNA
CTD PMID:20471514 NCBI chr 7:110,226,864...110,229,027
Ensembl chr 7:110,226,868...110,229,027
JBrowse link
G Aff1 AF4/FMR2 family, member 1 increases expression ISO Bortezomib results in increased expression of AFF1 mRNA CTD PMID:20977926 NCBI chr 5:103,840,307...104,003,188
Ensembl chr 5:103,840,240...104,003,188
JBrowse link
G Aff4 AF4/FMR2 family, member 4 increases expression ISO Bortezomib results in increased expression of AFF4 mRNA CTD PMID:20977926 NCBI chr11:53,240,807...53,312,657
Ensembl chr11:53,241,660...53,312,657
JBrowse link
G Afg2a AFG2 AAA ATPase homolog A increases expression ISO Bortezomib results in increased expression of AFG2A mRNA CTD PMID:20977926 NCBI chr 3:37,474,052...37,633,245
Ensembl chr 3:37,474,045...37,633,245
JBrowse link
G Ager advanced glycosylation end product-specific receptor increases expression
multiple interactions
ISO Bortezomib results in increased expression of AGER mRNA
Berberine inhibits the reaction [Bortezomib results in increased expression of AGER mRNA]
CTD PMID:35121005 NCBI chr17:34,816,545...34,819,911
Ensembl chr17:34,816,836...34,819,910
JBrowse link
G Agk acylglycerol kinase decreases expression ISO Bortezomib results in decreased expression of AGK mRNA CTD PMID:20977926 NCBI chr 6:40,302,010...40,378,723
Ensembl chr 6:40,302,106...40,373,696
JBrowse link
G Agrn agrin decreases expression ISO Bortezomib results in decreased expression of AGRN mRNA CTD PMID:20977926 NCBI chr 4:156,249,747...156,281,997
Ensembl chr 4:156,249,747...156,281,945
JBrowse link
G Agtpbp1 ATP/GTP binding protein 1 increases expression ISO Bortezomib results in increased expression of AGTPBP1 mRNA CTD PMID:20977926 NCBI chr13:59,597,348...59,705,184
Ensembl chr13:59,593,556...59,733,041
JBrowse link
G Agtrap angiotensin II, type I receptor-associated protein decreases expression ISO Bortezomib results in decreased expression of AGTRAP mRNA CTD PMID:20977926 NCBI chr 4:148,161,518...148,172,521
Ensembl chr 4:148,161,518...148,172,488
JBrowse link
G AI837181 expressed sequence AI837181 decreases expression ISO Bortezomib results in decreased expression of C11ORF68 mRNA CTD PMID:20977926 NCBI chr19:5,475,172...5,477,345
Ensembl chr19:5,475,172...5,477,341
JBrowse link
G Aifm1 apoptosis-inducing factor, mitochondrion-associated 1 affects localization
multiple interactions
ISO Bortezomib affects the localization of AIFM1 protein
[Bortezomib co-treated with Butyrates] affects the localization of AIFM1 protein; [Bortezomib co-treated with vorinostat] affects the localization of AIFM1 protein
CTD PMID:12893773 PMID:16024631 NCBI chr  X:47,563,821...47,602,440
Ensembl chr  X:47,563,821...47,602,440
JBrowse link
G Aifm2 apoptosis-inducing factor, mitochondrion-associated 2 increases expression ISO Bortezomib results in increased expression of AIFM2 mRNA CTD PMID:20977926 NCBI chr10:61,551,042...61,575,474
Ensembl chr10:61,551,042...61,575,039
JBrowse link
G Aim2 absent in melanoma 2 increases expression ISO Bortezomib results in increased expression of AIM2 mRNA CTD PMID:20977926 NCBI chr 1:173,177,105...173,293,606
Ensembl chr 1:173,178,445...173,293,606
JBrowse link
G Airim AFG2 interacting ribosome maturation factor increases expression ISO Bortezomib results in increased expression of AIRIM mRNA CTD PMID:20977926 NCBI chr 4:124,830,777...124,838,454
Ensembl chr 4:124,830,841...124,838,449
JBrowse link
G Akr1b1 aldo-keto reductase family 1 member B increases expression ISO Bortezomib results in increased expression of AKR1B1 mRNA; Bortezomib results in increased expression of AKR1B1 protein CTD PMID:21215737 NCBI chr 6:34,280,865...34,294,424
Ensembl chr 6:34,279,369...34,294,413
JBrowse link
G Akr1b10 aldo-keto reductase family 1, member B10 increases expression ISO Bortezomib results in increased expression of AKR1B10 mRNA; Bortezomib results in increased expression of AKR1B10 protein CTD PMID:21215737 NCBI chr 6:34,361,182...34,373,884
Ensembl chr 6:34,361,153...34,373,885
JBrowse link
G Akr1c18 aldo-keto reductase family 1, member C18 increases expression ISO Bortezomib results in increased expression of AKR1C3 mRNA CTD PMID:21215737 NCBI chr13:4,182,614...4,200,645
Ensembl chr13:4,182,614...4,200,653
JBrowse link
G Akr1c20 aldo-keto reductase family 1, member C20 multiple interactions
increases expression
ISO [Arsenic Trioxide co-treated with Bortezomib] results in increased expression of AKR1C1 mRNA
Bortezomib results in increased expression of AKR1C1 mRNA
CTD PMID:21215737 PMID:25913414 NCBI chr13:4,536,855...4,573,353
Ensembl chr13:4,536,848...4,573,344
JBrowse link
G Akr1c21 aldo-keto reductase family 1, member C21 affects expression ISO Bortezomib affects the expression of AKR1C2 mRNA CTD PMID:21215737 NCBI chr13:4,624,074...4,636,542
Ensembl chr13:4,624,074...4,636,540
JBrowse link
G Akr7a5 aldo-keto reductase family 7, member A5 multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of AKR7A2 mRNA CTD PMID:25522274 NCBI chr 4:139,038,005...139,046,097
Ensembl chr 4:139,038,055...139,045,737
JBrowse link
G Akt1 thymoma viral proto-oncogene 1 multiple interactions
decreases expression
decreases activity
ISO [alvocidib co-treated with Bortezomib] results in decreased expression of AKT1 protein modified form; [Bortezomib co-treated with lapatinib] results in decreased phosphorylation of AKT1 protein; [Bortezomib co-treated with lonafarnib] results in decreased expression of AKT1 protein; [Bortezomib co-treated with lonafarnib] results in decreased expression of AKT1 protein modified form; [Bortezomib co-treated with panobinostat] results in decreased activity of AKT1 protein; [Bortezomib co-treated with sorafenib] results in decreased phosphorylation of AKT1 protein; [Bortezomib results in decreased activity of CBL protein] promotes the reaction [arsenic trioxide results in increased activity of AKT1 protein]; [geldanamycin co-treated with Bortezomib] results in decreased expression of AKT1 protein; [vorinostat co-treated with Bortezomib] results in decreased phosphorylation of and results in decreased expression of AKT1 protein; AKT1 protein inhibits the reaction [[Bortezomib co-treated with sorafenib] results in increased cleavage of CASP3 protein]; AKT1 protein inhibits the reaction [[Bortezomib co-treated with sorafenib] results in increased cleavage of CASP9 protein]; AKT1 protein inhibits the reaction [[Bortezomib co-treated with sorafenib] results in increased cleavage of PARP1 protein]; AKT1 protein inhibits the reaction [[Bortezomib co-treated with TNFSF10 protein] results in increased activity of CASP8 protein]; AKT1 protein inhibits the reaction [[Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of PARP1 protein]; AKT1 protein results in decreased susceptibility to [Bortezomib co-treated with sorafenib]; Bortezomib inhibits the reaction [TNFSF10 protein results in increased activity of AKT1 protein]; Okadaic Acid inhibits the reaction [Bortezomib results in decreased expression of AKT1 protein modified form]
Bortezomib results in decreased activity of AKT1 protein
CTD PMID:15039284 PMID:15781649 PMID:16118318 PMID:16985072 PMID:18445700 More... NCBI chr12:112,620,260...112,641,266
Ensembl chr12:112,620,255...112,641,318
JBrowse link
G Alad aminolevulinate, delta-, dehydratase decreases activity
multiple interactions
EXP Bortezomib results in decreased activity of ALAD protein
Curcumin inhibits the reaction [Bortezomib results in decreased activity of ALAD protein]
CTD PMID:25352650 NCBI chr 4:62,422,762...62,438,300
Ensembl chr 4:62,427,406...62,438,155
JBrowse link
G Aldh18a1 aldehyde dehydrogenase 18 family, member A1 decreases expression ISO Bortezomib results in decreased expression of ALDH18A1 mRNA CTD PMID:20977926 NCBI chr19:40,538,701...40,576,907
Ensembl chr19:40,538,701...40,576,907
JBrowse link
G Aldh5a1 aldhehyde dehydrogenase family 5, subfamily A1 decreases expression ISO Bortezomib results in decreased expression of ALDH5A1 mRNA CTD PMID:20977926 NCBI chr13:25,091,562...25,121,740
Ensembl chr13:25,091,562...25,121,644
Ensembl chr13:25,091,562...25,121,644
JBrowse link
G Aldh6a1 aldehyde dehydrogenase family 6, subfamily A1 decreases expression ISO Bortezomib results in decreased expression of ALDH6A1 mRNA CTD PMID:20977926 NCBI chr12:84,477,491...84,497,798
Ensembl chr12:84,477,491...84,497,778
JBrowse link
G Alox12 arachidonate 12-lipoxygenase increases response to substance ISO ALOX12 gene SNP results in increased susceptibility to Bortezomib CTD PMID:20864405 NCBI chr11:70,132,283...70,146,206
Ensembl chr11:70,132,283...70,146,179
JBrowse link
G Anapc11 anaphase promoting complex subunit 11 decreases expression ISO Bortezomib results in decreased expression of ANAPC11 mRNA CTD PMID:17659339 NCBI chr11:120,489,247...120,499,024
Ensembl chr11:120,489,247...120,499,024
JBrowse link
G Anapc5 anaphase-promoting complex subunit 5 decreases expression
increases expression
ISO Bortezomib results in decreased expression of ANAPC5 mRNA
Bortezomib results in increased expression of ANAPC5 mRNA
CTD PMID:17895889 PMID:20977926 NCBI chr 5:122,925,522...122,960,402
Ensembl chr 5:122,925,522...122,959,402
JBrowse link
G Ankrd9 ankyrin repeat domain 9 increases expression ISO Bortezomib results in increased expression of ANKRD9 mRNA CTD PMID:20977926 NCBI chr12:110,942,854...110,945,516
Ensembl chr12:110,941,787...110,945,474
JBrowse link
G Ano10 anoctamin 10 increases expression ISO Bortezomib results in increased expression of ANO10 mRNA CTD PMID:20977926 NCBI chr 9:122,004,958...122,123,440
Ensembl chr 9:122,004,940...122,123,489
JBrowse link
G Ap1s1 adaptor protein complex AP-1, sigma 1 decreases expression ISO Bortezomib results in decreased expression of AP1S1 mRNA CTD PMID:20977926 NCBI chr 5:137,063,852...137,074,917
Ensembl chr 5:137,063,847...137,074,989
JBrowse link
G Ap2a1 adaptor-related protein complex 2, alpha 1 subunit decreases expression ISO Bortezomib results in decreased expression of AP2A1 mRNA CTD PMID:20977926 NCBI chr 7:44,549,797...44,578,914
Ensembl chr 7:44,549,797...44,578,920
JBrowse link
G Apobr apolipoprotein B receptor decreases expression ISO Bortezomib results in decreased expression of APOBR mRNA CTD PMID:20977926 NCBI chr 7:126,184,092...126,188,297
Ensembl chr 7:126,184,114...126,188,284
JBrowse link
G Apol9a apolipoprotein L 9a decreases expression ISO Bortezomib results in decreased expression of APOL4 mRNA CTD PMID:20977926 NCBI chr15:77,287,989...77,295,280
Ensembl chr15:77,287,989...77,295,335
JBrowse link
G Apool apolipoprotein O-like increases expression ISO Bortezomib results in increased expression of APOOL mRNA CTD PMID:20977926 NCBI chr  X:111,221,049...111,282,452
Ensembl chr  X:111,221,031...111,282,452
JBrowse link
G Aqp3 aquaporin 3 increases expression ISO Bortezomib results in increased expression of AQP3 mRNA CTD PMID:20977926 NCBI chr 4:41,092,724...41,098,183
Ensembl chr 4:41,092,722...41,098,183
JBrowse link
G Ar androgen receptor multiple interactions ISO Bortezomib binds to and results in decreased activity of AR protein; Bortezomib inhibits the reaction [Metribolone results in increased activity of AR protein] CTD PMID:25752796 PMID:30818834 NCBI chr  X:97,192,363...97,366,824
Ensembl chr  X:97,192,375...97,366,821
JBrowse link
G Arf6 ADP-ribosylation factor 6 increases expression ISO Bortezomib results in increased expression of ARF6 mRNA CTD PMID:20977926 NCBI chr12:69,418,924...69,422,754
Ensembl chr12:69,418,924...69,420,557
JBrowse link
G Arfgap1 ADP-ribosylation factor GTPase activating protein 1 decreases expression ISO Bortezomib results in decreased expression of ARFGAP1 mRNA CTD PMID:20977926 NCBI chr 2:180,608,290...180,624,319
Ensembl chr 2:180,609,018...180,624,319
JBrowse link
G Arhgap1 Rho GTPase activating protein 1 decreases expression ISO Bortezomib results in decreased expression of ARHGAP1 mRNA CTD PMID:20977926 NCBI chr 2:91,480,463...91,502,670
Ensembl chr 2:91,480,205...91,502,671
JBrowse link
G Arhgdia Rho GDP dissociation inhibitor alpha decreases expression ISO Bortezomib results in decreased expression of ARHGDIA mRNA CTD PMID:20977926 NCBI chr11:120,468,925...120,472,450
Ensembl chr11:120,468,930...120,472,450
JBrowse link
G Arid3b AT-rich interaction domain 3B multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of ARID3B mRNA CTD PMID:25522274 NCBI chr 9:57,697,636...57,744,130
Ensembl chr 9:57,697,636...57,744,076
JBrowse link
G Arl4c ADP-ribosylation factor-like 4C decreases expression ISO Bortezomib results in decreased expression of ARL4C mRNA CTD PMID:20977926 NCBI chr 1:88,625,947...88,629,913
Ensembl chr 1:88,600,847...88,629,943
JBrowse link
G Arl8a ADP-ribosylation factor-like 8A increases expression ISO Bortezomib results in increased expression of ARL8A mRNA CTD PMID:20977926 NCBI chr 1:135,074,572...135,084,007
Ensembl chr 1:135,074,562...135,084,007
JBrowse link
G Arrb1 arrestin, beta 1 decreases expression ISO Bortezomib results in decreased expression of ARRB1 mRNA CTD PMID:20977926 NCBI chr 7:99,184,356...99,255,979
Ensembl chr 7:99,184,673...99,255,978
JBrowse link
G Asap1 ArfGAP with SH3 domain, ankyrin repeat and PH domain1 decreases expression ISO Bortezomib results in decreased expression of ASAP1 mRNA CTD PMID:20977926 NCBI chr15:63,958,704...64,254,922
Ensembl chr15:63,958,706...64,254,768
JBrowse link
G Ate1 arginyltransferase 1 increases expression ISO Bortezomib results in increased expression of ATE1 mRNA CTD PMID:20977926 NCBI chr 7:129,993,219...130,122,349
Ensembl chr 7:129,993,223...130,122,099
JBrowse link
G Atf2 activating transcription factor 2 multiple interactions
increases phosphorylation
increases expression
ISO pyrazolanthrone inhibits the reaction [Bortezomib results in increased phosphorylation of ATF2 protein]
Bortezomib results in increased expression of ATF2 mRNA
CTD PMID:12393500 PMID:20977926 NCBI chr 2:73,646,853...73,723,094
Ensembl chr 2:73,646,853...73,722,983
JBrowse link
G Atf3 activating transcription factor 3 increases response to substance
multiple interactions
increases expression
ISO
EXP
ATF3 results in increased susceptibility to Bortezomib
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of ATF3 mRNA; ATF3 mutant form promotes the reaction [Bortezomib results in increased expression of PMAIP1 mRNA]
Bortezomib results in increased expression of ATF3; Bortezomib results in increased expression of ATF3 mRNA; Bortezomib results in increased expression of ATF3 protein
CTD PMID:17898295 PMID:20022965 PMID:20830808 PMID:21762082 PMID:25522274 NCBI chr 1:190,902,493...190,915,530
Ensembl chr 1:190,902,493...190,950,236
JBrowse link
G Atf4 activating transcription factor 4 multiple interactions
increases expression
decreases response to substance
ISO
EXP
1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt inhibits the reaction [Bortezomib results in increased expression of ATF4 protein]; ATF4 mutant form inhibits the reaction [Bortezomib results in increased expression of PMAIP1 mRNA]; ATF4 mutant form inhibits the reaction [Bortezomib results in increased expression of PMAIP1 protein]; Bortezomib promotes the reaction [ATF4 protein binds to PMAIP1 promoter]; Dactinomycin inhibits the reaction [Bortezomib results in increased expression of ATF4 mRNA]; Dactinomycin inhibits the reaction [Bortezomib results in increased expression of ATF4 protein]; NUPR1 mutant form promotes the reaction [Bortezomib results in increased expression of ATF4 mRNA]
Bortezomib results in increased expression of ATF4 mRNA; Bortezomib results in increased expression of ATF4 protein
ATF4 results in decreased susceptibility to Bortezomib
CTD PMID:15509775 PMID:16928686 PMID:20022965 NCBI chr15:80,139,385...80,141,746
Ensembl chr15:80,139,385...80,141,742
JBrowse link
G Atf5 activating transcription factor 5 increases expression ISO Bortezomib results in increased expression of ATF5 mRNA CTD PMID:17898295 NCBI chr 7:44,461,680...44,466,082
Ensembl chr 7:44,461,680...44,466,082
JBrowse link
G Atg5 autophagy related 5 multiple interactions EXP ATG5 gene mutant form inhibits the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]; ATG5 gene mutant form inhibits the reaction [HRAS protein promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]] CTD PMID:22842577 NCBI chr10:44,144,325...44,240,295
Ensembl chr10:44,144,354...44,240,287
JBrowse link
G Atm ataxia telangiectasia mutated multiple interactions
increases cleavage
ISO [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of ATM protein]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [Bortezomib results in increased cleavage of ATM protein] CTD PMID:12393500 NCBI chr 9:53,348,422...53,448,125
Ensembl chr 9:53,350,449...53,448,040
JBrowse link
G Atp1a3 ATPase, Na+/K+ transporting, alpha 3 polypeptide decreases expression ISO Bortezomib results in decreased expression of ATP1A3 mRNA CTD PMID:20977926 NCBI chr 7:24,677,592...24,705,338
Ensembl chr 7:24,677,592...24,705,383
JBrowse link
G Atp2a1 ATPase, Ca++ transporting, cardiac muscle, fast twitch 1 multiple interactions
affects response to substance
ISO ATP2A1 protein affects the reaction [Bortezomib results in decreased expression of ABCB1]
ATP2A1 protein affects the susceptibility to Bortezomib
CTD PMID:25576094 NCBI chr 7:126,045,032...126,062,245
Ensembl chr 7:126,045,030...126,062,280
JBrowse link
G Atp6v0e ATPase, H+ transporting, lysosomal V0 subunit E increases expression ISO Bortezomib results in increased expression of ATP6V0E1 mRNA CTD PMID:20977926 NCBI chr17:26,895,370...26,918,621
Ensembl chr17:26,882,205...26,918,621
JBrowse link
G B2m beta-2 microglobulin decreases expression ISO Bortezomib results in decreased expression of B2M protein CTD PMID:17204182 NCBI chr 2:121,978,168...121,983,563
Ensembl chr 2:121,978,167...121,983,564
JBrowse link
G B3gnt2 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2 decreases expression ISO Bortezomib results in decreased expression of B3GNT2 mRNA CTD PMID:20977926 NCBI chr11:22,784,739...22,810,336
Ensembl chr11:22,709,738...22,810,961
JBrowse link
G B4galt6 UDP-Gal:betaGlcNAc beta 1,4-galactosyltransferase, polypeptide 6 increases expression ISO Bortezomib results in increased expression of B4GALT6 mRNA CTD PMID:20977926 NCBI chr18:20,817,656...20,879,461
Ensembl chr18:20,817,656...20,879,461
JBrowse link
G Bag3 BCL2-associated athanogene 3 increases expression ISO Bortezomib results in increased expression of BAG3 mRNA CTD PMID:15509775 PMID:17659339 PMID:20471514 NCBI chr 7:128,125,307...128,148,705
Ensembl chr 7:128,125,340...128,148,705
JBrowse link
G Bak1 BCL2-antagonist/killer 1 multiple interactions
increases expression
ISO
EXP
[nutlin 3 co-treated with Bortezomib] results in increased activity of BAK1 protein; BAK1 affects the reaction [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein]
BAK1 protein results in increased susceptibility to [Bortezomib co-treated with TNFSF10 protein]
Bortezomib results in increased expression of BAK1 protein
CTD PMID:12902978 PMID:17326159 PMID:20850924 NCBI chr17:27,238,786...27,247,601
Ensembl chr17:27,238,784...27,247,983
JBrowse link
G Bard1 BRCA1 associated RING domain 1 increases response to substance ISO BARD1 mutant form results in increased susceptibility to Bortezomib CTD PMID:25522274 NCBI chr 1:71,066,694...71,142,300
Ensembl chr 1:71,066,657...71,142,305
JBrowse link
G Bax BCL2-associated X protein multiple interactions
increases expression
ISO [Bortezomib co-treated with arsenic trioxide] affects the expression of BAX protein; [nutlin 3 co-treated with Bortezomib] results in increased activity of BAX protein; BAX results in increased susceptibility to [Bortezomib co-treated with panobinostat]; Bortezomib inhibits the reaction [BAX mutant form inhibits the reaction [TNFSF10 protein results in increased localization of DIABLO protein]]
Bortezomib results in increased expression of BAX protein
CTD PMID:12902978 PMID:18445700 PMID:18718063 PMID:20383943 PMID:20850924 NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322
JBrowse link
G Bbc3 BCL2 binding component 3 increases expression ISO Bortezomib results in increased expression of BBC3 mRNA; Bortezomib results in increased expression of BBC3 protein CTD PMID:17898295 PMID:20051518 NCBI chr 7:16,042,307...16,052,130
Ensembl chr 7:16,042,318...16,052,130
JBrowse link
G Bbln bublin coiled coil protein decreases expression ISO Bortezomib results in decreased expression of BBLN mRNA CTD PMID:20977926 NCBI chr 2:32,269,120...32,271,877
Ensembl chr 2:32,267,109...32,271,950
JBrowse link
G BC005537 cDNA sequence BC005537 increases expression ISO Bortezomib results in increased expression of C6ORF62 mRNA CTD PMID:20977926 NCBI chr13:24,985,640...24,996,882
Ensembl chr13:24,985,640...25,000,180
JBrowse link
G Bcl2 B cell leukemia/lymphoma 2 multiple interactions
decreases expression
increases cleavage
increases expression
ISO [arsenic trioxide co-treated with Bortezomib] results in decreased expression of BCL2 mRNA; [Bortezomib co-treated with arsenic trioxide] affects the expression of BCL2 protein; [Bortezomib co-treated with arsenic trioxide] results in decreased expression of BCL2 protein; [Bortezomib co-treated with Butyrates] results in increased cleavage of BCL2 protein; [Bortezomib co-treated with Daunorubicin] results in decreased expression of BCL2 mRNA; [Bortezomib co-treated with vorinostat] results in increased cleavage of BCL2 protein; [geldanamycin co-treated with Bortezomib] results in decreased expression of BCL2 protein; [vorinostat co-treated with Bortezomib] results in decreased expression of BCL2 protein; BCL2 affects the reaction [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein]; lonafarnib promotes the reaction [Bortezomib results in increased cleavage of BCL2 protein modified form]
Bortezomib results in decreased expression of BCL2 mRNA; Bortezomib results in decreased expression of BCL2 protein
Bortezomib results in increased expression of BCL2 mRNA; Bortezomib results in increased expression of BCL2 protein
CTD PMID:15173093 PMID:15781649 PMID:16022909 PMID:16118318 PMID:16446371 More... NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004
JBrowse link
G Bcl2a1b B cell leukemia/lymphoma 2 related protein A1b multiple interactions
increases expression
ISO [romidepsin co-treated with Bortezomib] results in decreased expression of BCL2A1 protein
Bortezomib results in increased expression of BCL2A1A protein
CTD PMID:18223231 PMID:20051518 NCBI chr 9:89,081,326...89,089,891
Ensembl chr 9:89,081,262...89,089,880
JBrowse link
G Bcl2l1 BCL2-like 1 multiple interactions
decreases expression
increases expression
increases cleavage
decreases response to substance
ISO [alvocidib co-treated with Bortezomib] results in decreased expression of BCL2L1 protein; [geldanamycin co-treated with Bortezomib] results in decreased expression of BCL2L1 protein; [romidepsin co-treated with Bortezomib] results in decreased expression of BCL2L1 protein; [Vorinostat co-treated with Bortezomib] results in decreased expression of BCL2L1 protein alternative form; [Vorinostat co-treated with Bortezomib] results in increased expression of BCL2L1 mRNA alternative form; [Vorinostat co-treated with Bortezomib] results in increased expression of BCL2L1 protein alternative form; BCL2L1 affects the reaction [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein]; BCL2L1 protein results in decreased susceptibility to [Bortezomib co-treated with trichostatin A]; Bortezomib promotes the reaction [capillarisin results in decreased expression of BCL2L1 protein]; lonafarnib promotes the reaction [Bortezomib results in increased cleavage of BCL2L1 protein]; SCIO-469 promotes the reaction [Bortezomib results in decreased expression of BCL2L1 protein]; trichostatin A promotes the reaction [Bortezomib results in decreased expression of BCL2L1 mRNA]; trichostatin A promotes the reaction [Bortezomib results in decreased expression of BCL2L1 protein]
Bortezomib results in decreased expression of BCL2L1 mRNA; Bortezomib results in decreased expression of BCL2L1 protein
Bortezomib results in increased expression of BCL2L1 protein
BCL2L1 protein results in decreased susceptibility to Bortezomib
CTD PMID:15039284 PMID:15543232 PMID:15781649 PMID:16118318 PMID:16446371 More... NCBI chr 2:152,600,652...152,673,632
Ensembl chr 2:152,622,588...152,673,648
JBrowse link
G Bcl2l11 BCL2 like 11 multiple interactions
increases expression
increases activity
increases response to substance
ISO [Bortezomib co-treated with romidepsin] results in increased expression of BCL2L11 protein; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with romidepsin] results in increased expression of BCL2L11 protein]; Bortezomib inhibits the reaction [Arsenic Trioxide results in increased degradation of BCL2L11 protein]
Bortezomib results in increased expression of BCL2L11 protein
Bortezomib results in increased activity of BCL2L11 protein
BCL2L11 results in increased susceptibility to Bortezomib
CTD PMID:15173094 PMID:16024631 PMID:16446371 PMID:17326159 PMID:18566236 More... NCBI chr 2:127,967,958...128,004,467
Ensembl chr 2:127,967,958...128,004,467
JBrowse link
G Bcl2l2 BCL2-like 2 increases expression ISO Bortezomib results in increased expression of BCL2L2 mRNA CTD PMID:18928586 NCBI chr14:55,120,900...55,125,691
Ensembl chr14:55,120,834...55,125,691
JBrowse link
G Bcl3 B cell leukemia/lymphoma 3 multiple interactions
decreases expression
ISO [arsenic trioxide co-treated with Bortezomib] results in decreased expression of BCL3 mRNA
Bortezomib results in decreased expression of BCL3 mRNA
CTD PMID:20471514 PMID:20977926 NCBI chr 7:19,542,387...19,556,691
Ensembl chr 7:19,542,387...19,556,695
JBrowse link
G Bcl6 B cell leukemia/lymphoma 6 increases expression ISO Bortezomib results in increased expression of BCL6 mRNA CTD PMID:20977926 NCBI chr16:23,780,058...23,807,602
Ensembl chr16:23,783,802...23,807,602
JBrowse link
G Bcl7a B cell CLL/lymphoma 7A decreases expression ISO Bortezomib results in decreased expression of BCL7A mRNA CTD PMID:20977926 NCBI chr 5:123,482,511...123,512,146
Ensembl chr 5:123,481,897...123,513,055
JBrowse link
G Bcr BCR activator of RhoGEF and GTPase decreases expression ISO Bortezomib results in decreased expression of BCR mRNA CTD PMID:20977926 NCBI chr10:74,896,384...75,020,753
Ensembl chr10:74,896,424...75,020,753
JBrowse link
G Becn1 beclin 1, autophagy related multiple interactions
decreases response to substance
ISO BECN1 mutant form promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]
BECN1 protein results in decreased susceptibility to Bortezomib
CTD PMID:22842577 NCBI chr11:101,179,084...101,193,112
Ensembl chr11:101,176,778...101,193,112
JBrowse link
G Bid BH3 interacting domain death agonist increases cleavage
multiple interactions
ISO Bortezomib results in increased cleavage of BID protein
[Bortezomib co-treated with Butyrates] results in decreased expression of BID protein; [Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of BID protein; [Bortezomib co-treated with vorinostat] results in decreased expression of BID protein; [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein] which results in increased cleavage of BID protein; [TNFSF10 protein co-treated with Bortezomib] results in increased cleavage of BID protein; [vorinostat co-treated with Bortezomib] results in increased cleavage of BID protein; Bortezomib promotes the reaction [TNFSF10 protein results in increased cleavage of BID protein]
CTD PMID:12893773 PMID:12902978 PMID:15930312 PMID:17326159 PMID:17351739 More... NCBI chr 6:120,870,080...120,894,074
Ensembl chr 6:120,868,891...120,893,814
JBrowse link
G Bik BCL2-interacting killer increases response to substance
increases expression
increases activity
ISO BIK results in increased susceptibility to Bortezomib
Bortezomib results in increased expression of BIK protein
Bortezomib results in increased activity of BIK protein
CTD PMID:16446371 PMID:18566236 NCBI chr15:83,410,992...83,428,836
Ensembl chr15:83,411,063...83,428,835
JBrowse link
G Bin1 bridging integrator 1 increases expression ISO Bortezomib results in increased expression of BIN1 mRNA CTD PMID:17659339 NCBI chr18:32,509,671...32,568,793
Ensembl chr18:32,510,283...32,568,790
JBrowse link
G Birc2 baculoviral IAP repeat-containing 2 decreases expression
multiple interactions
ISO Bortezomib results in decreased expression of BIRC2 protein
[geldanamycin co-treated with Bortezomib] results in decreased expression of BIRC2 protein; [romidepsin co-treated with Bortezomib] results in decreased expression of BIRC2 protein
CTD PMID:15543232 PMID:15781649 PMID:17626072 PMID:18223231 NCBI chr 9:7,818,227...7,837,123
Ensembl chr 9:7,818,228...7,837,065
JBrowse link
G Birc3 baculoviral IAP repeat-containing 3 decreases expression
increases expression
multiple interactions
ISO Bortezomib results in decreased expression of BIRC3 protein
Bortezomib results in increased expression of BIRC3 mRNA; Bortezomib results in increased expression of BIRC3 protein
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of BIRC3 mRNA
CTD PMID:17626072 PMID:24085292 PMID:25522274 NCBI chr 9:7,848,698...7,873,199
Ensembl chr 9:7,848,700...7,873,187
JBrowse link
G Birc5 baculoviral IAP repeat-containing 5 decreases expression
multiple interactions
increases expression
ISO Bortezomib results in decreased expression of BIRC5 mRNA; Bortezomib results in decreased expression of BIRC5 protein
[Irinotecan co-treated with Bortezomib] results in decreased expression of BIRC5 protein; [romidepsin co-treated with Bortezomib] results in increased cleavage of BIRC5 protein; Bortezomib promotes the reaction [capillarisin results in decreased expression of BIRC5 protein]
Bortezomib results in increased expression of BIRC5 protein
CTD PMID:16373703 PMID:17510429 PMID:17898295 PMID:18223231 PMID:18850583 More... NCBI chr11:117,740,063...117,746,569
Ensembl chr11:117,740,077...117,746,569
JBrowse link
G Birc7 baculoviral IAP repeat-containing 7 multiple interactions
decreases expression
ISO arsenic trioxide promotes the reaction [Bortezomib results in decreased expression of BIRC7 mRNA] CTD PMID:21867610 NCBI chr 2:180,570,402...180,575,803
Ensembl chr 2:180,570,816...180,575,803
JBrowse link
G Blk B lymphoid kinase decreases expression ISO Bortezomib results in decreased expression of BLK mRNA CTD PMID:20977926 NCBI chr14:63,610,286...63,654,636
Ensembl chr14:63,610,285...63,654,486
JBrowse link
G Blvrb biliverdin reductase B increases expression ISO Bortezomib results in increased expression of BLVRB mRNA CTD PMID:20977926 NCBI chr 7:27,147,403...27,165,406
Ensembl chr 7:27,147,403...27,165,569
JBrowse link
G Bnip3 BCL2/adenovirus E1B interacting protein 3 increases expression ISO Bortezomib results in increased expression of BNIP3 protein CTD PMID:20110775 NCBI chr 7:138,492,565...138,511,235
Ensembl chr 7:138,492,565...138,511,248
JBrowse link
G Brca1 breast cancer 1, early onset decreases expression
increases response to substance
decreases ubiquitination
multiple interactions
ISO
EXP
Bortezomib results in decreased expression of BRCA1 mRNA
BRCA1 mutant form results in increased susceptibility to Bortezomib
Bortezomib results in decreased ubiquitination of BRCA1 protein
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of AKR7A2 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of CCNF mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of CCNG2 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of CRYGEP mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of DAPK2 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of DLGAP5 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of EGLN3 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of FZD2 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of H3C6 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of LGR4 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of RPS7P5 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of THRA mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of TNFAIP8L1 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of TNKS mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased activity of E2F1 protein; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased cleavage of PARP1 protein; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of ARID3B mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of ATF3 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of BIRC3 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of CCNB1 protein; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of CRYAB mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of CTH mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of DUSP5 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of ERN1 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of FGF21 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of GADD45A mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of GDF15 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of HECW1 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of HIKESHI mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of IL7R mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of KRTAP21-1 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of MIR568 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of PAWR mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of PCYT1A mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of RND3 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of TNFAIP3 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of TNFRSF9 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of TRIB3 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of TRIML2 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of ZNF613 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased phosphorylation of RB1 protein; TP53BP1 protein affects the reaction [[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased cleavage of PARP1 protein]; TP53BP1 protein affects the reaction [[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased phosphorylation of RB1 protein]
BRCA1 gene mutant form results in increased susceptibility to Bortezomib
BRCA1 protein inhibits the reaction [BRCA1 gene mutant form results in increased susceptibility to Bortezomib]
CTD PMID:21917757 PMID:25522274 NCBI chr11:101,379,587...101,442,808
Ensembl chr11:101,379,590...101,442,781
JBrowse link
G Brca2 breast cancer 2, early onset decreases expression
multiple interactions
ISO Bortezomib results in decreased expression of BRCA2 mRNA
[arsenic trioxide co-treated with Bortezomib] results in increased expression of BRCA2 mRNA
CTD PMID:21917757 PMID:25913414 NCBI chr 5:150,445,759...150,493,612
Ensembl chr 5:150,446,095...150,493,794
JBrowse link
G Brcc3 BRCA1/BRCA2-containing complex, subunit 3 decreases expression ISO Bortezomib results in decreased expression of BRCC3 mRNA CTD PMID:20977926 NCBI chr  X:74,460,234...74,499,307
Ensembl chr  X:74,460,234...74,497,607
JBrowse link
G Brf2 BRF2, RNA polymerase III transcription initiation factor 50kDa subunit increases expression ISO Bortezomib results in increased expression of BRF2 mRNA CTD PMID:20977926 NCBI chr 8:27,613,367...27,618,743
Ensembl chr 8:27,613,392...27,618,708
JBrowse link
G Bsdc1 BSD domain containing 1 increases expression ISO Bortezomib results in increased expression of BSDC1 mRNA CTD PMID:20977926 NCBI chr 4:129,355,472...129,382,291
Ensembl chr 4:129,355,374...129,382,291
JBrowse link
G Caap1 caspase activity and apoptosis inhibitor 1 increases expression ISO Bortezomib results in increased expression of CAAP1 mRNA CTD PMID:20977926 NCBI chr 4:94,388,318...94,445,033
Ensembl chr 4:94,388,318...94,445,033
JBrowse link
G Cacna1h calcium channel, voltage-dependent, T type, alpha 1H subunit decreases degradation EXP Bortezomib results in decreased degradation of CACNA1H protein CTD PMID:30552955 NCBI chr17:25,593,259...25,655,308
Ensembl chr17:25,593,259...25,652,759
JBrowse link
G Calr calreticulin multiple interactions
increases expression
ISO
EXP
[CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of and affects the localization of CALR protein]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of CALR mRNA]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [Bortezomib results in increased expression of and affects the localization of CALR protein]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [Bortezomib results in increased expression of CALR mRNA]; [Chloroquine co-treated with Bortezomib] promotes the reaction [CEBPB protein alternative form binds to CALR promoter]; [Chloroquine co-treated with Bortezomib] results in increased expression of and affects the localization of CALR protein; [Chloroquine co-treated with Bortezomib] results in increased expression of CALR mRNA; Bortezomib promotes the reaction [CEBPB protein alternative form binds to CALR promoter]; Bortezomib results in increased expression of and affects the localization of CALR protein; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of and affects the localization of CALR protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CALR mRNA]; CEBPB protein alternative form promotes the reaction [Bortezomib results in increased expression of and affects the localization of CALR protein]; CEBPB protein alternative form promotes the reaction [Bortezomib results in increased expression of CALR mRNA]; DDIT3 protein affects the reaction [[Chloroquine co-treated with Bortezomib] affects the localization of CALR protein]; DDIT3 protein affects the reaction [Bortezomib affects the localization of CALR protein]; Doxorubicin promotes the reaction [[Chloroquine co-treated with Bortezomib] affects the localization of CALR protein]; Doxorubicin promotes the reaction [Bortezomib affects the localization of CALR protein]
[Chloroquine co-treated with Bortezomib] results in increased expression of CALR protein; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CALR protein]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CALR protein]]
CTD PMID:30482226 NCBI chr 8:85,568,717...85,573,560
Ensembl chr 8:85,568,479...85,573,563
JBrowse link
G Capn15 calpain 15 decreases expression ISO Bortezomib results in decreased expression of CAPN15 mRNA CTD PMID:20977926 NCBI chr17:26,177,338...26,204,753
Ensembl chr17:26,177,338...26,204,770
JBrowse link
G Car9 carbonic anhydrase 9 decreases expression ISO Bortezomib results in decreased expression of CA9 protein CTD PMID:16061869 NCBI chr 4:43,507,026...43,513,729
Ensembl chr 4:43,506,966...43,513,729
JBrowse link
G Card9 caspase recruitment domain family, member 9 multiple interactions ISO [arsenic trioxide co-treated with Bortezomib] results in increased expression of CARD9 mRNA CTD PMID:20471514 NCBI chr 2:26,242,199...26,250,957
Ensembl chr 2:26,242,188...26,250,930
JBrowse link
G Casp12 caspase 12 increases cleavage EXP Bortezomib results in increased cleavage of CASP12 protein CTD PMID:15509775 PMID:16357177 NCBI chr 9:5,345,419...5,373,034
Ensembl chr 9:5,345,430...5,373,032
JBrowse link
G Casp2 caspase 2 multiple interactions
increases response to substance
increases cleavage
ISO benzoylcarbonyl-valyl-aspartyl-valyl-alanyl-aspartyl-fluoromethyl ketone inhibits the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP2 protein]; Bortezomib promotes the reaction [Brefeldin A results in increased cleavage of and results in increased activity of CASP2 protein]; Bortezomib results in increased cleavage of and results in increased activity of CASP2 protein; Brefeldin A promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP2 protein]; CASP2 protein affects the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP9 protein]
CASP2 results in increased susceptibility to Bortezomib
Bortezomib results in increased cleavage of CASP2 protein
CTD PMID:15509775 PMID:16446371 PMID:18723477 NCBI chr 6:42,241,942...42,259,442
Ensembl chr 6:42,241,919...42,259,442
JBrowse link
G Casp3 caspase 3 increases activity
increases cleavage
increases expression
multiple interactions
ISO
EXP
Bortezomib results in increased activity of CASP3 protein
Bortezomib results in increased cleavage of CASP3 protein
Bortezomib results in increased expression of CASP3 protein
1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt affects the reaction [Bortezomib results in increased cleavage of CASP3 protein]; 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased cleavage of CASP3 protein]; [Arsenic Trioxide co-treated with Bortezomib] results in increased activity of CASP3 protein; [Arsenic Trioxide co-treated with Bortezomib] results in increased cleavage of CASP3 protein; [Bortezomib co-treated with 1-(2-cyano-3,12-dioxooleana-1,9-dien-28-oyl) imidazole] results in increased activity of CASP3 protein; [Bortezomib co-treated with abexinostat] results in increased activity of CASP3 protein; [Bortezomib co-treated with Arsenic Trioxide] affects the expression of CASP3 protein; [Bortezomib co-treated with Arsenic Trioxide] results in increased activity of CASP3 protein; [Bortezomib co-treated with Arsenic Trioxide] results in increased expression of CASP3 protein; [Bortezomib co-treated with Butyrates] results in increased cleavage of and results in increased activity of CASP3 protein; [Bortezomib co-treated with Chloroquine] results in increased cleavage of CASP3 protein; [Bortezomib co-treated with Doxorubicin] results in increased cleavage of CASP3 protein; [Bortezomib co-treated with N,N-dimethylsphingosine] results in increased cleavage of and results in increased activity of CASP3 protein; [Bortezomib co-treated with oblimersen co-treated with Cyclophosphamide] results in increased activity of CASP3 protein; [Bortezomib co-treated with Sorafenib] results in increased cleavage of CASP3 protein; [Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of CASP3 protein; [Bortezomib co-treated with trichostatin A] results in increased cleavage of and results in increased activity of CASP3 protein; [Bortezomib co-treated with Vorinostat] results in increased activity of CASP3 protein; [Bortezomib co-treated with Vorinostat] results in increased cleavage of and results in increased activity of CASP3 protein; [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein] which results in increased cleavage of CASP3 protein; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of ATM protein]; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of MDM2 protein]; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of PRKDC protein]; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased phosphorylation of TP53 protein]; [Cisplatin co-treated with Bortezomib] results in increased activity of CASP3 protein; [Dexamethasone co-treated with Bortezomib] results in increased activity of CASP3 protein; [gambogic acid co-treated with Bortezomib] results in increased activity of CASP3 protein; [lonafarnib co-treated with Bortezomib] results in increased cleavage of CASP3 protein; [nutlin 3 co-treated with Bortezomib] results in increased activity of CASP3 protein; [TNFSF10 protein co-treated with Bortezomib] results in increased activity of CASP3 protein; [trichostatin A co-treated with Bortezomib] results in increased cleavage of CASP3 protein; [Vorinostat co-treated with Bortezomib] results in increased activity of CASP3 protein; [Vorinostat co-treated with Bortezomib] results in increased cleavage of CASP3 protein; AKT1 protein inhibits the reaction [[Bortezomib co-treated with Sorafenib] results in increased cleavage of CASP3 protein]; BECN1 mutant form promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [[gambogic acid co-treated with Bortezomib] results in increased activity of CASP3 protein]; Betulinic Acid inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; Betulinic Acid inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; Boc-D-FMK inhibits the reaction [[Bortezomib co-treated with Sorafenib] results in increased cleavage of CASP3 protein]; Bortezomib promotes the reaction [belinostat results in increased cleavage of CASP3 protein]; Bortezomib promotes the reaction [Butyrates results in increased activity of CASP3 protein]; Bortezomib promotes the reaction [capillarisin results in increased cleavage of CASP3 protein]; Bortezomib promotes the reaction [gallium nitrate results in increased activity of CASP3 protein]; Bortezomib promotes the reaction [NSC606985 results in increased activity of CASP3 protein]; Bortezomib promotes the reaction [romidepsin results in increased cleavage of CASP3 protein]; Bortezomib promotes the reaction [Thapsigargin results in increased activity of CASP3 protein]; Bortezomib promotes the reaction [TNFSF10 protein results in increased activity of CASP3 protein]; Bortezomib promotes the reaction [Tunicamycin results in increased activity of CASP3 protein]; Bortezomib promotes the reaction [Vorinostat results in increased activity of CASP3 protein]; Bortezomib promotes the reaction [ZFAND2A protein affects the cleavage of CASP3 protein]; Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein; DDIT3 protein affects the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; DDIT3 protein affects the reaction [Bortezomib results in increased cleavage of CASP3 protein]; Doxorubicin promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; Doxorubicin promotes the reaction [Bortezomib results in increased cleavage of CASP3 protein]; MAPK14 mutant form inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; Nitroprusside promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; Nitroprusside promotes the reaction [Bortezomib results in increased cleavage of CASP3 protein]; PMAIP1 protein promotes the reaction [[Bortezomib co-treated with Arsenic Trioxide] results in increased activity of CASP3 protein]; pyrazolanthrone inhibits the reaction [Bortezomib results in increased activity of CASP3 protein]; pyrazolanthrone inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; ricolinostat promotes the reaction [Bortezomib results in increased cleavage of CASP3 protein]; SCIO-469 promotes the reaction [Bortezomib results in increased cleavage of CASP3 protein]; STK4 mutant form inhibits the reaction [Bortezomib results in increased activity of CASP3 protein]; TNFRSF10B mutant form inhibits the reaction [[Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of CASP3 protein]; TNFRSF10B mutant form inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; TNFSF10 protein promotes the reaction [Bortezomib results in increased activity of CASP3 protein]; ZFAND2A protein inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]
1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased cleavage of CASP3 protein]; [Bortezomib co-treated with Chloroquine] results in increased cleavage of CASP3 protein; [Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein; [SCIO-469 co-treated with Bortezomib] results in increased activity of CASP3 protein; ATG5 gene mutant form inhibits the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]; ATG5 gene mutant form inhibits the reaction [HRAS protein promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]]; Betulinic Acid inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; Betulinic Acid inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; Doxorubicin promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased cleavage of CASP3 protein]; Doxorubicin promotes the reaction [Bortezomib results in increased cleavage of CASP3 protein]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]]; HRAS protein promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]; Nitroprusside promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; Nitroprusside promotes the reaction [Bortezomib results in increased cleavage of CASP3 protein]
CTD PMID:12393500 PMID:12893773 PMID:15070698 PMID:15173093 PMID:15509775 More... NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724
JBrowse link
G Casp4 caspase 4, apoptosis-related cysteine peptidase multiple interactions
increases response to substance
increases cleavage
increases activity
ISO [Bortezomib co-treated with vorinostat] results in increased activity of CASP4 protein; CASP4 protein results in increased susceptibility to [Cisplatin co-treated with Bortezomib]; PMAIP1 protein promotes the reaction [[Bortezomib co-treated with vorinostat] results in increased activity of CASP4 protein]; pyrazolanthrone inhibits the reaction [Bortezomib results in increased cleavage of CASP4 protein]
CASP4 protein results in increased susceptibility to Bortezomib
Bortezomib results in increased activity of CASP4 protein
CTD PMID:16357177 PMID:18641367 NCBI chr 9:5,308,816...5,336,791
Ensembl chr 9:5,308,828...5,336,783
JBrowse link
G Casp6 caspase 6 multiple interactions
increases cleavage
ISO Bortezomib promotes the reaction [TNFSF10 protein results in increased cleavage of CASP6 protein]; SCIO-469 promotes the reaction [Bortezomib results in increased cleavage of CASP6 protein] CTD PMID:16617327 PMID:17510429 NCBI chr 3:129,695,064...129,707,761
Ensembl chr 3:129,695,074...129,707,752
JBrowse link
G Casp7 caspase 7 multiple interactions
increases cleavage
increases activity
ISO [Bortezomib co-treated with trichostatin A] results in increased cleavage of and results in increased activity of CASP7 protein; Bortezomib promotes the reaction [ZFAND2A protein affects the cleavage of CASP7 protein]; Bortezomib results in increased cleavage of and results in increased activity of CASP7 protein; SCIO-469 promotes the reaction [Bortezomib results in increased cleavage of CASP7 protein]; ZFAND2A protein affects the reaction [Bortezomib results in increased cleavage of CASP7 protein]
Bortezomib results in increased activity of CASP7 protein
CTD PMID:16024631 PMID:16617327 PMID:16904634 PMID:18342500 PMID:18534018 More... NCBI chr19:56,382,640...56,430,780
Ensembl chr19:56,385,561...56,430,776
JBrowse link
G Casp8 caspase 8 multiple interactions
increases cleavage
ISO [Arsenic Trioxide co-treated with Bortezomib] results in decreased expression of CASP8 mRNA; [Bortezomib co-treated with 1-(2-cyano-3,12-dioxooleana-1,9-dien-28-oyl) imidazole] results in increased activity of CASP8 protein; [Bortezomib co-treated with Arsenic Trioxide] results in increased expression of CASP8 protein; [Bortezomib co-treated with Butyrates] results in increased cleavage of and results in increased activity of CASP8 protein; [Bortezomib co-treated with TNFSF10 protein] results in increased activity of CASP8 protein; [Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of CASP8 protein; [Bortezomib co-treated with trichostatin A] results in increased cleavage of and results in increased activity of CASP8 protein; [Bortezomib co-treated with Vorinostat] results in increased activity of CASP8 protein; [Bortezomib co-treated with Vorinostat] results in increased cleavage of and results in increased activity of CASP8 protein; [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein] which results in increased cleavage of CASP8 protein; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of ATM protein]; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of MDM2 protein]; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of PRKDC protein]; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased phosphorylation of TP53 protein]; [gambogic acid co-treated with Bortezomib] results in increased activity of CASP8 protein; [IFNA2 protein co-treated with Bortezomib] results in increased activity of CASP8 protein; [lonafarnib co-treated with Bortezomib] results in increased cleavage of CASP8 protein; [TNFSF10 protein co-treated with Bortezomib] results in increased cleavage of CASP8 protein; [trichostatin A co-treated with Bortezomib] results in increased cleavage of CASP8 protein; [Vorinostat co-treated with Bortezomib] results in increased cleavage of CASP8 protein; AKT1 protein inhibits the reaction [[Bortezomib co-treated with TNFSF10 protein] results in increased activity of CASP8 protein]; Bortezomib promotes the reaction [abexinostat results in increased cleavage of CASP8 protein]; Bortezomib promotes the reaction [Arsenic Trioxide results in increased activity of CASP8 protein]; Bortezomib promotes the reaction [Butyrates results in increased activity of CASP8 protein]; Bortezomib promotes the reaction [TNFSF10 protein results in increased activity of CASP8 protein]; Bortezomib promotes the reaction [TNFSF10 protein results in increased cleavage of CASP8 protein]; Bortezomib promotes the reaction [Vorinostat results in increased activity of CASP8 protein]; Bortezomib promotes the reaction [ZFAND2A protein affects the cleavage of CASP8 protein]; Bortezomib results in increased cleavage of and results in increased activity of CASP8 protein; CDKN1A protein affects the reaction [[TNFSF10 protein co-treated with Bortezomib] results in increased cleavage of CASP8 protein]; ricolinostat promotes the reaction [Bortezomib results in increased cleavage of CASP8 protein]; SCIO-469 promotes the reaction [Bortezomib results in increased cleavage of CASP8 protein]; TNFRSF10B mutant form inhibits the reaction [[Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of CASP8 protein]; TNFRSF10B mutant form inhibits the reaction [Bortezomib results in increased cleavage of CASP8 protein]; ZFAND2A protein affects the reaction [Bortezomib results in increased cleavage of CASP8 protein] CTD PMID:12393500 PMID:12893773 PMID:12902978 PMID:15070698 PMID:15173093 More... NCBI chr 1:58,834,553...58,886,663
Ensembl chr 1:58,834,533...58,886,662
JBrowse link
G Casp9 caspase 9 multiple interactions
increases expression
increases response to substance
increases cleavage
ISO 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt affects the reaction [Bortezomib results in increased cleavage of CASP9 protein]; [Bortezomib co-treated with 1-(2-cyano-3,12-dioxooleana-1,9-dien-28-oyl) imidazole] results in increased activity of CASP9 protein; [Bortezomib co-treated with Arsenic Trioxide] results in increased activity of CASP9 protein; [Bortezomib co-treated with Arsenic Trioxide] results in increased expression of CASP9 protein; [Bortezomib co-treated with Butyrates] results in increased cleavage of and results in increased activity of CASP9 protein; [Bortezomib co-treated with Sorafenib] results in increased cleavage of CASP9 protein; [Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of CASP9 protein; [Bortezomib co-treated with trichostatin A] results in increased cleavage of and results in increased activity of CASP9 protein; [Bortezomib co-treated with Vorinostat] results in increased activity of CASP9 protein; [Bortezomib co-treated with Vorinostat] results in increased cleavage of and results in increased activity of CASP9 protein; [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein] which results in increased cleavage of CASP9 protein; [gambogic acid co-treated with Bortezomib] results in increased activity of CASP9 protein; [lonafarnib co-treated with Bortezomib] results in increased cleavage of CASP9 protein; [nutlin 3 co-treated with Bortezomib] results in increased activity of CASP9 protein; [ricolinostat co-treated with Bortezomib] results in increased cleavage of CASP9 protein; [trichostatin A co-treated with Bortezomib] results in increased cleavage of CASP9 protein; AKT1 protein inhibits the reaction [[Bortezomib co-treated with Sorafenib] results in increased cleavage of CASP9 protein]; benzoylcarbonyl-valyl-aspartyl-valyl-alanyl-aspartyl-fluoromethyl ketone inhibits the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP9 protein]; benzyloxycarbonyl-leucyl-glutamyl-histidyl-aspartic acid fluoromethyl ketone inhibits the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP9 protein]; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [[gambogic acid co-treated with Bortezomib] results in increased activity of CASP9 protein]; Bortezomib promotes the reaction [abexinostat results in increased cleavage of CASP9 protein]; Bortezomib promotes the reaction [Arsenic Trioxide results in increased activity of CASP9 protein]; Bortezomib promotes the reaction [belinostat results in increased cleavage of CASP9 protein]; Bortezomib promotes the reaction [Butyrates results in increased activity of CASP9 protein]; Bortezomib promotes the reaction [romidepsin results in increased cleavage of CASP9 protein]; Bortezomib promotes the reaction [Vorinostat results in increased activity of CASP9 protein]; Bortezomib promotes the reaction [ZFAND2A protein affects the cleavage of CASP9 protein]; Bortezomib results in increased cleavage of and results in increased activity of CASP9 protein; CASP2 protein affects the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP9 protein]; SCIO-469 promotes the reaction [Bortezomib results in increased cleavage of CASP9 protein]; TNFSF10 protein promotes the reaction [Bortezomib results in increased cleavage of CASP9 protein]; ZFAND2A protein affects the reaction [Bortezomib results in increased cleavage of CASP9 protein]
Bortezomib results in increased expression of CASP9 protein
CASP9 gene SNP results in increased susceptibility to Bortezomib; CASP9 results in increased susceptibility to Bortezomib
CTD PMID:12893773 PMID:15070698 PMID:15173093 PMID:15509775 PMID:16024631 More... NCBI chr 4:141,520,923...141,543,289
Ensembl chr 4:141,520,923...141,543,287
JBrowse link
G Cat catalase decreases expression
multiple interactions
ISO Bortezomib results in decreased expression of CAT protein
Berberine inhibits the reaction [Bortezomib results in decreased expression of CAT protein]
CTD PMID:35121005 NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505
JBrowse link
G Cbl Casitas B-lineage lymphoma multiple interactions ISO [Bortezomib results in decreased activity of CBL protein] promotes the reaction [arsenic trioxide results in increased activity of AKT1 protein] CTD PMID:19457607 NCBI chr 9:44,054,273...44,145,556
Ensembl chr 9:44,054,273...44,145,346
JBrowse link
G Cbr3 carbonyl reductase 3 increases expression ISO [Bortezomib results in increased expression of NFE2L2 protein] which results in increased expression of CBR3 mRNA; Bortezomib results in increased expression of CBR3 mRNA CTD PMID:20806931 PMID:20977926 NCBI chr16:93,480,107...93,487,879
Ensembl chr16:93,480,103...93,487,878
JBrowse link
G Cbx3 chromobox 3 increases expression ISO Bortezomib results in increased expression of CBX3 mRNA CTD PMID:20977926 NCBI chr 6:51,447,596...51,460,684
Ensembl chr 6:51,447,340...51,460,684
JBrowse link
G Ccar1 cell division cycle and apoptosis regulator 1 increases expression ISO Bortezomib results in increased expression of CCAR1 protein CTD PMID:21594647 PMID:21903591 NCBI chr10:62,579,707...62,628,147
Ensembl chr10:62,579,707...62,628,065
JBrowse link
G Ccdc186 coiled-coil domain containing 186 increases expression ISO Bortezomib results in increased expression of CCDC186 mRNA CTD PMID:20977926 NCBI chr19:56,775,917...56,810,631
Ensembl chr19:56,775,913...56,810,622
JBrowse link
G Ccdc32 coiled-coil domain containing 32 increases expression ISO Bortezomib results in increased expression of CCDC32 mRNA CTD PMID:20977926 NCBI chr 2:118,848,260...118,859,887
Ensembl chr 2:118,848,260...118,859,874
JBrowse link
G Ccdc6 coiled-coil domain containing 6 decreases expression ISO Bortezomib results in decreased expression of CCDC6 mRNA CTD PMID:20977926 NCBI chr10:69,932,709...70,029,030
Ensembl chr10:69,932,951...70,029,030
JBrowse link
G Ccdc82 coiled-coil domain containing 82 increases expression ISO Bortezomib results in increased expression of CCDC82 mRNA CTD PMID:20977926 NCBI chr 9:13,246,573...13,292,867
Ensembl chr 9:13,246,536...13,292,867
JBrowse link
G Ccl2 C-C motif chemokine ligand 2 decreases expression ISO Bortezomib results in decreased expression of CCL2 mRNA CTD PMID:20471514 NCBI chr11:81,926,403...81,928,278
Ensembl chr11:81,926,397...81,928,279
JBrowse link
G Ccl3 C-C motif chemokine ligand 3 increases expression
decreases expression
ISO
EXP
Bortezomib results in increased expression of CCL3 mRNA; Bortezomib results in increased expression of CCL3 protein
Bortezomib results in decreased expression of CCL3 mRNA
CTD PMID:18089816 PMID:20830808 NCBI chr11:83,538,669...83,540,204
Ensembl chr11:83,538,670...83,540,181
JBrowse link
G Ccl8 C-C motif chemokine ligand 8 affects expression ISO Bortezomib affects the expression of CCL8 protein CTD PMID:19922463 NCBI chr11:82,006,011...82,007,625
Ensembl chr11:82,006,011...82,007,625
JBrowse link
G Ccnb1 cyclin B1 multiple interactions
increases expression
ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of CCNB1 protein; Bortezomib results in increased ubiquitination of and results in increased expression of CCNB1 protein
Bortezomib results in increased expression of CCNB1 protein
CTD PMID:19074855 PMID:20367638 PMID:25522274 NCBI chr13:100,915,247...100,922,994
Ensembl chr13:100,915,158...100,923,078
JBrowse link
G Ccnd1 cyclin D1 multiple interactions ISO [[Bortezomib co-treated with Butyrates] results in increased abundance of Reactive Oxygen Species] which results in decreased expression of CCND1 protein; [[Bortezomib co-treated with Vorinostat] results in increased abundance of Reactive Oxygen Species] which results in decreased expression of CCND1 protein; [Bortezomib co-treated with Butyrates] results in decreased expression of CCND1 protein; [Bortezomib co-treated with Vorinostat] results in decreased expression of CCND1 protein; [geldanamycin co-treated with Bortezomib] results in decreased expression of CCND1 protein; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with Butyrates] results in decreased expression of CCND1 protein]; Boc-D-FMK inhibits the reaction [[Bortezomib co-treated with Butyrates] results in decreased expression of CCND1 protein]; Boc-D-FMK inhibits the reaction [[Bortezomib co-treated with Vorinostat] results in decreased expression of CCND1 protein]; Bortezomib promotes the reaction [capillarisin results in decreased expression of CCND1 protein] CTD PMID:12893773 PMID:15173093 PMID:15781649 PMID:24333736 NCBI chr 7:144,483,668...144,493,568
Ensembl chr 7:144,483,668...144,493,662
JBrowse link
G Ccnd2 cyclin D2 decreases expression ISO Bortezomib results in decreased expression of CCND2 mRNA CTD PMID:20977926 NCBI chr 6:127,102,125...127,131,913
Ensembl chr 6:127,102,125...127,129,156
JBrowse link
G Ccnf cyclin F multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of CCNF mRNA CTD PMID:25522274 NCBI chr17:24,441,518...24,470,333
Ensembl chr17:24,441,172...24,470,458
JBrowse link
G Ccng2 cyclin G2 multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of CCNG2 mRNA CTD PMID:25522274 NCBI chr 5:93,415,432...93,424,090
Ensembl chr 5:93,415,116...93,424,090
JBrowse link
G Ccpg1 cell cycle progression 1 increases expression ISO Bortezomib results in increased expression of CCPG1 mRNA CTD PMID:20471514 PMID:20977926 NCBI chr 9:72,892,692...72,923,622
Ensembl chr 9:72,892,711...72,923,622
JBrowse link
G Cd27 CD27 antigen increases expression ISO Bortezomib results in increased expression of CD27 mRNA CTD PMID:17895889 NCBI chr 6:125,209,583...125,214,014
Ensembl chr 6:125,209,585...125,213,973
JBrowse link
G Cd38 CD38 antigen decreases expression ISO Bortezomib results in decreased expression of CD38 mRNA CTD PMID:20977926 NCBI chr 5:44,026,153...44,069,714
Ensembl chr 5:44,025,895...44,069,717
JBrowse link
G Cd5 CD5 antigen decreases expression ISO Bortezomib results in decreased expression of CD5 mRNA CTD PMID:20977926 NCBI chr19:10,695,471...10,716,390
Ensembl chr19:10,694,480...10,716,366
JBrowse link
G Cd69 CD69 antigen increases expression ISO Bortezomib results in increased expression of CD69 mRNA CTD PMID:20977926 NCBI chr 6:129,244,287...129,252,332
Ensembl chr 6:129,244,288...129,252,399
JBrowse link
G Cd79a CD79A antigen (immunoglobulin-associated alpha) decreases expression ISO Bortezomib results in decreased expression of CD79A mRNA CTD PMID:20977926 NCBI chr 7:24,596,922...24,601,283
Ensembl chr 7:24,596,806...24,601,622
JBrowse link
G Cd82 CD82 antigen decreases expression ISO Bortezomib results in decreased expression of CD82 mRNA CTD PMID:20977926 NCBI chr 2:93,249,447...93,293,295
Ensembl chr 2:93,249,456...93,293,485
JBrowse link
G Cd9 CD9 antigen increases expression ISO Bortezomib results in increased expression of CD9 mRNA CTD PMID:20977926 NCBI chr 6:125,437,229...125,471,723
Ensembl chr 6:125,437,229...125,471,754
JBrowse link
G Cdc23 CDC23 cell division cycle 23 increases expression ISO Bortezomib results in increased expression of CDC23 mRNA CTD PMID:20977926 NCBI chr18:34,761,401...34,784,802
Ensembl chr18:34,764,004...34,784,788
JBrowse link
G Cdc34 cell division cycle 34 increases expression ISO Bortezomib results in increased expression of CDC34 mRNA CTD PMID:20977926 NCBI chr10:79,518,029...79,524,232
Ensembl chr10:79,518,029...79,524,232
JBrowse link
G Cdc37 cell division cycle 37 increases expression ISO Bortezomib results in increased expression of CDC37 mRNA CTD PMID:17895889 NCBI chr 9:21,050,727...21,061,230
Ensembl chr 9:21,044,518...21,061,278
JBrowse link
G Cdc42 cell division cycle 42 decreases expression ISO Bortezomib results in decreased expression of CDC42 mRNA CTD PMID:20977926 NCBI chr 4:137,047,011...137,085,007
Ensembl chr 4:137,047,007...137,085,031
JBrowse link
G Cdc42se2 CDC42 small effector 2 decreases expression ISO Bortezomib results in decreased expression of CDC42SE2 mRNA CTD PMID:20977926 NCBI chr11:54,608,241...54,678,549
Ensembl chr11:54,608,282...54,678,501
JBrowse link
G Cdk1 cyclin dependent kinase 1 multiple interactions
increases phosphorylation
increases activity
decreases activity
ISO Bortezomib inhibits the reaction [docetaxel results in increased activity of CDK1 protein]
Bortezomib results in increased phosphorylation of CDK1 protein
Bortezomib results in increased activity of CDK1 protein
Bortezomib results in decreased activity of CDK1 protein
CTD PMID:14749476 PMID:16928825 PMID:19074855 PMID:20367638 NCBI chr10:69,170,976...69,188,742
Ensembl chr10:69,170,976...69,188,768
JBrowse link
G Cdk2 cyclin dependent kinase 2 multiple interactions
decreases activity
ISO Bortezomib inhibits the reaction [docetaxel results in increased activity of CDK2 protein]
Bortezomib results in decreased activity of CDK2 protein
CTD PMID:14749476 NCBI chr10:128,533,807...128,540,920
Ensembl chr10:128,533,808...128,540,900
JBrowse link
G Cdkn1a cyclin dependent kinase inhibitor 1A increases stability
multiple interactions
decreases response to substance
increases expression
ISO Bortezomib results in increased stability of CDKN1A protein
[Bortezomib co-treated with Butyrates] results in increased cleavage of CDKN1A protein; [Bortezomib co-treated with Butyrates] results in increased expression of and results in increased cleavage of CDKN1A protein; [Bortezomib co-treated with vorinostat] results in increased cleavage of CDKN1A protein; [Bortezomib co-treated with vorinostat] results in increased expression of and results in increased cleavage of CDKN1A protein; [TNFSF10 protein co-treated with Bortezomib] results in increased expression of CDKN1A protein; [trichostatin A co-treated with Bortezomib] results in increased expression of CDKN1A mRNA; [trichostatin A co-treated with Bortezomib] results in increased expression of CDKN1A protein; [vorinostat co-treated with Bortezomib] results in increased expression of CDKN1A protein; Bortezomib promotes the reaction [abexinostat results in increased expression of CDKN1A protein]; CDKN1A protein affects the reaction [[TNFSF10 protein co-treated with Bortezomib] results in increased cleavage of CASP8 protein]; CDKN1A results in decreased susceptibility to [Bortezomib co-treated with docetaxel]
CDKN1A results in decreased susceptibility to Bortezomib
Bortezomib results in increased expression of CDKN1A mRNA; Bortezomib results in increased expression of CDKN1A protein
CTD PMID:12893773 PMID:12902978 PMID:14749476 PMID:15173093 PMID:15543232 More... NCBI chr17:29,309,953...29,319,696
Ensembl chr17:29,309,950...29,319,701
JBrowse link
G Cdkn1b cyclin dependent kinase inhibitor 1B multiple interactions
increases stability
increases expression
ISO [Bortezomib co-treated with Butyrates] results in increased cleavage of CDKN1B protein; [Bortezomib co-treated with vorinostat] results in increased cleavage of CDKN1B protein; [vorinostat co-treated with Bortezomib] results in increased expression of CDKN1B protein; Bortezomib promotes the reaction [lapatinib results in increased expression of CDKN1B protein]; Cisplatin promotes the reaction [Bortezomib results in increased expression of CDKN1B protein]; lapatinib promotes the reaction [Bortezomib results in increased expression of CDKN1B protein]
Bortezomib results in increased stability of CDKN1B protein
CTD PMID:14749476 PMID:15173093 PMID:15543232 PMID:18223318 PMID:18445700 More... NCBI chr 6:134,897,364...134,902,488
Ensembl chr 6:134,897,364...134,902,476
JBrowse link
G Cdt1 chromatin licensing and DNA replication factor 1 decreases expression ISO Bortezomib results in decreased expression of CDT1 mRNA CTD PMID:17659339 NCBI chr 8:123,294,754...123,299,869
Ensembl chr 8:123,294,754...123,300,293
JBrowse link
G Cebpa CCAAT/enhancer binding protein alpha multiple interactions ISO Bortezomib inhibits the reaction [NSC606985 results in decreased expression of CEBPA protein] CTD PMID:19662097 NCBI chr 7:34,818,718...34,821,353
Ensembl chr 7:34,818,718...34,821,353
JBrowse link
G Cebpb CCAAT/enhancer binding protein beta multiple interactions
decreases expression
increases expression
ISO
EXP
1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of CEBPB protein alternative form]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of CEBPB protein alternative form]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of and affects the localization of CALR protein]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of CALR mRNA]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [Bortezomib results in increased expression of and affects the localization of CALR protein]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [Bortezomib results in increased expression of CALR mRNA]; [Chloroquine co-treated with Bortezomib] promotes the reaction [CEBPB protein alternative form binds to CALR promoter]; [Chloroquine co-treated with Bortezomib] results in increased expression of CEBPB protein alternative form; Betulinic Acid inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CEBPB protein alternative form]; Betulinic Acid inhibits the reaction [Bortezomib results in increased expression of CEBPB protein alternative form]; Bortezomib inhibits the reaction [Arsenic Trioxide results in decreased expression of CEBPB mRNA]; Bortezomib promotes the reaction [CEBPB protein alternative form binds to CALR promoter]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of and affects the localization of CALR protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CALR mRNA]; CEBPB protein alternative form promotes the reaction [Bortezomib results in increased expression of and affects the localization of CALR protein]; CEBPB protein alternative form promotes the reaction [Bortezomib results in increased expression of CALR mRNA]; Doxorubicin promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CEBPB protein alternative form]; Doxorubicin promotes the reaction [Bortezomib results in increased expression of CEBPB protein alternative form]
Bortezomib results in decreased expression of CEBPB mRNA
1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CEBPB protein alternative form]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of CEBPB protein alternative form]; [Chloroquine co-treated with Bortezomib] results in increased expression of CEBPB protein alternative form; Betulinic Acid inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CEBPB protein alternative form]; Betulinic Acid inhibits the reaction [Bortezomib results in increased expression of CEBPB protein alternative form]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in decreased expression of ABCB1A protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CALR protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of IFNG protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of MKI67 protein]; Doxorubicin promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CEBPB protein alternative form]; Doxorubicin promotes the reaction [Bortezomib results in increased expression of CEBPB protein alternative form]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in decreased expression of ABCB1A protein]]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CALR protein]]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of IFNG protein]]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of MKI67 protein]]
CTD PMID:20471514 PMID:20830808 PMID:30482226 NCBI chr 2:167,530,835...167,532,352
Ensembl chr 2:167,530,835...167,532,338
JBrowse link
G Cenpc1 centromere protein C1 increases expression ISO Bortezomib results in increased expression of CENPC mRNA CTD PMID:20977926 NCBI chr 5:86,159,877...86,214,325
Ensembl chr 5:86,159,883...86,213,442
JBrowse link
G Cep290 centrosomal protein 290 increases expression ISO Bortezomib results in increased expression of CEP290 mRNA CTD PMID:20977926 NCBI chr10:100,323,410...100,409,527
Ensembl chr10:100,323,420...100,410,702
JBrowse link
G Cers2 ceramide synthase 2 multiple interactions ISO Bortezomib inhibits the reaction [CERS2 protein affects the expression of ABCB1 protein] CTD PMID:34915026 NCBI chr 3:95,222,077...95,230,910
Ensembl chr 3:95,222,102...95,230,910
JBrowse link
G Cers6 ceramide synthase 6 multiple interactions ISO Bortezomib inhibits the reaction [CERS6 protein affects the expression of ABCB1 protein] CTD PMID:34915026 NCBI chr 2:68,691,489...68,944,628
Ensembl chr 2:68,691,785...68,944,626
JBrowse link
G Cflar CASP8 and FADD-like apoptosis regulator affects expression
multiple interactions
decreases response to substance
decreases expression
increases expression
ISO Bortezomib affects the expression of CFLAR protein
[Bortezomib co-treated with TNFSF10 protein] results in decreased expression of CFLAR protein; [romidepsin co-treated with Bortezomib] results in decreased expression of CFLAR protein; TNFSF10 protein promotes the reaction [Bortezomib results in decreased expression of CFLAR protein]
CFLAR protein alternative form results in decreased susceptibility to Bortezomib; CFLAR results in decreased susceptibility to Bortezomib
Bortezomib results in decreased expression of CFLAR mRNA; Bortezomib results in decreased expression of CFLAR protein
Bortezomib results in increased expression of CFLAR protein; Bortezomib results in increased expression of CFLAR protein alternative form; Bortezomib results in increased expression of CFLAR protein modified form
CTD PMID:17326159 PMID:17327374 PMID:17351739 PMID:17510429 PMID:17659339 More... NCBI chr 1:58,750,353...58,798,043
Ensembl chr 1:58,750,667...58,798,043
JBrowse link
G Cgref1 cell growth regulator with EF hand domain 1 increases expression ISO Bortezomib results in increased expression of CGREF1 mRNA CTD PMID:17895889 NCBI chr 5:31,090,487...31,102,771
Ensembl chr 5:31,090,487...31,102,935
JBrowse link
G Chac1 ChaC, cation transport regulator 1 increases expression ISO Bortezomib results in increased expression of CHAC1 mRNA CTD PMID:15509775 NCBI chr 2:119,181,723...119,184,807
Ensembl chr 2:119,181,710...119,184,862
JBrowse link
G Chaf1a chromatin assembly factor 1, subunit A decreases expression ISO Bortezomib results in decreased expression of CHAF1A mRNA CTD PMID:17659339 NCBI chr17:56,347,404...56,375,027
Ensembl chr17:56,347,439...56,379,289
JBrowse link
G Chd2 chromodomain helicase DNA binding protein 2 increases expression ISO Bortezomib results in increased expression of CHD2 mRNA CTD PMID:20977926 NCBI chr 7:73,076,400...73,191,494
Ensembl chr 7:73,076,386...73,191,578
JBrowse link
G Chfr checkpoint with forkhead and ring finger domains decreases expression ISO Bortezomib results in decreased expression of CHFR mRNA CTD PMID:20977926 NCBI chr 5:110,283,599...110,319,839
Ensembl chr 5:110,283,708...110,319,838
JBrowse link
G Chst11 carbohydrate sulfotransferase 11 decreases expression ISO Bortezomib results in decreased expression of CHST11 mRNA CTD PMID:20977926 NCBI chr10:82,820,274...83,031,738
Ensembl chr10:82,821,332...83,031,734
JBrowse link
G Chst2 carbohydrate sulfotransferase 2 decreases expression ISO Bortezomib results in decreased expression of CHST2 mRNA CTD PMID:20977926 NCBI chr 9:95,282,979...95,289,323
Ensembl chr 9:95,281,345...95,288,775
JBrowse link
G Chuk conserved helix-loop-helix ubiquitous kinase increases expression
increases activity
ISO Bortezomib results in increased expression of CHUK mRNA
Bortezomib results in increased activity of CHUK protein
CTD PMID:20471514 PMID:24085292 NCBI chr19:44,061,773...44,095,940
Ensembl chr19:44,061,774...44,095,919
JBrowse link
G Cideb cell death-inducing DNA fragmentation factor, alpha subunit-like effector B decreases expression ISO Bortezomib results in decreased expression of CIDEB mRNA CTD PMID:17659339 NCBI chr14:55,991,509...55,995,881
Ensembl chr14:55,991,507...55,995,915
JBrowse link
G Cilk1 ciliogenesis associated kinase 1 increases expression ISO Bortezomib results in increased expression of CILK1 mRNA CTD PMID:20977926 NCBI chr 9:78,016,425...78,079,396
Ensembl chr 9:78,016,474...78,079,389
JBrowse link
G Clec7a C-type lectin domain family 7, member a increases expression ISO Bortezomib results in increased expression of CLEC7A mRNA CTD PMID:20977926 NCBI chr 6:129,438,554...129,449,748
Ensembl chr 6:129,438,554...129,449,742
JBrowse link
G Clip4 CAP-GLY domain containing linker protein family, member 4 increases expression ISO Bortezomib results in increased expression of CLIP4 mRNA CTD PMID:20977926 NCBI chr17:72,076,674...72,171,205
Ensembl chr17:72,075,468...72,171,268
JBrowse link
G Cln6 ceroid-lipofuscinosis, neuronal 6 decreases expression ISO Bortezomib results in decreased expression of CLN6 mRNA CTD PMID:20977926 NCBI chr 9:62,746,067...62,759,288
Ensembl chr 9:62,746,067...62,759,288
JBrowse link
G Clptm1 cleft lip and palate associated transmembrane protein 1 decreases expression ISO Bortezomib results in decreased expression of CLPTM1 mRNA CTD PMID:20977926 NCBI chr 7:19,365,505...19,398,955
Ensembl chr 7:19,365,496...19,398,958
JBrowse link
G Clu clusterin increases expression ISO Bortezomib results in increased expression of CLU mRNA CTD PMID:20977926 NCBI chr14:66,206,093...66,218,992
Ensembl chr14:66,205,932...66,218,996
JBrowse link
G Cox8a cytochrome c oxidase subunit 8A decreases expression ISO Bortezomib results in decreased expression of COX8A mRNA CTD PMID:30818834 NCBI chr19:7,192,523...7,194,981
Ensembl chr19:7,192,518...7,194,981
JBrowse link
G Cpt1c carnitine palmitoyltransferase 1c increases response to substance ISO CPT1C gene SNP results in increased susceptibility to Bortezomib CTD PMID:20864405 NCBI chr 7:44,607,907...44,624,304
Ensembl chr 7:44,608,796...44,624,275
JBrowse link
G Creb1 cAMP responsive element binding protein 1 multiple interactions
decreases expression
ISO Berberine inhibits the reaction [Bortezomib results in decreased expression of CREB1 protein] CTD PMID:35121005 NCBI chr 1:64,571,963...64,643,707
Ensembl chr 1:64,571,804...64,643,707
JBrowse link
G Crebbp CREB binding protein decreases expression ISO Bortezomib results in decreased expression of CREBBP mRNA CTD PMID:25913414 NCBI chr16:3,899,198...4,031,864
Ensembl chr16:3,899,192...4,031,861
JBrowse link
G Crem cAMP responsive element modulator increases expression ISO Bortezomib results in increased expression of CREM mRNA CTD PMID:20977926 NCBI chr18:3,263,181...3,337,688
Ensembl chr18:3,266,048...3,337,748
JBrowse link
G Crip2 cysteine rich protein 2 decreases expression ISO Bortezomib results in decreased expression of CRIP2 mRNA CTD PMID:20977926 NCBI chr12:113,103,856...113,109,126
Ensembl chr12:113,103,856...113,109,126
JBrowse link
G Cripto cripto, EGF-CFC family member increases expression ISO Bortezomib results in increased expression of CRIPTO mRNA CTD PMID:17895889 NCBI chr 9:110,768,676...110,775,226
Ensembl chr 9:110,768,671...110,775,226
JBrowse link
G Crkl v-crk avian sarcoma virus CT10 oncogene homolog-like multiple interactions ISO [alvocidib co-treated with Bortezomib co-treated with ABL1] results in decreased phosphorylation of CRKL protein CTD PMID:15039284 NCBI chr16:17,269,849...17,305,304
Ensembl chr16:17,269,851...17,305,298
JBrowse link
G Cryab crystallin, alpha B multiple interactions
increases expression
ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of CRYAB mRNA
Bortezomib results in increased expression of CRYAB mRNA
CTD PMID:20830808 PMID:25522274 NCBI chr 9:50,657,251...50,667,936
Ensembl chr 9:50,662,625...50,667,936
JBrowse link
G Cst7 cystatin F (leukocystatin) increases expression ISO Bortezomib results in increased expression of CST7 mRNA CTD PMID:20977926 NCBI chr 2:150,412,335...150,420,864
Ensembl chr 2:150,412,335...150,420,864
JBrowse link
G Ctdspl2 CTD small phosphatase like 2 decreases expression ISO Bortezomib results in decreased expression of CTDSPL2 mRNA CTD PMID:20977926 NCBI chr 2:121,785,879...121,845,807
Ensembl chr 2:121,786,482...121,844,123
JBrowse link
G Cth cystathionine gamma lyase multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of CTH mRNA CTD PMID:25522274 NCBI chr 3:157,599,885...157,630,718
Ensembl chr 3:157,599,885...157,630,714
JBrowse link
G Ctnnb1 catenin beta 1 multiple interactions
decreases response to substance
increases expression
ISO 2-methoxyestradiol inhibits the reaction [CTNNB1 protein results in decreased susceptibility to Bortezomib]; arsenic trioxide inhibits the reaction [CTNNB1 protein results in decreased susceptibility to Bortezomib]; TNFSF10 protein inhibits the reaction [Bortezomib results in increased expression of CTNNB1 protein] CTD PMID:18485479 PMID:19100720 NCBI chr 9:120,762,466...120,789,573
Ensembl chr 9:120,758,282...120,789,573
JBrowse link
G Ctsb cathepsin B multiple interactions
increases localization
ISO 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt inhibits the reaction [Bortezomib results in increased localization of CTSB protein] CTD PMID:16446371 NCBI chr14:63,359,911...63,383,372
Ensembl chr14:63,359,911...63,383,372
JBrowse link
G Ctsd cathepsin D increases expression ISO Bortezomib results in increased expression of CTSD mRNA CTD PMID:20977926 NCBI chr 7:141,929,647...141,941,564
Ensembl chr 7:141,929,648...141,941,775
JBrowse link
G Cul1 cullin 1 increases expression ISO Bortezomib results in increased expression of CUL1 mRNA CTD PMID:17895889 NCBI chr 6:47,430,516...47,503,078
Ensembl chr 6:47,430,332...47,503,073
JBrowse link
G Cul3 cullin 3 decreases expression ISO Bortezomib results in decreased expression of CUL3 mRNA CTD PMID:17659339 NCBI chr 1:80,242,640...80,318,426
Ensembl chr 1:80,242,640...80,318,197
JBrowse link
G Cwf19l1 CWF19 like cell cycle control factor 1 decreases expression ISO Bortezomib results in decreased expression of CWF19L1 mRNA CTD PMID:20977926 NCBI chr19:44,097,076...44,124,324
Ensembl chr19:44,097,076...44,124,315
JBrowse link
G Cxcl1 C-X-C motif chemokine ligand 1 increases expression ISO Bortezomib results in increased expression of CXCL1 mRNA CTD PMID:15509775 NCBI chr 5:91,039,104...91,040,980
Ensembl chr 5:91,039,100...91,040,974
JBrowse link
G Cxcl15 C-X-C motif chemokine ligand 15 increases expression
multiple interactions
increases secretion
ISO Bortezomib results in increased expression of CXCL8 mRNA
Bortezomib inhibits the reaction [Vorinostat results in increased expression of CXCL8 mRNA]; SC 514 inhibits the reaction [Bortezomib results in increased secretion of CXCL8 protein]
CTD PMID:15509775 PMID:15514602 PMID:17172406 PMID:24085292 NCBI chr 5:90,942,393...90,950,926
Ensembl chr 5:90,942,393...90,950,926
JBrowse link
G Cxcl2 C-X-C motif chemokine ligand 2 increases expression
multiple interactions
EXP
ISO
Bortezomib results in increased expression of CXCL2 mRNA
Bortezomib results in increased expression of CXCL2 mRNA; Bortezomib results in increased expression of CXCL2 protein
Bortezomib inhibits the reaction [Fluorouracil results in increased expression of CXCL2 mRNA]
CTD PMID:20830808 PMID:27194111 NCBI chr 5:91,051,758...91,053,797
Ensembl chr 5:91,051,730...91,053,797
JBrowse link
G Cxcl3 C-X-C motif chemokine ligand 3 multiple interactions
increases expression
EXP
ISO
Bortezomib inhibits the reaction [Fluorouracil results in increased expression of CXCL1 mRNA]
Bortezomib results in increased expression of CXCL1 mRNA
CTD PMID:15509775 PMID:27194111 NCBI chr 5:90,933,960...90,935,952
Ensembl chr 5:90,933,962...90,937,459
JBrowse link
G Cxcr4 C-X-C motif chemokine receptor 4 decreases expression ISO Bortezomib results in decreased expression of CXCR4 mRNA CTD PMID:20977926 NCBI chr 1:128,515,936...128,520,036
Ensembl chr 1:128,515,936...128,520,030
JBrowse link
G Cyb5r1 cytochrome b5 reductase 1 increases expression ISO Bortezomib results in increased expression of CYB5R1 mRNA CTD PMID:20977926 NCBI chr 1:134,333,519...134,339,476
Ensembl chr 1:134,333,297...134,339,478
JBrowse link
G Cyba cytochrome b-245, alpha polypeptide decreases expression ISO Bortezomib results in decreased expression of CYBA mRNA CTD PMID:20977926 NCBI chr 8:123,151,510...123,159,679
Ensembl chr 8:123,151,515...123,159,669
JBrowse link
G Cycs cytochrome c, somatic multiple interactions
affects localization
ISO [Bortezomib co-treated with Butyrates] affects the localization of CYCS protein; [Bortezomib co-treated with vorinostat] affects the localization of CYCS protein
Bortezomib affects the localization of CYCS protein
CTD PMID:12893773 PMID:16024631 NCBI chr 6:50,539,543...50,543,549
Ensembl chr 6:50,539,543...50,543,518
JBrowse link
G Cyp1a2 cytochrome P450, family 1, subfamily a, polypeptide 2 affects metabolic processing ISO CYP1A2 protein affects the metabolism of Bortezomib CTD PMID:15764713 NCBI chr 9:57,584,220...57,590,938
Ensembl chr 9:57,584,220...57,590,986
JBrowse link
G Cyp2c38 cytochrome P450, family 2, subfamily c, polypeptide 38 affects metabolic processing ISO CYP2C19 protein affects the metabolism of Bortezomib CTD PMID:15764713 NCBI chr19:39,379,109...39,451,519
Ensembl chr19:39,378,000...39,451,519
JBrowse link
G Cyp2c65 cytochrome P450, family 2, subfamily c, polypeptide 65 affects metabolic processing ISO CYP2C9 protein affects the metabolism of Bortezomib CTD PMID:15764713 NCBI chr19:39,049,450...39,082,392
Ensembl chr19:39,049,459...39,082,388
JBrowse link
G Cyp2d22 cytochrome P450, family 2, subfamily d, polypeptide 22 affects metabolic processing ISO CYP2D6 protein affects the metabolism of Bortezomib CTD PMID:15764713 NCBI chr15:82,254,728...82,264,461
Ensembl chr15:82,254,728...82,264,461
JBrowse link
G Cyp2u1 cytochrome P450, family 2, subfamily u, polypeptide 1 increases expression ISO Bortezomib results in increased expression of CYP2U1 mRNA CTD PMID:20977926 NCBI chr 3:131,084,140...131,097,806
Ensembl chr 3:131,082,090...131,096,876
JBrowse link
G Cytip cytohesin 1 interacting protein increases expression ISO Bortezomib results in increased expression of CYTIP mRNA CTD PMID:20977926 NCBI chr 2:58,019,151...58,085,559
Ensembl chr 2:58,019,149...58,085,544
JBrowse link
G D430019H16Rik RIKEN cDNA D430019H16 gene decreases expression ISO Bortezomib results in decreased expression of C14ORF132 mRNA CTD PMID:20977926 NCBI chr12:105,420,115...105,459,354
Ensembl chr12:105,420,115...105,459,354
JBrowse link
G Dap3 death associated protein 3 increases expression ISO Bortezomib results in increased expression of DAP3 mRNA CTD PMID:17659339 NCBI chr 3:88,828,110...88,858,504
Ensembl chr 3:88,828,110...88,858,488
JBrowse link
G Dapk2 death-associated protein kinase 2 multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of DAPK2 mRNA CTD PMID:25522274 NCBI chr 9:66,065,364...66,179,524
Ensembl chr 9:66,065,505...66,179,524
JBrowse link
G Dazap2 DAZ associated protein 2 decreases expression ISO Bortezomib results in decreased expression of DAZAP2 mRNA CTD PMID:20977926 NCBI chr15:100,513,543...100,518,642
Ensembl chr15:100,513,230...100,518,642
JBrowse link
G Dbn1 drebrin 1 increases expression ISO Bortezomib results in increased expression of DBN1 mRNA CTD PMID:20977926 NCBI chr13:55,621,241...55,635,874
Ensembl chr13:55,621,242...55,635,924
JBrowse link
G Dcaf11 DDB1 and CUL4 associated factor 11 decreases expression ISO Bortezomib results in decreased expression of DCAF11 mRNA CTD PMID:20977926 NCBI chr14:55,796,557...55,807,522
Ensembl chr14:55,797,463...55,807,522
JBrowse link
G Dcaf13 DDB1 and CUL4 associated factor 13 increases expression ISO Bortezomib results in increased expression of DCAF13 mRNA CTD PMID:20977926 NCBI chr15:38,976,300...39,010,251
Ensembl chr15:38,976,260...39,010,251
JBrowse link
G Dcps decapping enzyme, scavenger decreases expression ISO Bortezomib results in decreased expression of DCPS mRNA CTD PMID:20977926 NCBI chr 9:35,035,710...35,087,283
Ensembl chr 9:35,035,704...35,087,357
JBrowse link
G Ddit3 DNA-damage inducible transcript 3 multiple interactions
increases expression
decreases response to substance
ISO
EXP
1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of DDIT3 protein]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; [Bortezomib co-treated with Chloroquine] results in increased expression of DDIT3 protein; Betulinic Acid inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; Betulinic Acid inhibits the reaction [Bortezomib results in increased expression of DDIT3 protein]; Bortezomib inhibits the reaction [Tunicamycin results in increased expression of DDIT3 protein]; Bortezomib promotes the reaction [gambogic acid results in increased expression of DDIT3 protein]; DDIT3 protein affects the reaction [[Chloroquine co-treated with Bortezomib] affects the localization of CALR protein]; DDIT3 protein affects the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; DDIT3 protein affects the reaction [Bortezomib affects the localization of CALR protein]; DDIT3 protein affects the reaction [Bortezomib results in increased cleavage of CASP3 protein]; Doxorubicin promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of DDIT3 protein]; Doxorubicin promotes the reaction [Bortezomib results in increased expression of DDIT3 protein]; gambogic acid promotes the reaction [Bortezomib results in increased expression of DDIT3 protein]; Nitroprusside promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; Nitroprusside promotes the reaction [Bortezomib results in increased expression of DDIT3 protein]
Bortezomib results in increased expression of DDIT3 mRNA; Bortezomib results in increased expression of DDIT3 protein
1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt inhibits the reaction [Bortezomib results in increased expression of DDIT3 protein]; 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of DDIT3 protein]; [Bortezomib co-treated with Chloroquine] results in increased expression of DDIT3 protein; [Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein; Betulinic Acid inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; Betulinic Acid inhibits the reaction [Bortezomib results in increased expression of DDIT3 protein]; Bortezomib inhibits the reaction [1,2-dithiol-3-thione inhibits the reaction [Tunicamycin results in increased expression of DDIT3 mRNA]]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; Doxorubicin promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of DDIT3 protein]; Doxorubicin promotes the reaction [Bortezomib results in increased expression of DDIT3 protein]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]]; Nitroprusside inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; Nitroprusside inhibits the reaction [Bortezomib results in increased expression of DDIT3 protein]
DDIT3 results in decreased susceptibility to Bortezomib
CTD PMID:15509775 PMID:16024631 PMID:16357177 PMID:17659339 PMID:17709599 More... NCBI chr10:127,126,662...127,132,160
Ensembl chr10:127,126,643...127,132,157
Ensembl chr10:127,126,643...127,132,157
JBrowse link
G Ddx11 DEAD/H box helicase 11 decreases expression ISO Bortezomib results in decreased expression of DDX11 mRNA CTD PMID:20977926 NCBI chr17:66,430,508...66,459,169
Ensembl chr17:66,430,515...66,459,169
JBrowse link
G Deaf1 DEAF1, transcription factor decreases expression ISO Bortezomib results in decreased expression of DEAF1 mRNA CTD PMID:20977926 NCBI chr 7:140,877,089...140,918,758
Ensembl chr 7:140,877,093...140,907,603
JBrowse link
G Dedd2 death effector domain-containing DNA binding protein 2 increases expression ISO Bortezomib results in increased expression of DEDD2 mRNA CTD PMID:17659339 NCBI chr 7:24,899,337...24,920,035
Ensembl chr 7:24,899,340...24,920,040
JBrowse link
G Def6 differentially expressed in FDCP 6 decreases expression ISO Bortezomib results in decreased expression of DEF6 mRNA CTD PMID:20977926 NCBI chr17:28,426,752...28,447,582
Ensembl chr17:28,426,752...28,447,582
JBrowse link
G Dennd4a DENN domain containing 4A increases expression ISO Bortezomib results in increased expression of DENND4A mRNA CTD PMID:20977926 NCBI chr 9:64,713,408...64,826,949
Ensembl chr 9:64,718,622...64,826,949
JBrowse link
G Dennd4b DENN domain containing 4B increases expression ISO Bortezomib results in increased expression of DENND4B mRNA CTD PMID:15509775 NCBI chr 3:90,172,281...90,187,972
Ensembl chr 3:90,172,492...90,187,976
JBrowse link
G Dennd4c DENN domain containing 4C increases expression ISO Bortezomib results in increased expression of DENND4C mRNA CTD PMID:20977926 NCBI chr 4:86,666,761...86,768,841
Ensembl chr 4:86,666,792...86,768,840
JBrowse link
G Dgke diacylglycerol kinase, epsilon decreases expression ISO Bortezomib results in decreased expression of DGKE mRNA CTD PMID:20977926 NCBI chr11:88,926,005...88,951,644
Ensembl chr11:88,926,005...88,957,676
JBrowse link
G Diablo diablo, IAP-binding mitochondrial protein affects localization
increases localization
increases expression
multiple interactions
ISO Bortezomib affects the localization of DIABLO protein
Bortezomib results in increased localization of DIABLO protein
Bortezomib results in increased expression of DIABLO mRNA; Bortezomib results in increased expression of DIABLO protein
[alvocidib co-treated with Bortezomib] results in increased secretion of DIABLO protein; [Bortezomib co-treated with 1-(2-cyano-3,12-dioxooleana-1,9-dien-28-oyl) imidazole] results in decreased localization of DIABLO protein; [Bortezomib co-treated with Butyrates] affects the localization of DIABLO protein; [Bortezomib co-treated with TNFSF10 protein] results in increased expression of DIABLO protein; [Bortezomib co-treated with vorinostat] affects the localization of DIABLO protein; Bortezomib inhibits the reaction [BAX mutant form inhibits the reaction [TNFSF10 protein results in increased localization of DIABLO protein]]; Bortezomib promotes the reaction [TNFSF10 protein results in increased localization of DIABLO protein]
CTD PMID:12893773 PMID:12902978 PMID:14555532 PMID:15039284 PMID:15070698 More... NCBI chr 5:123,649,393...123,664,825
Ensembl chr 5:123,647,828...123,662,239
JBrowse link
G Dlgap5 DLG associated protein 5 multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of DLGAP5 mRNA CTD PMID:25522274 NCBI chr14:47,625,238...47,655,657
Ensembl chr14:47,625,236...47,655,864
JBrowse link
G Dnaaf5 dynein, axonemal assembly factor 5 decreases expression ISO Bortezomib results in decreased expression of DNAAF5 mRNA CTD PMID:20977926 NCBI chr 5:139,135,888...139,172,265
Ensembl chr 5:139,135,978...139,172,265
JBrowse link
G Dnajb1 DnaJ heat shock protein family (Hsp40) member B1 increases expression ISO Bortezomib results in increased expression of DNAJB1 mRNA CTD PMID:15509775 NCBI chr 8:84,334,804...84,339,282
Ensembl chr 8:84,334,822...84,339,282
JBrowse link
G Dnajc14 DnaJ heat shock protein family (Hsp40) member C14 decreases expression ISO Bortezomib results in decreased expression of DNAJC14 mRNA CTD PMID:20977926 NCBI chr10:128,641,423...128,655,317
Ensembl chr10:128,639,931...128,655,315
JBrowse link
G Dnajc4 DnaJ heat shock protein family (Hsp40) member C4 decreases expression ISO Bortezomib results in decreased expression of DNAJC4 mRNA CTD PMID:20977926 NCBI chr19:6,965,279...6,969,954
Ensembl chr19:6,965,279...6,969,940
JBrowse link
G Dnm2 dynamin 2 decreases expression ISO Bortezomib results in decreased expression of DNM2 mRNA CTD PMID:20977926 NCBI chr 9:21,336,167...21,419,055
Ensembl chr 9:21,336,204...21,419,055
JBrowse link
G Dpy19l4 dpy-19 like 4 increases expression ISO Bortezomib results in increased expression of DPY19L4 mRNA CTD PMID:20977926 NCBI chr 4:11,261,315...11,322,153
Ensembl chr 4:11,261,315...11,322,137
JBrowse link
G Dst dystonin increases expression ISO Bortezomib results in increased expression of DST mRNA CTD PMID:17659339 NCBI chr 1:33,946,969...34,347,743
Ensembl chr 1:33,947,306...34,347,742
JBrowse link
G Dusp15 dual specificity phosphatase-like 15 decreases expression ISO Bortezomib results in decreased expression of DUSP15 mRNA CTD PMID:20977926 NCBI chr 2:152,782,915...152,794,200
Ensembl chr 2:152,782,917...152,793,618
JBrowse link
G Dusp4 dual specificity phosphatase 4 decreases expression ISO Bortezomib results in decreased expression of DUSP4 mRNA CTD PMID:20977926 NCBI chr 8:35,274,448...35,289,106
Ensembl chr 8:35,274,451...35,287,048
JBrowse link
G Dusp5 dual specificity phosphatase 5 multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of DUSP5 mRNA CTD PMID:25522274 NCBI chr19:53,517,576...53,530,240
Ensembl chr19:53,517,540...53,530,862
JBrowse link
G Dync1i1 dynein cytoplasmic 1 intermediate chain 1 increases expression ISO Bortezomib results in increased expression of DYNC1I1 mRNA CTD PMID:20977926 NCBI chr 6:5,725,772...6,028,030
Ensembl chr 6:5,725,639...6,028,039
JBrowse link
G E2f1 E2F transcription factor 1 multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased activity of E2F1 protein CTD PMID:25522274 NCBI chr 2:154,401,320...154,411,812
Ensembl chr 2:154,401,327...154,411,812
JBrowse link
G Ecpas Ecm29 proteasome adaptor and scaffold increases expression ISO Bortezomib results in increased expression of ECPAS mRNA CTD PMID:20977926 NCBI chr 4:58,797,234...58,917,748
Ensembl chr 4:58,798,911...58,912,749
JBrowse link
G Edaradd EDAR associated via death domain increases expression ISO Bortezomib results in increased expression of EDARADD mRNA CTD PMID:17895889 NCBI chr13:12,486,090...12,535,413
Ensembl chr13:12,487,513...12,535,319
JBrowse link
G Egln3 egl-9 family hypoxia-inducible factor 3 multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of EGLN3 mRNA CTD PMID:25522274 NCBI chr12:54,225,767...54,250,660
Ensembl chr12:54,225,767...54,250,646
JBrowse link
G Egr1 early growth response 1 increases expression ISO Bortezomib results in increased expression of EGR1 mRNA CTD PMID:20471514 NCBI chr18:34,994,260...34,998,009
Ensembl chr18:34,992,876...34,998,037
JBrowse link
G Egr2 early growth response 2 decreases expression EXP
ISO
Bortezomib results in decreased expression of EGR2 mRNA
Bortezomib results in decreased expression of EGR2 mRNA; Bortezomib results in decreased expression of EGR2 protein
CTD PMID:20830808 NCBI chr10:67,370,334...67,383,354
Ensembl chr10:67,371,305...67,378,018
JBrowse link
G Ehmt2 euchromatic histone lysine N-methyltransferase 2 decreases expression ISO Bortezomib results in decreased expression of EHMT2 mRNA CTD PMID:20977926 NCBI chr17:35,117,427...35,133,049
Ensembl chr17:35,117,445...35,133,028
JBrowse link
G Eif1 eukaryotic translation initiation factor 1 increases expression ISO Bortezomib results in increased expression of EIF1 mRNA CTD PMID:20977926 NCBI chr11:100,210,775...100,212,925
Ensembl chr11:100,210,711...100,212,922
JBrowse link
G Eif2a eukaryotic translation initiation factor 2A decreases phosphorylation ISO Bortezomib results in decreased phosphorylation of EIF2A protein CTD PMID:18641367 NCBI chr 3:58,433,252...58,464,922
Ensembl chr 3:58,433,242...58,464,922
JBrowse link
G Eif2ak3 eukaryotic translation initiation factor 2 alpha kinase 3 increases phosphorylation
multiple interactions
decreases response to substance
ISO
EXP
Bortezomib results in increased phosphorylation of EIF2AK3 protein
Bortezomib inhibits the reaction [1,2-dithiol-3-thione inhibits the reaction [Tunicamycin results in increased expression of EIF2AK3 mRNA]]
Bortezomib promotes the reaction [ricolinostat results in increased phosphorylation of EIF2AK3 protein]; EIF2AK3 mutant form inhibits the reaction [Bortezomib results in increased phosphorylation of EIF2S1 protein]
EIF2AK3 results in decreased susceptibility to Bortezomib
CTD PMID:15509775 PMID:16928686 PMID:20022965 PMID:22262760 PMID:22959925 NCBI chr 6:70,821,468...70,882,225
Ensembl chr 6:70,821,499...70,882,229
JBrowse link
G Eif2s1 eukaryotic translation initiation factor 2, subunit 1 alpha multiple interactions
increases phosphorylation
ISO
EXP
Bortezomib affects the reaction [ricolinostat results in increased phosphorylation of EIF2S1 protein]; Bortezomib inhibits the reaction [Tunicamycin results in increased phosphorylation of EIF2S1 protein]; EIF2AK3 mutant form inhibits the reaction [Bortezomib results in increased phosphorylation of EIF2S1 protein] CTD PMID:16357177 PMID:20022965 PMID:21090173 PMID:22262760 NCBI chr12:78,908,846...78,933,784
Ensembl chr12:78,908,593...78,933,784
JBrowse link
G Eif2s3x eukaryotic translation initiation factor 2, subunit 3, structural gene X-linked decreases expression ISO Bortezomib results in decreased expression of EIF2S3 mRNA CTD PMID:20977926 NCBI chr  X:93,232,315...93,256,257
Ensembl chr  X:93,232,313...93,256,468
JBrowse link
G Eif4ebp1 eukaryotic translation initiation factor 4E binding protein 1 multiple interactions ISO [trichostatin A co-treated with Bortezomib] results in decreased phosphorylation of EIF4EBP1 protein CTD PMID:21345073 NCBI chr 8:27,750,355...27,765,684
Ensembl chr 8:27,750,357...27,766,702
JBrowse link
G Eif5a eukaryotic translation initiation factor 5A decreases expression ISO Bortezomib results in decreased expression of EIF5A mRNA CTD PMID:20977926 NCBI chr11:69,807,538...69,812,784
Ensembl chr11:69,807,540...69,812,784
JBrowse link
G Elp5 elongator acetyltransferase complex subunit 5 decreases expression ISO Bortezomib results in decreased expression of ELP5 mRNA CTD PMID:20977926 NCBI chr11:69,859,050...69,872,352
Ensembl chr11:69,859,048...69,873,343
JBrowse link
G Eno2 enolase 2, gamma neuronal increases expression ISO Bortezomib results in increased expression of ENO2 mRNA CTD PMID:20977926 NCBI chr 6:124,737,018...124,746,489
Ensembl chr 6:124,737,016...124,746,636
JBrowse link
G Epha1 Eph receptor A1 decreases expression ISO Bortezomib results in decreased expression of EPHA1 mRNA CTD PMID:20977926 NCBI chr 6:42,335,421...42,350,249
Ensembl chr 6:42,335,421...42,350,202
JBrowse link
G Ephb2 Eph receptor B2 decreases expression ISO Bortezomib results in decreased expression of EPHB2 mRNA CTD PMID:20977926 NCBI chr 4:136,374,850...136,563,637
Ensembl chr 4:136,374,850...136,563,299
JBrowse link
G Erbb2 erb-b2 receptor tyrosine kinase 2 multiple interactions
decreases phosphorylation
ISO Bortezomib promotes the reaction [lapatinib results in decreased phosphorylation of ERBB2 protein]; lapatinib promotes the reaction [Bortezomib results in decreased phosphorylation of ERBB2 protein] CTD PMID:20701607 NCBI chr11:98,303,310...98,328,542
Ensembl chr11:98,303,296...98,328,542
JBrowse link
G Ercc3 excision repair cross-complementing rodent repair deficiency, complementation group 3 increases response to substance ISO ERCC3 gene SNP results in increased susceptibility to Bortezomib CTD PMID:20864405 NCBI chr18:32,373,357...32,403,206
Ensembl chr18:32,373,353...32,403,204
JBrowse link
G Ercc4 excision repair cross-complementing rodent repair deficiency, complementation group 4 increases response to substance ISO ERCC4 gene SNP results in increased susceptibility to Bortezomib CTD PMID:20864405 NCBI chr16:12,927,600...12,969,873
Ensembl chr16:12,927,548...12,968,481
JBrowse link
G Erlin2 ER lipid raft associated 2 decreases expression ISO Bortezomib results in decreased expression of ERLIN2 mRNA CTD PMID:20977926 NCBI chr 8:27,513,399...27,529,465
Ensembl chr 8:27,513,289...27,530,356
JBrowse link
G Ern1 endoplasmic reticulum to nucleus signalling 1 multiple interactions
decreases response to substance
ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of ERN1 mRNA; Bortezomib affects the reaction [ricolinostat affects the phosphorylation of ERN1 protein]
ERN1 results in decreased susceptibility to Bortezomib
CTD PMID:16357177 PMID:22262760 PMID:25522274 NCBI chr11:106,285,474...106,378,701
Ensembl chr11:106,285,476...106,378,678
JBrowse link
G Esf1 ESF1 nucleolar pre-rRNA processing protein homolog increases expression ISO Bortezomib results in increased expression of ESF1 mRNA CTD PMID:20977926 NCBI chr 2:139,961,800...140,012,498
Ensembl chr 2:139,961,803...140,012,484
JBrowse link
G Esr1 estrogen receptor 1 (alpha) multiple interactions ISO Bortezomib binds to and results in decreased activity of ESR1 protein; Bortezomib inhibits the reaction [Estradiol results in increased activity of ESR1 protein] CTD PMID:25752796 PMID:30818834 NCBI chr10:4,561,989...4,955,633
Ensembl chr10:4,561,593...4,955,614
JBrowse link
G Esr2 estrogen receptor 2 (beta) multiple interactions ISO [Arsenic Trioxide co-treated with Bortezomib] results in decreased expression of ESR2 mRNA; Bortezomib binds to and results in decreased activity of ESR2 protein; Bortezomib inhibits the reaction [Estradiol results in increased activity of ESR2 protein] CTD PMID:25752796 PMID:25913414 PMID:30818834 NCBI chr12:76,167,193...76,224,033
Ensembl chr12:76,167,193...76,224,033
JBrowse link
G Esrra estrogen related receptor, alpha decreases expression
multiple interactions
ISO Bortezomib results in decreased expression of ESRRA mRNA
Bortezomib inhibits the reaction [PPARGC1A protein results in increased activity of ESRRA protein]; Bortezomib inhibits the reaction [XCT790 results in decreased activity of ESRRA protein]
CTD PMID:20977926 PMID:30818834 NCBI chr19:6,888,345...6,899,182
Ensembl chr19:6,888,345...6,899,208
JBrowse link
G Esyt2 extended synaptotagmin-like protein 2 decreases expression ISO Bortezomib results in decreased expression of ESYT2 mRNA CTD PMID:20977926 NCBI chr12:116,242,903...116,354,555
Ensembl chr12:116,244,816...116,354,670
JBrowse link
G Etv4 ets variant 4 decreases expression ISO Bortezomib results in decreased expression of ETV4 mRNA CTD PMID:20977926 NCBI chr11:101,660,573...101,677,963
Ensembl chr11:101,660,568...101,676,197
JBrowse link
G F2rl1 F2R like trypsin receptor 1 decreases expression ISO Bortezomib results in decreased expression of F2RL1 mRNA CTD PMID:20977926 NCBI chr13:95,648,226...95,661,748
Ensembl chr13:95,648,240...95,661,735
JBrowse link
G F3 coagulation factor III increases expression
multiple interactions
ISO Bortezomib results in increased expression of F3 protein
[Dexamethasone co-treated with lenalidomide co-treated with Bortezomib] results in increased expression of F3 mRNA; [Dexamethasone co-treated with lenalidomide co-treated with Bortezomib] results in increased expression of F3 protein
CTD PMID:23696885 NCBI chr 3:121,517,186...121,528,701
Ensembl chr 3:121,517,186...121,528,697
JBrowse link
G Fads2 fatty acid desaturase 2 decreases expression ISO Bortezomib results in decreased expression of FADS2 mRNA CTD PMID:20977926 NCBI chr19:10,040,129...10,078,867
Ensembl chr19:10,040,129...10,079,110
JBrowse link
G Faf1 Fas-associated factor 1 increases expression ISO Bortezomib results in increased expression of FAF1 mRNA CTD PMID:17895889 NCBI chr 4:109,533,873...109,821,157
Ensembl chr 4:109,533,785...109,821,157
JBrowse link
G Fam118b family with sequence similarity 118, member B increases expression ISO Bortezomib results in increased expression of FAM118B mRNA CTD PMID:20977926 NCBI chr 9:35,128,261...35,179,172
Ensembl chr 9:35,128,261...35,179,101
JBrowse link
G Fam168a family with sequence similarity 168, member A increases expression ISO Bortezomib results in increased expression of FAM168A mRNA CTD PMID:20977926 NCBI chr 7:100,355,594...100,490,853
Ensembl chr 7:100,355,842...100,490,863
JBrowse link
G Fam20b FAM20B, glycosaminoglycan xylosylkinase decreases expression ISO Bortezomib results in decreased expression of FAM20B mRNA CTD PMID:20977926 NCBI chr 1:156,506,127...156,547,204
Ensembl chr 1:156,506,102...156,546,656
JBrowse link
G Fam219a family with sequence similarity 219, member A increases expression ISO Bortezomib results in increased expression of FAM219A mRNA CTD PMID:20977926 NCBI chr 4:41,517,691...41,569,538
Ensembl chr 4:41,517,691...41,569,538
JBrowse link
G Fam241b family with sequence similarity 241, member B increases expression ISO Bortezomib results in increased expression of FAM241B mRNA CTD PMID:20977926 NCBI chr10:61,943,435...61,946,829
Ensembl chr10:61,943,434...61,979,699
JBrowse link
G Fam43a family with sequence similarity 43, member A decreases expression ISO Bortezomib results in decreased expression of FAM43A mRNA CTD PMID:20977926 NCBI chr16:30,418,541...30,421,615
Ensembl chr16:30,418,541...30,421,615
JBrowse link
G Fam76a family with sequence similarity 76, member A increases expression ISO Bortezomib results in increased expression of FAM76A mRNA CTD PMID:20977926 NCBI chr 4:132,626,524...132,649,849
Ensembl chr 4:132,626,524...132,649,869
JBrowse link
G Fancd2 Fanconi anemia, complementation group D2 decreases expression ISO Bortezomib results in decreased expression of FANCD2 mRNA; Bortezomib results in decreased expression of FANCD2 protein CTD PMID:19934314 PMID:21917757 NCBI chr 6:113,508,622...113,573,981
Ensembl chr 6:113,508,643...113,573,978
JBrowse link
G Farsa phenylalanyl-tRNA synthetase, alpha subunit decreases expression ISO Bortezomib results in decreased expression of FARSA mRNA CTD PMID:20977926 NCBI chr 8:85,583,597...85,595,886
Ensembl chr 8:85,583,618...85,595,886
JBrowse link
G Fas Fas cell surface death receptor multiple interactions
decreases expression
increases expression
ISO [Bortezomib co-treated with vorinostat] results in increased expression of FAS protein
Bortezomib results in decreased expression of FAS mRNA
Bortezomib results in increased expression of FAS mRNA; Bortezomib results in increased expression of FAS protein
CTD PMID:17351739 PMID:20471514 PMID:25913414 NCBI chr19:34,267,926...34,305,175
Ensembl chr19:34,268,066...34,305,172
JBrowse link
G Fasl Fas ligand multiple interactions
increases expression
ISO [Bortezomib co-treated with vorinostat] results in increased expression of FASLG mRNA; [Bortezomib co-treated with vorinostat] results in increased expression of FASLG protein; Bortezomib promotes the reaction [arsenic trioxide results in increased activity of FASLG]; Curcumin inhibits the reaction [[vorinostat co-treated with Bortezomib] results in increased expression of FASLG protein]
Bortezomib results in increased expression of FASLG protein
CTD PMID:17351739 PMID:20471514 NCBI chr 1:161,608,260...161,616,064
Ensembl chr 1:161,608,258...161,616,064
JBrowse link
G Fastk Fas-activated serine/threonine kinase decreases expression ISO Bortezomib results in decreased expression of FASTK mRNA CTD PMID:20977926 NCBI chr 5:24,646,036...24,650,280
Ensembl chr 5:24,643,438...24,650,285
JBrowse link
G Fbln5 fibulin 5 decreases expression ISO Bortezomib results in decreased expression of FBLN5 mRNA CTD PMID:20977926 NCBI chr12:101,712,820...101,785,541
Ensembl chr12:101,712,824...101,785,314
JBrowse link
G Fbxw7 F-box and WD-40 domain protein 7 decreases expression ISO Bortezomib results in decreased expression of FBXW7 mRNA CTD PMID:20977926 NCBI chr 3:84,721,901...84,886,505
Ensembl chr 3:84,722,575...84,886,505
JBrowse link
G Fgf21 fibroblast growth factor 21 multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of FGF21 mRNA CTD PMID:25522274 NCBI chr 7:45,263,314...45,264,914
Ensembl chr 7:45,263,310...45,264,914
JBrowse link
G Fgfr1op2 FGFR1 oncogene partner 2 increases expression ISO Bortezomib results in increased expression of FGFR1OP2 mRNA CTD PMID:20977926 NCBI chr 6:146,479,401...146,500,696
Ensembl chr 6:146,478,701...146,500,696
JBrowse link
G Fkbp1a FK506 binding protein 1a decreases expression ISO Bortezomib results in decreased expression of FKBP1A mRNA CTD PMID:20977926 NCBI chr 2:151,384,403...151,403,611
Ensembl chr 2:151,384,403...151,403,612
JBrowse link
G Fkbp5 FK506 binding protein 5 decreases expression ISO Bortezomib results in decreased expression of FKBP5 mRNA CTD PMID:20977926 NCBI chr17:28,617,727...28,705,123
Ensembl chr17:28,618,068...28,736,501
JBrowse link
G Flcn folliculin increases expression ISO Bortezomib results in increased expression of FLCN mRNA CTD PMID:20977926 NCBI chr11:59,682,234...59,706,138
Ensembl chr11:59,682,234...59,700,842
JBrowse link
G Fmr1 fragile X messenger ribonucleoprotein 1 decreases expression ISO Bortezomib results in decreased expression of FMR1 mRNA CTD PMID:17659339 NCBI chr  X:67,722,144...67,761,569
Ensembl chr  X:67,722,147...67,761,569
JBrowse link
G Folr1 folate receptor alpha decreases expression ISO Bortezomib results in decreased expression of FOLR1 mRNA CTD PMID:20977926 NCBI chr 7:101,507,551...101,519,974
Ensembl chr 7:101,507,538...101,519,995
JBrowse link
G Foxa1 forkhead box A1 multiple interactions
decreases expression
ISO [arsenic trioxide co-treated with Bortezomib] results in increased expression of FOXA1 mRNA
Bortezomib results in decreased expression of FOXA1 mRNA
CTD PMID:20471514 PMID:25913414 NCBI chr12:57,585,750...57,594,815
Ensembl chr12:57,587,414...57,593,702
JBrowse link
G Fry FRY microtubule binding protein increases expression ISO Bortezomib results in increased expression of FRY mRNA CTD PMID:20977926 NCBI chr 5:150,042,083...150,421,218
Ensembl chr 5:150,042,110...150,421,218
JBrowse link
G Fsd1l fibronectin type III and SPRY domain containing 1-like increases expression ISO Bortezomib results in increased expression of FSD1L mRNA CTD PMID:20977926 NCBI chr 4:53,631,383...53,707,009
Ensembl chr 4:53,631,471...53,707,009
JBrowse link
G Fzd2 frizzled class receptor 2 multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of FZD2 mRNA CTD PMID:25522274 NCBI chr11:102,495,257...102,498,884
Ensembl chr11:102,495,222...102,498,884
JBrowse link
G G6pdx glucose-6-phosphate dehydrogenase X-linked decreases expression ISO Bortezomib results in decreased expression of G6PD mRNA CTD PMID:20977926 NCBI chr  X:73,453,089...73,472,486
Ensembl chr  X:73,453,089...73,472,800
JBrowse link
G Gabarapl1 GABA type A receptor associated protein like 1 increases expression ISO Bortezomib results in increased expression of GABARAPL1 mRNA CTD PMID:20977926 NCBI chr 6:129,510,155...129,519,294
Ensembl chr 6:129,510,123...129,519,309
JBrowse link
G Gadd45a growth arrest and DNA-damage-inducible 45 alpha increases expression
multiple interactions
ISO Bortezomib results in increased expression of GADD45A mRNA
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of GADD45A mRNA
CTD PMID:20830808 PMID:20977926 PMID:25522274 NCBI chr 6:67,012,080...67,014,391
Ensembl chr 6:67,012,080...67,014,441
JBrowse link
G Gadd45b growth arrest and DNA-damage-inducible 45 beta increases expression
multiple interactions
ISO
EXP
Bortezomib results in increased expression of GADD45B mRNA
Bortezomib inhibits the reaction [lipopolysaccharide A results in increased expression of GADD45B mRNA]
CTD PMID:15509775 PMID:15797874 PMID:17895889 PMID:17898295 NCBI chr10:80,765,925...80,768,038
Ensembl chr10:80,765,907...80,768,038
JBrowse link
G Gadd45g growth arrest and DNA-damage-inducible 45 gamma increases expression ISO Bortezomib results in increased expression of GADD45G mRNA CTD PMID:17898295 NCBI chr13:52,000,711...52,002,511
Ensembl chr13:52,000,714...52,002,504
JBrowse link
G Galnt4 polypeptide N-acetylgalactosaminyltransferase 4 increases expression ISO Bortezomib results in increased expression of GALNT4 mRNA CTD PMID:20977926 NCBI chr10:98,943,997...98,949,109
Ensembl chr10:98,944,021...98,949,109
JBrowse link
G Ganab alpha glucosidase 2 alpha neutral subunit decreases expression ISO Bortezomib results in decreased expression of GANAB mRNA CTD PMID:20977926 NCBI chr19:8,875,440...8,894,098
Ensembl chr19:8,875,435...8,894,036
JBrowse link
G Gas7 growth arrest specific 7 decreases expression ISO Bortezomib results in decreased expression of GAS7 mRNA CTD PMID:20977926 NCBI chr11:67,344,083...67,579,818
Ensembl chr11:67,345,917...67,575,800
JBrowse link
G Gbp2 guanylate binding protein 2 increases expression ISO Bortezomib results in increased expression of GBP2 mRNA CTD PMID:20977926 NCBI chr 3:142,326,424...142,343,769
Ensembl chr 3:142,326,363...142,343,769
JBrowse link
G Gclc glutamate-cysteine ligase, catalytic subunit increases expression
multiple interactions
ISO Bortezomib results in increased expression of GCLC mRNA
Berberine inhibits the reaction [Bortezomib results in increased expression of GCLC mRNA]
CTD PMID:35121005 NCBI chr 9:77,661,817...77,701,771
Ensembl chr 9:77,661,817...77,701,767
JBrowse link
G Gclm glutamate-cysteine ligase, modifier subunit increases expression
multiple interactions
ISO Bortezomib results in increased expression of GCLM mRNA
Berberine inhibits the reaction [Bortezomib results in increased expression of GCLM mRNA]
CTD PMID:35121005 NCBI chr 3:122,039,206...122,060,864
Ensembl chr 3:122,039,206...122,064,381
JBrowse link
G Gcnt2 glucosaminyl (N-acetyl) transferase 2 (I blood group) increases expression ISO Bortezomib results in increased expression of GCNT2 mRNA CTD PMID:20977926 NCBI chr13:41,013,417...41,114,368
Ensembl chr13:41,013,230...41,114,368
JBrowse link
G Gdf15 growth differentiation factor 15 increases expression
multiple interactions
ISO Bortezomib results in increased expression of GDF15 mRNA
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of GDF15 mRNA
CTD PMID:20830808 PMID:25522274 NCBI chr 8:71,082,043...71,085,106
Ensembl chr 8:71,082,043...71,085,106
JBrowse link
G Gfap glial fibrillary acidic protein increases expression
multiple interactions
ISO Bortezomib results in increased expression of GFAP mRNA
Berberine inhibits the reaction [Bortezomib results in increased expression of GFAP mRNA]
CTD PMID:35121005 NCBI chr11:102,778,162...102,791,368
Ensembl chr11:102,778,162...102,791,738
JBrowse link
G Ghr growth hormone receptor increases expression ISO Bortezomib results in increased expression of GHR mRNA CTD PMID:17895889 NCBI chr15:3,347,237...3,612,834
Ensembl chr15:3,347,242...3,612,974
JBrowse link
G Git1 GIT ArfGAP 1 decreases expression ISO Bortezomib results in decreased expression of GIT1 mRNA CTD PMID:20977926 NCBI chr11:77,384,114...77,398,600
Ensembl chr11:77,384,388...77,398,612
JBrowse link
G Gkap1 G kinase anchoring protein 1 increases expression ISO Bortezomib results in increased expression of GKAP1 mRNA CTD PMID:20977926 NCBI chr13:58,381,160...58,422,691
Ensembl chr13:58,381,160...58,423,513
JBrowse link
G Gla galactosidase, alpha increases expression ISO Bortezomib results in increased expression of GLA mRNA CTD PMID:20977926 NCBI chr  X:133,488,912...133,501,707
Ensembl chr  X:133,488,898...133,501,874
JBrowse link
G Glb1 galactosidase, beta 1 increases expression
multiple interactions
ISO Bortezomib results in increased expression of GLB1 protein
TERT protein inhibits the reaction [Bortezomib results in increased expression of GLB1 protein]
CTD PMID:36401358 NCBI chr 9:114,230,146...114,303,447
Ensembl chr 9:114,230,144...114,303,966
JBrowse link
G Gnai3 G protein subunit alpha i3 increases expression ISO Bortezomib results in increased expression of GNAI3 mRNA CTD PMID:20977926 NCBI chr 3:108,014,591...108,053,468
Ensembl chr 3:108,014,596...108,053,462
JBrowse link
G Gosr2 golgi SNAP receptor complex member 2 increases expression ISO Bortezomib results in increased expression of GOSR2 mRNA CTD PMID:20977926 NCBI chr11:103,567,675...103,590,139
Ensembl chr11:103,567,675...103,588,724
JBrowse link
G Gpank1 G patch domain and ankyrin repeats 1 increases expression ISO Bortezomib results in increased expression of GPANK1 mRNA CTD PMID:20977926 NCBI chr17:35,340,472...35,343,791
Ensembl chr17:35,340,431...35,343,790
JBrowse link
G Gpat3 glycerol-3-phosphate acyltransferase 3 increases expression ISO Bortezomib results in increased expression of GPAT3 mRNA CTD PMID:20977926 NCBI chr 5:100,994,095...101,046,968
Ensembl chr 5:100,993,579...101,046,968
JBrowse link
G Gpatch2l G patch domain containing 2 like increases expression ISO Bortezomib results in increased expression of GPATCH2L mRNA CTD PMID:20977926 NCBI chr12:86,288,569...86,341,439
Ensembl chr12:86,288,632...86,338,558
JBrowse link
G Gphn gephyrin decreases expression ISO Bortezomib results in decreased expression of GPHN mRNA CTD PMID:20977926 NCBI chr12:78,264,099...78,731,546
Ensembl chr12:78,273,153...78,731,546
JBrowse link
G Gpr157 G protein-coupled receptor 157 decreases expression ISO Bortezomib results in decreased expression of GPR157 mRNA CTD PMID:20977926 NCBI chr 4:150,171,960...150,190,457
Ensembl chr 4:150,171,822...150,190,384
JBrowse link
G Gpsm3 G-protein signalling modulator 3 (AGS3-like, C. elegans) decreases expression ISO Bortezomib results in decreased expression of GPSM3 mRNA CTD PMID:20977926 NCBI chr17:34,808,780...34,810,728
Ensembl chr17:34,808,780...34,810,728
JBrowse link
G Gsk3a glycogen synthase kinase 3 alpha multiple interactions ISO [Bortezomib co-treated with lonafarnib] results in decreased expression of GSK3A protein modified form CTD PMID:16118318 NCBI chr 7:24,927,683...24,937,276
Ensembl chr 7:24,927,683...24,937,276
JBrowse link
G Gsk3b glycogen synthase kinase 3 beta multiple interactions ISO [Bortezomib co-treated with lonafarnib] results in decreased expression of GSK3B protein modified form; Bortezomib results in decreased activity of and results in increased phosphorylation of GSK3B protein; GSK3B protein mutant form inhibits the reaction [Bortezomib results in increased degradation of NFKBIA protein]; Wortmannin inhibits the reaction [Bortezomib results in decreased activity of and results in increased phosphorylation of GSK3B protein] CTD PMID:16118318 PMID:24085292 NCBI chr16:37,909,363...38,066,446
Ensembl chr16:37,909,363...38,066,446
JBrowse link
G Gspt1 G1 to S phase transition 1 decreases expression ISO Bortezomib results in decreased expression of GSPT1 mRNA CTD PMID:20977926 NCBI chr16:11,034,104...11,072,189
Ensembl chr16:11,037,156...11,072,189
JBrowse link
G Gsr glutathione reductase increases expression ISO Bortezomib results in increased expression of GSR mRNA CTD PMID:20977926 NCBI chr 8:34,143,266...34,188,190
Ensembl chr 8:34,142,551...34,188,191
JBrowse link
G Gstcd glutathione S-transferase, C-terminal domain containing decreases expression ISO Bortezomib results in decreased expression of GSTCD mRNA CTD PMID:20977926 NCBI chr 3:132,687,511...132,797,800
Ensembl chr 3:132,687,513...132,797,794
JBrowse link
G Gstm4 glutathione S-transferase, mu 4 decreases expression ISO Bortezomib results in decreased expression of GSTM4 mRNA CTD PMID:20977926 NCBI chr 3:107,937,887...107,952,495
Ensembl chr 3:107,947,724...107,952,210
JBrowse link
G Gtf3c2 general transcription factor IIIC, polypeptide 2, beta decreases expression ISO Bortezomib results in decreased expression of GTF3C2 mRNA CTD PMID:20977926 NCBI chr 5:31,313,350...31,337,488
Ensembl chr 5:31,313,349...31,337,488
JBrowse link
G Gtpbp1 GTP binding protein 1 decreases expression ISO Bortezomib results in decreased expression of GTPBP1 mRNA CTD PMID:20977926 NCBI chr15:79,574,202...79,605,680
Ensembl chr15:79,575,046...79,605,680
JBrowse link
G Gzma granzyme A decreases expression ISO Bortezomib results in decreased expression of GZMA mRNA CTD PMID:20977926 NCBI chr13:113,230,358...113,237,515
Ensembl chr13:113,230,359...113,237,515
JBrowse link
G Gzmb granzyme B increases expression ISO Bortezomib results in increased expression of GZMB mRNA CTD PMID:20977926 NCBI chr14:56,496,293...56,499,791
Ensembl chr14:56,496,295...56,499,717
JBrowse link
G H2-DMb1 histocompatibility 2, class II, locus Mb1 decreases expression ISO Bortezomib results in decreased expression of HLA-DMB mRNA CTD PMID:20977926 NCBI chr17:34,372,165...34,379,203
Ensembl chr17:34,372,046...34,379,204
JBrowse link
G H2-Ea histocompatibility 2, class II antigen E alpha decreases expression ISO Bortezomib results in decreased expression of HLA-DRA mRNA CTD PMID:20977926 NCBI chr17:34,560,926...34,563,619
Ensembl chr17:34,560,926...34,563,618
JBrowse link
G H2-Oa histocompatibility 2, O region alpha locus decreases expression ISO Bortezomib results in decreased expression of HLA-DOA mRNA CTD PMID:20977926 NCBI chr17:34,311,353...34,314,286
Ensembl chr17:34,311,314...34,314,208
JBrowse link
G H2ax H2A.X variant histone multiple interactions
decreases phosphorylation
increases expression
ISO [Bortezomib co-treated with romidepsin] results in increased phosphorylation of H2AX protein; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with romidepsin] results in increased phosphorylation of H2AX protein]; leptomycin B promotes the reaction [Bortezomib results in increased expression of H2AX protein modified form]
Bortezomib results in decreased phosphorylation of H2AX protein
Bortezomib inhibits the reaction [Doxorubicin results in increased expression of H2AX protein]; Bortezomib inhibits the reaction [Etoposide results in increased expression of H2AX protein]
CTD PMID:15173094 PMID:16778179 PMID:17875725 PMID:18790767 PMID:32482060 NCBI chr 9:44,246,012...44,247,374
Ensembl chr 9:44,245,991...44,247,374
JBrowse link
G H3c10 H3 clustered histone 10 multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of H3C6 mRNA CTD PMID:25522274 NCBI chr13:21,901,798...21,902,285
Ensembl chr13:21,901,829...21,902,239
JBrowse link
G H6pd hexose-6-phosphate dehydrogenase (glucose 1-dehydrogenase) decreases expression ISO Bortezomib results in decreased expression of H6PD mRNA CTD PMID:20977926 NCBI chr 4:150,063,931...150,093,480
Ensembl chr 4:150,063,932...150,093,480
JBrowse link
G Hadha hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit alpha increases expression ISO Bortezomib results in increased expression of HADHA mRNA CTD PMID:20977926 NCBI chr 5:30,324,421...30,359,978
Ensembl chr 5:30,323,302...30,360,160
JBrowse link
G Haus6 HAUS augmin-like complex, subunit 6 increases expression ISO Bortezomib results in increased expression of HAUS6 mRNA CTD PMID:20977926 NCBI chr 4:86,497,092...86,530,317
Ensembl chr 4:86,497,092...86,530,292
JBrowse link
G Hdac10 histone deacetylase 10 decreases expression ISO Bortezomib results in decreased expression of HDAC10 mRNA CTD PMID:20977926 NCBI chr15:89,007,506...89,012,903
Ensembl chr15:89,007,510...89,012,903
JBrowse link
G Hdac4 histone deacetylase 4 decreases expression ISO Bortezomib results in decreased expression of HDAC4 mRNA CTD PMID:17659339 NCBI chr 1:91,856,501...92,123,424
Ensembl chr 1:91,856,501...92,123,421
JBrowse link
G Hdac6 histone deacetylase 6 decreases response to substance ISO HDAC6 results in decreased susceptibility to Bortezomib CTD PMID:16585204 NCBI chr  X:7,796,355...7,814,284
Ensembl chr  X:7,796,359...7,814,128
JBrowse link
G Hectd2 HECT domain E3 ubiquitin protein ligase 2 increases expression ISO Bortezomib results in increased expression of HECTD2 mRNA CTD PMID:20977926 NCBI chr19:36,531,420...36,598,535
Ensembl chr19:36,532,039...36,598,535
JBrowse link
G Hecw1 HECT, C2 and WW domain containing E3 ubiquitin protein ligase 1 multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of HECW1 mRNA CTD PMID:25522274 NCBI chr13:14,401,023...14,697,874
Ensembl chr13:14,401,023...14,697,813
JBrowse link
G Hexd hexosaminidase D decreases expression ISO Bortezomib results in decreased expression of HEXD mRNA CTD PMID:20977926 NCBI chr11:121,095,187...121,113,485
Ensembl chr11:121,095,259...121,113,481
JBrowse link
G Hif1a hypoxia inducible factor 1, alpha subunit increases expression ISO Bortezomib results in increased expression of HIF1A protein CTD PMID:16061869 NCBI chr12:73,948,186...73,994,304
Ensembl chr12:73,948,149...73,994,304
JBrowse link
G Hikeshi heat shock protein nuclear import factor multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of HIKESHI mRNA CTD PMID:25522274 NCBI chr 7:89,567,893...89,590,446
Ensembl chr 7:89,566,737...89,590,412
JBrowse link
G Hmox1 heme oxygenase 1 multiple interactions
increases expression
increases response to substance
ISO [arsenic trioxide co-treated with Bortezomib] results in decreased expression of HMOX1 mRNA; [cobaltiprotoporphyrin results in increased expression of HMOX1 protein] which results in increased susceptibility to Bortezomib; abexinostat promotes the reaction [Bortezomib results in increased expression of HMOX1 mRNA]
Bortezomib results in increased expression of HMOX1 mRNA; Bortezomib results in increased expression of HMOX1 protein
HMOX1 protein results in increased susceptibility to Bortezomib
Berberine inhibits the reaction [Bortezomib results in increased expression of HMOX1 mRNA]
CTD PMID:15509775 PMID:17895889 PMID:19417023 PMID:20471514 PMID:25913414 More... NCBI chr 8:75,820,246...75,827,221
Ensembl chr 8:75,820,249...75,827,217
JBrowse link
G Hmox2 heme oxygenase 2 multiple interactions ISO abexinostat promotes the reaction [Bortezomib results in decreased expression of HMOX2 mRNA] CTD PMID:19417023 NCBI chr16:4,544,225...4,584,606
Ensembl chr16:4,544,225...4,584,606
JBrowse link
G Hnrnpll heterogeneous nuclear ribonucleoprotein L-like increases expression ISO Bortezomib results in increased expression of HNRNPLL mRNA CTD PMID:20977926 NCBI chr17:80,336,916...80,369,697
Ensembl chr17:80,336,916...80,369,697
JBrowse link
G Hoxa11 homeobox A11 decreases expression ISO Bortezomib results in decreased expression of HOXA11 mRNA CTD PMID:20977926 NCBI chr 6:52,219,086...52,222,784
Ensembl chr 6:52,219,086...52,222,790
JBrowse link
G Hps3 HPS3, biogenesis of lysosomal organelles complex 2 subunit 1 decreases expression ISO Bortezomib results in decreased expression of HPS3 mRNA CTD PMID:20977926 NCBI chr 3:20,050,109...20,089,478
Ensembl chr 3:20,050,109...20,089,479
JBrowse link
G Hras Harvey rat sarcoma virus oncogene multiple interactions EXP ATG5 gene mutant form inhibits the reaction [HRAS protein promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]]; HRAS protein promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein] CTD PMID:22842577 NCBI chr 7:140,770,839...140,773,938
Ensembl chr 7:140,769,018...140,773,918
JBrowse link
G Hsf1 heat shock factor 1 increases expression
increases activity
multiple interactions
ISO Bortezomib results in increased expression of HSF1 mRNA
Bortezomib results in increased activity of HSF1 protein
Bortezomib promotes the reaction [HSF1 protein binds to HSPA1A promoter]; HSF1 protein promotes the reaction [Bortezomib results in increased expression of ZFAND2A protein]
CTD PMID:17895889 PMID:23874968 PMID:24619424 PMID:31540997 NCBI chr15:76,361,562...76,385,355
Ensembl chr15:76,361,622...76,386,113
JBrowse link
G Hsf2 heat shock factor 2 multiple interactions
increases expression
ISO HSF2 protein inhibits the reaction [Bortezomib results in increased expression of ZFAND2A protein]
Bortezomib results in increased expression of HSF2 mRNA; Bortezomib results in increased expression of HSF2 protein
CTD PMID:24619424 NCBI chr10:57,359,862...57,389,239
Ensembl chr10:57,362,481...57,389,231
JBrowse link
G Hsp90aa1 heat shock protein 90, alpha (cytosolic), class A member 1 increases expression
decreases expression
ISO Bortezomib results in increased expression of HSP90AA1 mRNA
Bortezomib results in decreased expression of HSP90AA1 mRNA
CTD PMID:17895889 PMID:20471514 PMID:20830808 NCBI chr12:110,657,470...110,662,829
Ensembl chr12:110,657,039...110,669,162
JBrowse link
G Hsp90ab1 heat shock protein 90 alpha (cytosolic), class B member 1 increases expression ISO Bortezomib results in increased expression of HSP90AB1 mRNA CTD PMID:17895889 NCBI chr17:45,878,704...45,884,187
Ensembl chr17:45,878,701...45,884,197
JBrowse link
G Hspa1a heat shock protein 1A multiple interactions
decreases response to substance
increases expression
ISO Bortezomib promotes the reaction [HSF1 protein binds to HSPA1A promoter]
HSPA1A protein results in decreased susceptibility to Bortezomib
Bortezomib results in increased expression of HSPA1A mRNA
CTD PMID:17895889 PMID:23874968 NCBI chr17:35,188,335...35,191,132
Ensembl chr17:35,188,166...35,191,132
JBrowse link
G Hspa1b heat shock protein 1B increases expression
affects response to substance
decreases response to substance
ISO Bortezomib results in increased expression of HSPA1B mRNA
HSPA1B protein affects the susceptibility to Bortezomib
HSPA1B protein results in decreased susceptibility to Bortezomib
CTD PMID:15509775 PMID:17895889 PMID:23874968 NCBI chr17:35,175,405...35,178,214
Ensembl chr17:35,175,412...35,178,214
JBrowse link
G Hspa4l heat shock protein 4 like increases expression ISO Bortezomib results in increased expression of HSPA4L mRNA CTD PMID:20830808 NCBI chr 3:40,698,664...40,750,538
Ensembl chr 3:40,699,814...40,750,538
JBrowse link
G Hspa5 heat shock protein 5 multiple interactions
increases expression
decreases response to substance
ISO
EXP
Bortezomib inhibits the reaction [Brefeldin A results in increased expression of HSPA5 protein]; Bortezomib inhibits the reaction [Tunicamycin results in increased expression of HSPA5 protein]; Bortezomib promotes the reaction [gambogic acid results in increased expression of HSPA5 protein]; Bortezomib promotes the reaction [geldanamycin results in increased expression of HSPA5 protein]; gambogic acid promotes the reaction [Bortezomib results in increased expression of HSPA5 protein]; geldanamycin promotes the reaction [Bortezomib results in increased expression of HSPA5 protein]; MYC protein promotes the reaction [Bortezomib results in increased expression of HSPA5 protein]
Bortezomib results in increased expression of HSPA5; Bortezomib results in increased expression of HSPA5 mRNA; Bortezomib results in increased expression of HSPA5 protein
HSPA5 results in decreased susceptibility to Bortezomib
CTD PMID:15141013 PMID:15509775 PMID:16024631 PMID:16357177 PMID:18641367 More... NCBI chr 2:34,662,102...34,666,541
Ensembl chr 2:34,661,982...34,667,559
JBrowse link
G Hspb1 heat shock protein 1 increases expression
decreases response to substance
ISO Bortezomib results in increased expression of HSPB1 mRNA
HSPB1 protein results in decreased susceptibility to Bortezomib
CTD PMID:14559800 PMID:20830808 NCBI chr 5:135,916,773...135,918,417
Ensembl chr 5:135,916,773...135,918,417
JBrowse link
G Hsph1 heat shock 105kDa/110kDa protein 1 increases expression ISO Bortezomib results in increased expression of HSPH1 mRNA CTD PMID:17898295 NCBI chr 5:149,540,308...149,562,594
Ensembl chr 5:149,537,752...149,559,841
JBrowse link
G Htr2b 5-hydroxytryptamine (serotonin) receptor 2B decreases expression ISO Bortezomib results in decreased expression of HTR2B mRNA CTD PMID:20977926 NCBI chr 1:86,025,268...86,043,960
Ensembl chr 1:86,026,748...86,039,692
JBrowse link
G Htra2 HtrA serine peptidase 2 affects localization ISO Bortezomib affects the localization of HTRA2 protein CTD PMID:16024631 NCBI chr 6:83,028,247...83,031,552
Ensembl chr 6:83,028,247...83,032,254
JBrowse link
G Ibtk inhibitor of Bruton agammaglobulinemia tyrosine kinase increases expression ISO Bortezomib results in increased expression of IBTK mRNA CTD PMID:20977926 NCBI chr 9:85,569,412...85,632,756
Ensembl chr 9:85,569,413...85,631,387
JBrowse link
G Icam1 intercellular adhesion molecule 1 multiple interactions
decreases expression
ISO [arsenic trioxide co-treated with Bortezomib] results in decreased expression of ICAM1 mRNA; [romidepsin co-treated with Bortezomib] results in decreased expression of ICAM1 protein
Bortezomib results in decreased expression of ICAM1 mRNA
CTD PMID:18223231 PMID:20471514 PMID:25913414 NCBI chr 9:20,927,236...20,940,110
Ensembl chr 9:20,927,281...20,940,113
JBrowse link
G Ide insulin degrading enzyme increases expression ISO Bortezomib results in increased expression of IDE mRNA CTD PMID:20977926 NCBI chr19:37,246,140...37,341,664
Ensembl chr19:37,246,142...37,340,010
JBrowse link
G Idh3a isocitrate dehydrogenase 3 (NAD+) alpha decreases expression ISO Bortezomib results in decreased expression of IDH3A mRNA CTD PMID:30818834 NCBI chr 9:54,493,795...54,511,946
Ensembl chr 9:54,493,618...54,511,945
JBrowse link
G Ifi44 interferon-induced protein 44 increases expression ISO Bortezomib results in increased expression of IFI44 mRNA CTD PMID:20977926 NCBI chr 3:151,436,559...151,455,580
Ensembl chr 3:151,436,559...151,455,597
JBrowse link
G Ifitm1 interferon induced transmembrane protein 1 decreases expression ISO Bortezomib results in decreased expression of IFITM1 mRNA CTD PMID:17659339 NCBI chr 7:140,547,342...140,549,740
Ensembl chr 7:140,547,134...140,549,738
JBrowse link
G Ifng interferon gamma multiple interactions EXP [Chloroquine co-treated with Bortezomib] results in increased expression of IFNG protein; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of IFNG protein]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of IFNG protein]] CTD PMID:30482226 NCBI chr10:118,276,951...118,281,799
Ensembl chr10:118,276,951...118,281,797
JBrowse link
G Ifrd2 interferon-related developmental regulator 2 decreases expression ISO Bortezomib results in decreased expression of IFRD2 mRNA CTD PMID:20977926 NCBI chr 9:107,464,917...107,470,237
Ensembl chr 9:107,464,841...107,470,584
JBrowse link
G Igf1r insulin-like growth factor I receptor increases response to substance ISO IGF1R gene SNP results in increased susceptibility to Bortezomib CTD PMID:20864405 NCBI chr 7:67,601,486...67,883,416
Ensembl chr 7:67,602,575...67,883,416
JBrowse link
G Igf2 insulin-like growth factor 2 multiple interactions
decreases response to substance
ISO Bortezomib inhibits the reaction [IGF2 protein results in increased expression of STS mRNA]; Bortezomib inhibits the reaction [IGF2 protein results in increased expression of STS protein]
Bortezomib results in decreased susceptibility to IGF2 protein
CTD PMID:24055520 NCBI chr 7:142,204,505...142,220,566
Ensembl chr 7:142,204,503...142,220,553
JBrowse link
G Igll1 immunoglobulin lambda-like polypeptide 1 decreases expression ISO Bortezomib results in decreased expression of IGLL1 mRNA CTD PMID:20977926 NCBI chr16:16,678,535...16,681,849
Ensembl chr16:16,678,535...16,681,849
JBrowse link
G Ikbkb inhibitor of kappaB kinase beta multiple interactions
decreases expression
ISO Bortezomib promotes the reaction [abexinostat results in decreased expression of IKBKB mRNA]; IKBKB protein affects the reaction [Bortezomib results in increased phosphorylation of and results in increased degradation of NFKBIA protein]
Bortezomib results in decreased expression of IKBKB mRNA
CTD PMID:19417023 PMID:20471514 PMID:24085292 NCBI chr 8:23,149,228...23,196,605
Ensembl chr 8:23,149,228...23,196,605
JBrowse link
G Ikzf1 IKAROS family zinc finger 1 decreases expression ISO Bortezomib results in decreased expression of IKZF1 mRNA CTD PMID:20977926 NCBI chr11:11,634,970...11,722,930
Ensembl chr11:11,634,980...11,722,926
JBrowse link
G Il10 interleukin 10 affects expression ISO Bortezomib affects the expression of IL10 protein CTD PMID:19922463 NCBI chr 1:130,947,459...130,952,707
Ensembl chr 1:130,947,582...130,952,711
JBrowse link
G Il15 interleukin 15 increases expression ISO Bortezomib results in increased expression of IL15 mRNA CTD PMID:20977926 NCBI chr 8:83,058,253...83,129,883
Ensembl chr 8:83,058,261...83,129,851
JBrowse link
G Il18r1 interleukin 18 receptor 1 increases expression ISO Bortezomib results in increased expression of IL18R1 mRNA CTD PMID:17895889 NCBI chr 1:40,504,712...40,540,014
Ensembl chr 1:40,504,712...40,540,014
JBrowse link
G Il1b interleukin 1 beta increases expression
multiple interactions
ISO Bortezomib results in increased expression of IL1B mRNA
Berberine inhibits the reaction [Bortezomib results in increased expression of IL1B mRNA]
CTD PMID:35121005 NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059
JBrowse link
G Il1r1 interleukin 1 receptor, type I increases expression ISO Bortezomib results in increased expression of IL1R1 mRNA CTD PMID:17895889 NCBI chr 1:40,261,651...40,355,361
Ensembl chr 1:40,264,240...40,356,417
JBrowse link
G Il23a interleukin 23, alpha subunit p19 increases expression ISO Bortezomib results in increased expression of IL23A mRNA CTD PMID:17895889 NCBI chr10:128,132,009...128,133,953
Ensembl chr10:128,132,008...128,134,621
JBrowse link
G Il6 interleukin 6 multiple interactions
decreases secretion
decreases expression
increases expression
ISO
EXP
[Dexamethasone co-treated with Bortezomib] inhibits the reaction [IL6 protein results in increased expression of SOD2 mRNA]; [Dexamethasone co-treated with Bortezomib] results in decreased expression of IL6 mRNA; [Dexamethasone co-treated with Bortezomib] results in decreased secretion of IL6 protein; Bortezomib inhibits the reaction [IL6 protein results in decreased susceptibility to Dexamethasone]
Bortezomib results in decreased secretion of IL6 protein
Bortezomib results in decreased expression of IL6 mRNA
Bortezomib results in increased expression of IL6 mRNA
Bortezomib inhibits the reaction [[Chloroquine co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL6 protein]; Bortezomib inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of IL6 protein]
Berberine inhibits the reaction [Bortezomib results in increased expression of IL6 mRNA]
CTD PMID:17895889 PMID:23063726 PMID:28134560 PMID:35121005 NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979
JBrowse link
G Il7r interleukin 7 receptor increases expression
multiple interactions
ISO Bortezomib results in increased expression of IL7R mRNA
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of IL7R mRNA
CTD PMID:20471514 PMID:25522274 NCBI chr15:9,505,880...9,530,270
Ensembl chr15:9,505,874...9,530,262
JBrowse link
G Ino80b INO80 complex subunit B decreases expression ISO Bortezomib results in decreased expression of INO80B mRNA CTD PMID:20977926 NCBI chr 6:83,098,746...83,102,100
Ensembl chr 6:83,098,746...83,102,412
JBrowse link
G Irak1 interleukin-1 receptor-associated kinase 1 decreases expression ISO Bortezomib results in decreased expression of IRAK1 mRNA CTD PMID:20471514 NCBI chr  X:73,057,520...73,067,527
Ensembl chr  X:73,057,520...73,067,524
JBrowse link
G Irak2 interleukin-1 receptor-associated kinase 2 increases expression ISO Bortezomib results in increased expression of IRAK2 mRNA CTD PMID:20977926 NCBI chr 6:113,615,428...113,671,987
Ensembl chr 6:113,615,428...113,671,987
JBrowse link
G Irf4 interferon regulatory factor 4 decreases expression
multiple interactions
ISO Bortezomib results in decreased expression of IRF4 protein
3-(5-(4-(cyclopentyloxy)-2-hydroxybenzoyl)-2-((3-hydroxy-1,2-benzisoxazol-6-yl)methoxy)phenyl)propionic acid promotes the reaction [Bortezomib results in decreased expression of IRF4 protein]; Bortezomib promotes the reaction [3-(5-(4-(cyclopentyloxy)-2-hydroxybenzoyl)-2-((3-hydroxy-1,2-benzisoxazol-6-yl)methoxy)phenyl)propionic acid results in decreased expression of IRF4 protein]
CTD PMID:37657595 NCBI chr13:30,933,191...30,950,965
Ensembl chr13:30,933,209...30,950,959
JBrowse link
G Irs1 insulin receptor substrate 1 decreases degradation ISO Bortezomib results in decreased degradation of IRS1 protein CTD PMID:16227402 NCBI chr 1:82,210,826...82,269,160
Ensembl chr 1:82,210,822...82,269,137
JBrowse link
G Isca1 iron-sulfur cluster assembly 1 increases expression ISO Bortezomib results in increased expression of ISCA1 mRNA CTD PMID:20977926 NCBI chr13:59,903,229...59,917,603
Ensembl chr13:59,903,223...59,917,624
JBrowse link
G Itga6 integrin alpha 6 decreases expression ISO Bortezomib results in decreased expression of ITGA6 mRNA CTD PMID:20977926 NCBI chr 2:71,617,236...71,688,761
Ensembl chr 2:71,575,960...71,688,760
JBrowse link
G Itgal integrin alpha L decreases expression ISO Bortezomib results in decreased expression of ITGAL mRNA CTD PMID:20977926 NCBI chr 7:126,895,404...126,934,309
Ensembl chr 7:126,895,432...126,934,310
JBrowse link
G Itgav integrin alpha V multiple interactions
increases expression
ISO [arsenic trioxide co-treated with Bortezomib] results in decreased expression of ITGAV mRNA
Bortezomib results in increased expression of ITGAV mRNA
CTD PMID:20471514 PMID:25913414 NCBI chr 2:83,554,796...83,637,261
Ensembl chr 2:83,554,741...83,637,260
JBrowse link
G Itgb6 integrin beta 6 increases expression ISO Bortezomib results in increased expression of ITGB6 mRNA CTD PMID:20977926 NCBI chr 2:60,428,636...60,553,005
Ensembl chr 2:60,428,636...60,552,987
JBrowse link
G Jak1 Janus kinase 1 decreases expression ISO Bortezomib results in decreased expression of JAK1 mRNA CTD PMID:20977926 NCBI chr 4:101,009,171...101,122,493
Ensembl chr 4:101,009,564...101,122,479
JBrowse link
G Jun jun proto-oncogene multiple interactions
decreases expression
increases phosphorylation
increases expression
ISO [arsenic trioxide co-treated with Bortezomib] results in decreased expression of JUN mRNA; [arsenic trioxide co-treated with Bortezomib] results in increased activity of JUN protein modified form; [Bortezomib co-treated with sorafenib] results in increased phosphorylation of JUN protein; pyrazolanthrone inhibits the reaction [Bortezomib results in increased phosphorylation of JUN protein]
Bortezomib results in decreased expression of JUN mRNA
Bortezomib results in increased expression of JUN mRNA; Bortezomib results in increased expression of JUN protein; Bortezomib results in increased expression of JUN protein modified form
CTD PMID:12393500 PMID:16357177 PMID:16985072 PMID:17351739 PMID:17495969 More... NCBI chr 4:94,937,273...94,940,459
Ensembl chr 4:94,937,271...94,940,459
JBrowse link
G Junb jun B proto-oncogene multiple interactions
decreases expression
ISO 3-(5-(4-(cyclopentyloxy)-2-hydroxybenzoyl)-2-((3-hydroxy-1,2-benzisoxazol-6-yl)methoxy)phenyl)propionic acid promotes the reaction [Bortezomib results in decreased expression of JUNB protein]; Bortezomib promotes the reaction [3-(5-(4-(cyclopentyloxy)-2-hydroxybenzoyl)-2-((3-hydroxy-1,2-benzisoxazol-6-yl)methoxy)phenyl)propionic acid results in decreased expression of JUNB protein] CTD PMID:37657595 NCBI chr 8:85,703,538...85,705,377
Ensembl chr 8:85,701,113...85,705,347
JBrowse link
G Jund jun D proto-oncogene decreases expression ISO Bortezomib results in decreased expression of JUND mRNA CTD PMID:20977926 NCBI chr 8:71,150,389...71,153,265
Ensembl chr 8:71,151,599...71,153,265
JBrowse link
G Kat2b K(lysine) acetyltransferase 2B decreases expression ISO Bortezomib results in decreased expression of KAT2B mRNA CTD PMID:20471514 NCBI chr17:53,873,802...53,979,749
Ensembl chr17:53,873,889...53,979,748
JBrowse link
G Kat6b K(lysine) acetyltransferase 6B decreases expression ISO Bortezomib results in decreased expression of KAT6B mRNA CTD PMID:20977926 NCBI chr14:21,549,284...21,722,546
Ensembl chr14:21,531,502...21,722,546
JBrowse link
G Katnal1 katanin p60 subunit A-like 1 increases expression ISO Bortezomib results in increased expression of KATNAL1 mRNA CTD PMID:20977926 NCBI chr 5:148,808,394...148,865,978
Ensembl chr 5:148,808,394...148,931,957
JBrowse link
G Kcmf1 potassium channel modulatory factor 1 increases expression ISO Bortezomib results in increased expression of KCMF1 mRNA CTD PMID:20977926 NCBI chr 6:72,818,097...72,876,962
Ensembl chr 6:72,818,097...72,876,962
JBrowse link
G Kctd10 potassium channel tetramerisation domain containing 10 increases expression ISO Bortezomib results in increased expression of KCTD10 mRNA CTD PMID:20977926 NCBI chr 5:114,501,633...114,518,566
Ensembl chr 5:114,501,628...114,518,569
JBrowse link
G Kdelr1 KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulum protein retention receptor 1 decreases expression ISO Bortezomib results in decreased expression of KDELR1 mRNA CTD PMID:20977926 NCBI chr 7:45,522,264...45,533,150
Ensembl chr 7:45,522,196...45,533,156
JBrowse link
G Kdm4b lysine (K)-specific demethylase 4B decreases expression ISO Bortezomib results in decreased expression of KDM4B mRNA CTD PMID:20977926 NCBI chr17:56,632,975...56,710,774
Ensembl chr17:56,633,062...56,709,870
JBrowse link
G Kdm5c lysine demethylase 5C decreases expression ISO Bortezomib results in decreased expression of KDM5C mRNA CTD PMID:20977926 NCBI chr  X:151,015,698...151,062,098
Ensembl chr  X:151,016,016...151,057,531
JBrowse link
G Kdr kinase insert domain protein receptor multiple interactions ISO [Bortezomib co-treated with sorafenib] results in decreased phosphorylation of KDR protein CTD PMID:16985072 NCBI chr 5:76,093,487...76,139,880
Ensembl chr 5:76,093,487...76,139,118
JBrowse link
G Kif22 kinesin family member 22 decreases expression ISO Bortezomib results in decreased expression of KIF22 mRNA CTD PMID:20977926 NCBI chr 7:126,626,901...126,641,639
Ensembl chr 7:126,626,901...126,641,643
JBrowse link
G Kif9 kinesin family member 9 decreases expression ISO Bortezomib results in decreased expression of KIF9 mRNA CTD PMID:20977926 NCBI chr 9:110,306,062...110,354,242
Ensembl chr 9:110,306,026...110,354,247
JBrowse link
G Kifc1 kinesin family member C1 decreases expression ISO Bortezomib results in decreased expression of KIFC1 mRNA CTD PMID:20977926 NCBI chr17:34,094,640...34,109,607
Ensembl chr17:34,094,633...34,109,635
JBrowse link
G Klf6 Kruppel-like transcription factor 6 increases expression ISO Bortezomib results in increased expression of KLF6 mRNA CTD PMID:20977926 NCBI chr13:5,911,488...5,920,392
Ensembl chr13:5,911,481...5,920,393
JBrowse link
G Klhdc7b kelch domain containing 7B increases expression ISO Bortezomib results in increased expression of KLHDC7B mRNA CTD PMID:20977926 NCBI chr15:89,268,262...89,274,025
Ensembl chr15:89,269,120...89,273,070
JBrowse link
G Klhl20 kelch-like 20 increases expression ISO Bortezomib results in increased expression of KLHL20 mRNA CTD PMID:20977926 NCBI chr 1:160,915,945...160,959,078
Ensembl chr 1:160,915,945...160,959,081
JBrowse link
G Klrk1 killer cell lectin-like receptor subfamily K, member 1 decreases expression ISO Bortezomib results in decreased expression of KLRK1 mRNA CTD PMID:20977926 NCBI chr 6:129,587,286...129,600,863
Ensembl chr 6:129,587,286...129,600,827
JBrowse link
G Kmt2a lysine (K)-specific methyltransferase 2A multiple interactions ISO [arsenic trioxide co-treated with Bortezomib] results in decreased expression of KMT2A mRNA CTD PMID:25913414 NCBI chr 9:44,714,652...44,793,492
Ensembl chr 9:44,714,652...44,792,594
JBrowse link
G Kpna2 karyopherin subunit alpha 2 increases expression ISO Bortezomib results in increased expression of KPNA2 mRNA CTD PMID:20977926 NCBI chr11:106,879,455...106,890,351
Ensembl chr11:106,879,455...106,890,367
JBrowse link
G Kri1 KRI1 homolog increases expression ISO Bortezomib results in increased expression of KRI1 mRNA CTD PMID:20977926 NCBI chr 9:21,184,753...21,199,265
Ensembl chr 9:21,184,753...21,199,265
JBrowse link
G Krit1 KRIT1, ankyrin repeat containing increases expression ISO Bortezomib results in increased expression of KRIT1 mRNA CTD PMID:20977926 NCBI chr 5:3,853,156...3,894,515
Ensembl chr 5:3,853,184...3,895,564
JBrowse link
G Ktn1 kinectin 1 increases expression ISO Bortezomib results in increased expression of KTN1 mRNA CTD PMID:20977926 NCBI chr14:47,886,551...47,974,021
Ensembl chr14:47,885,905...47,977,351
JBrowse link
G Lgals2 lectin, galactose-binding, soluble 2 decreases expression ISO Bortezomib results in decreased expression of LGALS2 mRNA CTD PMID:17659339 NCBI chr15:78,735,060...78,739,729
Ensembl chr15:78,735,060...78,739,729
JBrowse link
G Lgals8 lectin, galactose binding, soluble 8 increases expression ISO Bortezomib results in increased expression of LGALS8 mRNA CTD PMID:20977926 NCBI chr13:12,454,283...12,479,857
Ensembl chr13:12,454,296...12,479,825
JBrowse link
G Lgr4 leucine-rich repeat-containing G protein-coupled receptor 4 multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of LGR4 mRNA CTD PMID:25522274 NCBI chr 2:109,747,919...109,844,602
Ensembl chr 2:109,747,992...109,844,602
JBrowse link
G Lig4 ligase IV, DNA, ATP-dependent increases expression ISO Bortezomib results in increased expression of LIG4 mRNA CTD PMID:20977926 NCBI chr 8:10,020,020...10,027,680
Ensembl chr 8:10,019,049...10,027,686
JBrowse link
G Lima1 LIM domain and actin binding 1 increases expression ISO Bortezomib results in increased expression of LIMA1 mRNA CTD PMID:20977926 NCBI chr15:99,676,351...99,773,292
Ensembl chr15:99,676,351...99,773,337
JBrowse link
G Limd1 LIM domains containing 1 increases expression ISO Bortezomib results in increased expression of LIMD1 mRNA CTD PMID:20977926 NCBI chr 9:123,306,790...123,350,617
Ensembl chr 9:123,307,771...123,350,617
JBrowse link
G Lims1 LIM and senescent cell antigen-like domains 1 increases expression ISO Bortezomib results in increased expression of LIMS1 mRNA CTD PMID:20977926 NCBI chr10:58,159,164...58,260,513
Ensembl chr10:58,159,288...58,260,513
JBrowse link
G Lmna lamin A increases cleavage ISO Bortezomib results in increased cleavage of LMNA protein CTD PMID:20110775 NCBI chr 3:88,388,455...88,413,842
Ensembl chr 3:88,387,454...88,417,263
JBrowse link
G Lrfn4 leucine rich repeat and fibronectin type III domain containing 4 decreases expression ISO Bortezomib results in decreased expression of LRFN4 mRNA CTD PMID:20977926 NCBI chr19:4,661,817...4,665,720
Ensembl chr19:4,661,813...4,665,695
JBrowse link
G Lrrc41 leucine rich repeat containing 41 decreases expression ISO Bortezomib results in decreased expression of LRRC41 mRNA CTD PMID:20977926 NCBI chr 4:115,932,466...115,954,306
Ensembl chr 4:115,932,466...115,954,240
JBrowse link
G Lrrfip1 leucine rich repeat (in FLII) interacting protein 1 increases expression ISO Bortezomib results in increased expression of LRRFIP1 mRNA CTD PMID:20977926 NCBI chr 1:90,924,652...91,056,666
Ensembl chr 1:90,926,459...91,056,666
JBrowse link
G Lsm4 LSM4 homolog, U6 small nuclear RNA and mRNA degradation associated decreases expression ISO Bortezomib results in decreased expression of LSM4 mRNA CTD PMID:20977926 NCBI chr 8:71,124,663...71,131,402
Ensembl chr 8:71,125,898...71,131,402
JBrowse link
G Lst1 leukocyte specific transcript 1 decreases expression ISO Bortezomib results in decreased expression of LST1 mRNA CTD PMID:20977926 NCBI chr17:35,404,071...35,407,416
Ensembl chr17:35,404,071...35,407,415
JBrowse link
G Luc7l Luc7-like increases expression ISO Bortezomib results in increased expression of LUC7L mRNA CTD PMID:20977926 NCBI chr17:26,471,874...26,504,484
Ensembl chr17:26,471,870...26,504,478
JBrowse link
G Ly96 lymphocyte antigen 96 multiple interactions ISO [arsenic trioxide co-treated with Bortezomib] results in increased expression of LY96 mRNA CTD PMID:25913414 NCBI chr 1:16,758,680...16,779,829
Ensembl chr 1:16,758,275...16,779,835
JBrowse link
G Lyn LYN proto-oncogene, Src family tyrosine kinase multiple interactions ISO [alvocidib co-treated with Bortezomib co-treated with ABL1 protein] results in decreased phosphorylation of LYN protein CTD PMID:15039284 NCBI chr 4:3,676,865...3,791,613
Ensembl chr 4:3,678,115...3,813,122
JBrowse link
G Maf1 MAF1 homolog, negative regulator of RNA polymerase III multiple interactions ISO Bortezomib inhibits the reaction [Cycloheximide results in increased degradation of MAF1 protein] CTD PMID:31645432 NCBI chr15:76,235,494...76,238,578
Ensembl chr15:76,235,494...76,238,580
JBrowse link
G Mafg v-maf musculoaponeurotic fibrosarcoma oncogene family, protein G (avian) increases expression ISO Bortezomib results in increased expression of MAFG mRNA CTD PMID:20977926 NCBI chr11:120,515,943...120,525,771
Ensembl chr11:120,515,943...120,524,426
JBrowse link
G Malat1 metastasis associated lung adenocarcinoma transcript 1 (non-coding RNA) increases expression ISO Bortezomib results in increased expression of MALAT1 mRNA CTD PMID:20977926 NCBI chr19:5,845,718...5,852,700
Ensembl chr19:5,845,717...5,853,602
JBrowse link
G Map1lc3b microtubule-associated protein 1 light chain 3 beta multiple interactions ISO MAP1LC3B protein affects the reaction [Bortezomib results in increased phosphorylation of NFKBIA protein] CTD PMID:24085292 NCBI chr 8:122,317,177...122,325,499
Ensembl chr 8:122,317,100...122,325,499
JBrowse link
G Map2k1 mitogen-activated protein kinase kinase 1 multiple interactions ISO [Bortezomib co-treated with Butyrates] results in decreased expression of MAP2K1 protein; [Bortezomib co-treated with vorinostat] results in decreased expression of MAP2K1 protein CTD PMID:12893773 NCBI chr 9:64,093,066...64,160,887
Ensembl chr 9:64,093,052...64,160,913
JBrowse link
G Map2k2 mitogen-activated protein kinase kinase 2 decreases expression ISO Bortezomib results in decreased expression of MAP2K2 mRNA CTD PMID:20977926 NCBI chr10:80,941,749...80,960,531
Ensembl chr10:80,941,749...80,969,809
JBrowse link
G Map2k4 mitogen-activated protein kinase kinase 4 multiple interactions ISO alvocidib promotes the reaction [Bortezomib results in increased phosphorylation of and results in increased activity of MAP2K4 protein]; Bortezomib results in increased phosphorylation of and results in increased activity of MAP2K4 protein CTD PMID:15039284 NCBI chr11:65,579,070...65,679,185
Ensembl chr11:65,579,069...65,679,123
JBrowse link
G Map2k6 mitogen-activated protein kinase kinase 6 decreases expression ISO Bortezomib results in decreased expression of MAP2K6 mRNA CTD PMID:20977926 NCBI chr11:110,289,928...110,416,348
Ensembl chr11:110,289,948...110,416,348
JBrowse link
G Map4k3 mitogen-activated protein kinase kinase kinase kinase 3 increases expression ISO Bortezomib results in increased expression of MAP4K3 mRNA CTD PMID:20977926 NCBI chr17:80,887,942...81,039,118
Ensembl chr17:80,887,941...81,035,914
JBrowse link
G Map4k4 mitogen-activated protein kinase kinase kinase kinase 4 increases expression ISO Bortezomib results in increased expression of MAP4K4 mRNA CTD PMID:20977926 NCBI chr 1:39,939,806...40,065,470
Ensembl chr 1:39,940,073...40,065,470
JBrowse link
G Mapk1 mitogen-activated protein kinase 1 multiple interactions
increases expression
increases phosphorylation
decreases activity
ISO [Bortezomib co-treated with Butyrates] results in decreased expression of MAPK1 protein; [Bortezomib co-treated with panobinostat] results in decreased activity of MAPK1 protein; [Bortezomib co-treated with vorinostat] results in decreased expression of MAPK1 protein; alvocidib inhibits the reaction [Bortezomib results in increased expression of MAPK1 protein modified form]; Bortezomib promotes the reaction [Curcumin results in decreased phosphorylation of MAPK1 protein]; lapatinib inhibits the reaction [Bortezomib results in increased phosphorylation of MAPK1 protein]
Bortezomib results in decreased activity of MAPK1 protein
CTD PMID:12893773 PMID:15039284 PMID:18445700 PMID:19383353 PMID:20701607 NCBI chr16:16,801,246...16,865,317
Ensembl chr16:16,801,246...16,865,317
JBrowse link
G Mapk10 mitogen-activated protein kinase 10 multiple interactions ISO [[Bortezomib co-treated with Butyrates] results in increased abundance of Reactive Oxygen Species] which results in increased phosphorylation of and results in increased activity of MAPK10 protein; [[Bortezomib co-treated with vorinostat] results in increased abundance of Reactive Oxygen Species] which results in increased phosphorylation of and results in increased activity of MAPK10 protein; [Bortezomib co-treated with Butyrates] results in increased phosphorylation of and results in increased activity of MAPK10 protein; [Bortezomib co-treated with vorinostat] results in increased phosphorylation of and results in increased activity of MAPK10 protein; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with Butyrates] results in increased phosphorylation of and results in increased activity of MAPK10 protein]; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with vorinostat] results in increased phosphorylation of and results in increased activity of MAPK10 protein] CTD PMID:15173093 NCBI chr 5:103,056,413...103,359,200
Ensembl chr 5:103,055,814...103,359,200
JBrowse link
G Mapk14 mitogen-activated protein kinase 14 multiple interactions ISO [Bortezomib co-treated with Butyrates] results in increased phosphorylation of MAPK14 protein; [Bortezomib co-treated with vorinostat] results in increased phosphorylation of MAPK14 protein; MAPK14 mutant form inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein] CTD PMID:12893773 PMID:18790767 NCBI chr17:28,910,316...28,967,379
Ensembl chr17:28,910,303...28,967,380
JBrowse link
G Mapk3 mitogen-activated protein kinase 3 multiple interactions
increases expression
increases phosphorylation
decreases activity
ISO [Bortezomib co-treated with Butyrates] results in decreased expression of MAPK3 protein; [Bortezomib co-treated with panobinostat] results in decreased activity of MAPK3 protein; [Bortezomib co-treated with vorinostat] results in decreased expression of MAPK3 protein; alvocidib inhibits the reaction [Bortezomib results in increased expression of MAPK3 protein modified form]; Bortezomib promotes the reaction [Curcumin results in decreased phosphorylation of MAPK3 protein]; lapatinib inhibits the reaction [Bortezomib results in increased phosphorylation of MAPK3 protein]
Bortezomib results in decreased activity of MAPK3 protein
CTD PMID:12893773 PMID:15039284 PMID:18445700 PMID:19383353 PMID:20701607 NCBI chr 7:126,358,798...126,364,988
Ensembl chr 7:126,358,773...126,364,991
JBrowse link
G Mapk8 mitogen-activated protein kinase 8 multiple interactions
increases phosphorylation
ISO [[Bortezomib co-treated with Butyrates] results in increased abundance of Reactive Oxygen Species] which results in increased phosphorylation of and results in increased activity of MAPK8 protein; [[Bortezomib co-treated with vorinostat] results in increased abundance of Reactive Oxygen Species] which results in increased phosphorylation of and results in increased activity of MAPK8 protein; [Bortezomib co-treated with Butyrates] results in increased phosphorylation of and results in increased activity of MAPK8 protein; [Bortezomib co-treated with sorafenib] results in increased phosphorylation of MAPK8 protein; [Bortezomib co-treated with vorinostat] results in increased phosphorylation of and results in increased activity of MAPK8 protein; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with Butyrates] results in increased phosphorylation of and results in increased activity of MAPK8 protein]; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with vorinostat] results in increased phosphorylation of and results in increased activity of MAPK8 protein]; alvocidib promotes the reaction [Bortezomib results in increased phosphorylation of and results in increased activity of MAPK8 protein]; Bortezomib results in increased phosphorylation of and results in increased activity of MAPK8 protein; CGC 11093 promotes the reaction [Bortezomib results in increased phosphorylation of MAPK8 protein]; MAPK8 results in increased susceptibility to [Bortezomib co-treated with CGC 11093]
evodiamine inhibits the reaction [Bortezomib results in increased phosphorylation of MAPK8 protein]
CTD PMID:12893773 PMID:15039284 PMID:15173093 PMID:16985072 PMID:18559525 More... NCBI chr14:33,099,855...33,169,213
Ensembl chr14:33,099,855...33,169,115
JBrowse link
G Mapk9 mitogen-activated protein kinase 9 increases phosphorylation
multiple interactions
ISO Bortezomib results in increased phosphorylation of MAPK9 protein
[Bortezomib co-treated with arsenic trioxide] affects the expression of MAPK9 protein; [Bortezomib co-treated with sorafenib] results in increased phosphorylation of MAPK9 protein; CGC 11093 promotes the reaction [Bortezomib results in increased phosphorylation of MAPK9 protein]; MAPK9 results in increased susceptibility to [Bortezomib co-treated with CGC 11093]
CTD PMID:16985072 PMID:18559525 PMID:18718063 NCBI chr11:49,737,558...49,777,248
Ensembl chr11:49,737,578...49,777,248
JBrowse link
G Mapkap1 mitogen-activated protein kinase associated protein 1 decreases expression ISO Bortezomib results in decreased expression of MAPKAP1 mRNA CTD PMID:20977926 NCBI chr 2:34,296,783...34,514,970
Ensembl chr 2:34,296,783...34,514,962
JBrowse link
G Mapkapk2 MAP kinase-activated protein kinase 2 decreases expression ISO Bortezomib results in decreased expression of MAPKAPK2 mRNA CTD PMID:20977926 NCBI chr 1:130,981,437...131,025,580
Ensembl chr 1:130,981,437...131,025,563
JBrowse link
G Mark2 MAP/microtubule affinity regulating kinase 2 decreases expression ISO Bortezomib results in decreased expression of MARK2 mRNA CTD PMID:20977926 NCBI chr19:7,252,761...7,319,222
Ensembl chr19:7,252,761...7,319,225
JBrowse link
G Maz MYC-associated zinc finger protein (purine-binding transcription factor) decreases expression ISO Bortezomib results in decreased expression of MAZ mRNA CTD PMID:20977926 NCBI chr 7:126,621,306...126,626,177
Ensembl chr 7:126,621,302...126,626,209
JBrowse link
G Mbd1 methyl-CpG binding domain protein 1 decreases expression ISO Bortezomib results in decreased expression of MBD1 mRNA CTD PMID:20977926 NCBI chr18:74,400,676...74,415,808
Ensembl chr18:74,400,676...74,415,803
JBrowse link
G Mbd4 methyl-CpG binding domain protein 4 increases expression ISO Bortezomib results in increased expression of MBD4 mRNA CTD PMID:20977926 NCBI chr 6:115,817,658...115,830,361
Ensembl chr 6:115,817,658...115,830,332
JBrowse link
G Mbl2 mannose-binding lectin (protein C) 2 increases response to substance ISO MBL2 gene SNP results in increased susceptibility to Bortezomib CTD PMID:20864405 NCBI chr19:30,210,306...30,217,087
Ensembl chr19:30,210,342...30,217,087
JBrowse link
G Mbnl1 muscleblind like splicing regulator 1 decreases expression ISO Bortezomib results in decreased expression of MBNL1 mRNA CTD PMID:20977926 NCBI chr 3:60,380,209...60,537,171
Ensembl chr 3:60,380,251...60,537,171
JBrowse link
G Mbp myelin basic protein decreases expression ISO Bortezomib results in decreased expression of MBP mRNA CTD PMID:20977926 NCBI chr18:82,492,883...82,603,762
Ensembl chr18:82,493,271...82,603,762
JBrowse link
G Mcl1 myeloid cell leukemia sequence 1 multiple interactions
increases expression
decreases response to substance
increases cleavage
ISO
EXP
[[Bortezomib co-treated with Butyrates] results in increased abundance of Reactive Oxygen Species] which results in decreased expression of MCL1 protein; [[Bortezomib co-treated with vorinostat] results in increased abundance of Reactive Oxygen Species] which results in decreased expression of MCL1 protein; [Bortezomib co-treated with Butyrates] results in decreased expression of MCL1 protein; [Bortezomib co-treated with N,N-dimethylsphingosine] results in decreased expression of MCL1 protein; [Bortezomib co-treated with SCIO-469] results in decreased expression of MCL1 protein; [Bortezomib co-treated with SCIO-469] results in decreased expression of MCL1 protein modified form; [Bortezomib co-treated with vorinostat] results in decreased expression of MCL1 protein; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with Butyrates] results in decreased expression of MCL1 protein]; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with vorinostat] results in decreased expression of MCL1 protein]; Boc-D-FMK inhibits the reaction [[Bortezomib co-treated with Butyrates] results in decreased expression of MCL1 protein]; Boc-D-FMK inhibits the reaction [[Bortezomib co-treated with vorinostat] results in decreased expression of MCL1 protein]; romidepsin inhibits the reaction [Bortezomib results in increased expression of MCL1 protein]; SCIO-469 promotes the reaction [Bortezomib results in increased cleavage of MCL1 protein]; TNFSF10 protein inhibits the reaction [Bortezomib results in increased expression of MCL1 protein]
Bortezomib inhibits the reaction [Acetaminophen results in decreased expression of MCL1 protein]
MCL1 protein results in decreased susceptibility to Bortezomib; MCL1 results in decreased susceptibility to Bortezomib
Bortezomib results in increased expression of MCL1; Bortezomib results in increased expression of MCL1 protein
CTD PMID:12893773 PMID:15173093 PMID:16617327 PMID:18223231 PMID:18534018 More... NCBI chr 3:95,564,017...95,583,553
Ensembl chr 3:95,566,099...95,570,487
JBrowse link
G Mcm7 minichromosome maintenance complex component 7 decreases expression ISO Bortezomib results in decreased expression of MCM7 mRNA CTD PMID:17659339 NCBI chr 5:138,162,845...138,170,675
Ensembl chr 5:138,162,845...138,170,684
JBrowse link
G Mdc1 mediator of DNA damage checkpoint 1 decreases expression ISO Bortezomib results in decreased expression of MDC1 mRNA CTD PMID:20977926 NCBI chr17:36,152,390...36,170,562
Ensembl chr17:36,152,407...36,170,562
JBrowse link
G Mdm2 transformed mouse 3T3 cell double minute 2 multiple interactions
increases cleavage
affects expression
ISO [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of MDM2 protein]; Bortezomib promotes the reaction [TP53 protein binds to MDM2 protein]
Bortezomib affects the expression of MDM2 protein
CTD PMID:12393500 NCBI chr10:117,524,780...117,546,663
Ensembl chr10:117,524,780...117,546,663
JBrowse link
G Me1 malic enzyme 1, NADP(+)-dependent, cytosolic increases expression ISO Bortezomib results in increased expression of ME1 mRNA CTD PMID:20977926 NCBI chr 9:86,463,416...86,577,967
Ensembl chr 9:86,463,424...86,578,006
JBrowse link
G Mettl21a methyltransferase 21A, HSPA lysine increases expression ISO Bortezomib results in increased expression of METTL21A mRNA CTD PMID:20977926 NCBI chr 1:64,645,632...64,661,926
Ensembl chr 1:64,645,632...64,656,401
JBrowse link
G Mettl27 methyltransferase like 27 decreases expression ISO Bortezomib results in decreased expression of METTL27 mRNA CTD PMID:20977926 NCBI chr 5:134,961,158...134,971,491
Ensembl chr 5:134,961,222...134,971,491
JBrowse link
G Mex3d mex3 RNA binding family member D decreases expression ISO Bortezomib results in decreased expression of MEX3D mRNA CTD PMID:20977926 NCBI chr10:80,216,189...80,223,485
Ensembl chr10:80,216,189...80,223,493
JBrowse link
G Mfn1 mitofusin 1 decreases expression ISO Bortezomib results in decreased expression of MFN1 mRNA CTD PMID:20977926 NCBI chr 3:32,583,594...32,633,384
Ensembl chr 3:32,583,614...32,633,388
JBrowse link
G Mfng MFNG O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase decreases expression ISO Bortezomib results in decreased expression of MFNG mRNA CTD PMID:20977926 NCBI chr15:78,640,082...78,657,678
Ensembl chr15:78,640,082...78,657,675
JBrowse link
G Mgmt O-6-methylguanine-DNA methyltransferase multiple interactions ISO Bortezomib inhibits the reaction [Disulfiram results in increased degradation of MGMT protein] CTD PMID:24193513 NCBI chr 7:136,496,315...136,732,001
Ensembl chr 7:136,496,343...136,731,995
JBrowse link
G Mir21a microRNA 21a increases expression ISO Bortezomib results in increased expression of MIR21 mRNA CTD PMID:20977926 NCBI chr11:86,474,893...86,474,984
Ensembl chr11:86,474,893...86,474,984
JBrowse link
G Mir568 microRNA 568 multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of MIR568 mRNA CTD PMID:25522274 NCBI chr16:43,461,018...43,461,100
Ensembl chr16:43,461,018...43,461,100
JBrowse link
G Mki67 antigen identified by monoclonal antibody Ki 67 decreases expression
multiple interactions
ISO
EXP
Bortezomib results in decreased expression of MKI67 protein
[Chloroquine co-treated with Bortezomib] results in increased expression of MKI67 protein; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of MKI67 protein]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of MKI67 protein]]
CTD PMID:19372569 PMID:30482226 NCBI chr 7:135,291,513...135,318,286
Ensembl chr 7:135,291,513...135,318,090
JBrowse link
G Mllt11 myeloid/lymphoid or mixed-lineage leukemia; translocated to, 11 increases expression ISO Bortezomib results in increased expression of MLLT11 mRNA CTD PMID:20977926 NCBI chr 3:95,125,852...95,139,486
Ensembl chr 3:95,126,446...95,139,482
JBrowse link
G Mmp9 matrix metallopeptidase 9 multiple interactions ISO Bortezomib promotes the reaction [butein results in decreased expression of MMP9 protein]; Bortezomib promotes the reaction [capillarisin results in decreased expression of MMP9 protein] CTD PMID:20696233 PMID:24333736 NCBI chr 2:164,782,246...164,797,770
Ensembl chr 2:164,782,700...164,797,770
JBrowse link
G Mob3a MOB kinase activator 3A decreases expression ISO Bortezomib results in decreased expression of MOB3A mRNA CTD PMID:17659339 NCBI chr10:80,521,087...80,537,845
Ensembl chr10:80,521,087...80,537,811
JBrowse link
G Morc2a microrchidia 2A increases expression ISO Bortezomib results in increased expression of MORC2 mRNA CTD PMID:20977926 NCBI chr11:3,599,132...3,640,477
Ensembl chr11:3,599,191...3,640,477
JBrowse link
G Mpz myelin protein zero decreases expression ISO
EXP
Bortezomib results in decreased expression of MPZ mRNA; Bortezomib results in decreased expression of MPZ protein CTD PMID:20830808 NCBI chr 1:170,978,282...170,988,699
Ensembl chr 1:170,978,280...170,988,699
JBrowse link
G Mrpl19 mitochondrial ribosomal protein L19 increases expression ISO Bortezomib results in increased expression of MRPL19 mRNA CTD PMID:20977926 NCBI chr 6:81,934,807...81,942,930
Ensembl chr 6:81,934,832...81,942,939
JBrowse link
G Mrpl30 mitochondrial ribosomal protein L30 decreases expression ISO Bortezomib results in decreased expression of MRPL30 mRNA CTD PMID:20977926 NCBI chr 1:37,929,558...37,937,419
Ensembl chr 1:37,929,558...37,937,616
JBrowse link
G Mrps12 mitochondrial ribosomal protein S12 decreases expression ISO Bortezomib results in decreased expression of MRPS12 mRNA CTD PMID:20977926 NCBI chr 7:28,439,066...28,441,246
Ensembl chr 7:28,439,066...28,441,245
JBrowse link
G Mrps5 mitochondrial ribosomal protein S5 decreases expression ISO Bortezomib results in decreased expression of MRPS5 mRNA CTD PMID:20977926 NCBI chr 2:127,429,346...127,445,906
Ensembl chr 2:127,429,142...127,448,749
JBrowse link
G Msh6 mutS homolog 6 decreases expression ISO Bortezomib results in decreased expression of MSH6 mRNA CTD PMID:17659339 NCBI chr17:88,282,478...88,298,320
Ensembl chr17:88,282,490...88,298,320
JBrowse link
G Mtmr6 myotubularin related protein 6 increases expression ISO Bortezomib results in increased expression of MTMR6 mRNA CTD PMID:20977926 NCBI chr14:60,488,941...60,539,820
Ensembl chr14:60,502,677...60,539,819
JBrowse link
G Muc1 mucin 1, transmembrane decreases expression ISO Bortezomib results in decreased expression of MUC1 mRNA CTD PMID:20977926 NCBI chr 3:89,136,363...89,140,688
Ensembl chr 3:89,136,364...89,140,688
JBrowse link
G Mutyh mutY DNA glycosylase decreases expression ISO Bortezomib results in decreased expression of MUTYH mRNA CTD PMID:17659339 NCBI chr 4:116,664,846...116,676,641
Ensembl chr 4:116,664,920...116,676,637
JBrowse link
G Myc myelocytomatosis oncogene multiple interactions
increases expression
decreases expression
ISO [Bortezomib co-treated with abexinostat] results in decreased expression of MYC mRNA; Bortezomib promotes the reaction [abexinostat results in decreased expression of MYC protein]; MYC protein promotes the reaction [Bortezomib results in increased expression of HSPA5 protein]; MYC protein promotes the reaction [Bortezomib results in increased expression of PMAIP1 protein]
Bortezomib results in increased expression of MYC protein
Bortezomib results in decreased expression of MYC protein
CTD PMID:12902978 PMID:18641367 PMID:19417023 PMID:20022965 NCBI chr15:61,857,190...61,862,210
Ensembl chr15:61,857,240...61,862,223
JBrowse link
G Myd88 myeloid differentiation primary response gene 88 decreases expression ISO Bortezomib results in decreased expression of MYD88 mRNA CTD PMID:20471514 NCBI chr 9:119,165,000...119,169,084
Ensembl chr 9:119,165,000...119,170,477
JBrowse link
G Myl12a myosin, light chain 12A, regulatory, non-sarcomeric increases expression ISO Bortezomib results in increased expression of MYL12A mRNA CTD PMID:20977926 NCBI chr17:71,300,788...71,309,528
Ensembl chr17:71,300,651...71,309,873
JBrowse link
G